connect annual report mission global quest improve quality human life enable people feel well live long spirit undertake quest enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency strategic intent want indisputable leader industry glaxosmithkline plc english public limited company share list london stock exchange new york stock exchange glaxosmithkline plc acquire glaxo wellcome plc smithkline beecham plc th december way scheme arrangement merger company effective th december report annual report glaxosmithkline plc year end st december comprise single document annual report company accordance united kingdom requirement annual report formf securities exchange commission united states america summary report year annual review intend investor need detail annual report produce separate document annual review include joint statement chairman chief executive officer summary review operation summary financial statement summary remuneration report annual review issue shareholder annual report issue shareholder elect receive document available glaxosmithkline web site visit corporate home wwwgskcomglaxosmithkline glaxosmithkline plc annual report year end st december content report director financial summary joint statement chairman chief executive officer description business corporate governance remuneration report operate financial review prospect financial statement director statement responsibility independent auditor report consolidated statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement principal financial statement financial record investor information shareholder return taxation information shareholder shareholder information share capital cross reference form f glossary term annual report approve board index director th march publish th march contact detail glaxosmithkline financial summary increase business performance cer sale trading profit profit taxation earningsnet income earning share p p total result profit taxation earningsnet income earning share p p business performance primary performance measure management present exclude merger item integration restructuring cost disposal subsidiary management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement include consolidated statement profit loss page prepare accordance ukgaap total result include nonrecurre item cer represent growth constant exchange rate represent growth actual exchange rate financial highlight pharmaceutical sale cent exclude divested product strong growth region usa cent europe seven cent rest world cent strong growth key therapy area central nervous system cent respiratory cent hivaid cent new product cent billion represent cent total pharmaceutical sale seretideadvairachieve sale millionadvairlaunch successful pharmaceutical industry active inlicense programme deliver new product clinical development merger manufacturing cost saving million achieve billion share buyback programme billion share purchase complete strong business performance ep growth cent cent cer shareholder return dividend glaxosmithkline share p glaxo wellcome shareholder p smithkline beecham shareholder p dividend represent dividend pay glaxo wellcome smithkline beecham shareholder express dividend glaxosmithkline share cautionary statement forwardlooke statement group report file securities exchange commission commission include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual reportglaxosmithkline joint statement chairman chief executive officer time enhance marketing power possible combined salesforce give size quality flexibility achieve rapid uptake acceptance glaxosmithkline product example seretideadvair new asthma treatment enjoy remarkable success world fourth large product globally number europe achieve million worldwide sale usa advairlaunch successful pharmaceutical industry merger help position glaxosmithkline marketing power development expertise partner choice company seek large pharmaceutical company maximise value new product active inlicense programme deliver new product clinical development agreement include exciting compound vardenafil erectile dysfunction expect launch partner bayer innovative agreement provide access pipeline large pharmaceutical successful year glaxosmithkline company japan shionogi tanabe year merge company complete successfully reorganise rejuvenated entire rd organisation connect employee take advantage size maintain flexibility world second large pharmaceutical company large efficiency small entrepreneurial centre excellence pharmaceutical company europe fast drug discovery cedd current rd expenditure billion grow pharmaceutical company key market large industry merger enable line commitment shareholder please save reinvest million rd report deliver business performance earning share disappointing lose tranilast prevention restenosis growth cent cent constant compound treatment diabete exchange rate phaselll pipeline confidence continue performance company currently strong earlystage pipeline lead expect business performance earning share growth industry project clinical development include midteen lowteen well new chemical entity new vaccine line extension guidance assume glaxosmithkline successfully defend intellectual property surround augmentinand paxilin usa discovery development programme inlicense activity hasgiven glaxosmithkline strong start deliver merger benefit achieve ambition build good pipeline industry announce merger inform shareholder expect create company significant financial strength block drug successfully integrate consumer enhance marketing power improve rd productivity healthcare business achieve sale billion year great progress turn expectation acquisition add sensodyne polidentand poligripto oral reality care business number significant brand overthe counter medicines result acquisition glaxosmithkline glaxosmithkline strong financial shape business number company globally oral care performance profit tax cent constant critical mass add usa europe exchange rate billion net operating cashflow rest world billion nearly billion previous year achieve merger manufacturing restructuring saving excess position success million year increase estimate annual saving merger million remain begin second year glaxosmithkline company track deliver total annual merger manufacturing excellent shape position realise continue restructure saving billion future success strong portfolio build core product billion global sale seroxatpaxilfor depression financial strength enable announce augmentin antibiotic flixotidefloventfor asthma billion share buyback programme year end seretideadvairfor asthma imigranimitrexfor migraine half way completion group financial power avandiafor diabete undertake programme whilst retain flexibility consider investment opportunity arise new product represent cent total pharmaceutical sale grow cent constant exchange rate billion glaxosmithkline global leader key therapy area antiinfective respiratory central nervous system product glaxosmithklinejoint statement chairman chief executive officer expect new product indication contribute company recognise usa future growth receive approval seroxatpaxil poor citizen able afford medicine need indication generalise anxiety disorder posttraumatic glaxosmithkline take leadership position launch stress disorder coregfor severe heart failure augmentin esfor orange cardprogramme january help people low ear infection child twinrix combination income public private prescription drug hepatitis b vaccine january fda advisory coverage committee recommend approval seretideadvairfor programme reflect fundamental commitment treatment chronic obstructive pulmonary disease copd improve quality life patient globe associate bronchitis connect need community glaxosmithkline planning key regulatory filing employee live work compound hiv ariflofor copd ibandronate publish review glaxosmithkline postmenopausal osteoporosis file commitment society entitle performance integrity development partner roche lamictalfor bipolar disorder incorporate information press wellbutrin xlfor depression social environmental issue core business glaxosmithkline involve legal challenge usa europe infringement patent relate acknowledgement major product continue defend intellectual property right country want thank board member employee support year newly merge company commitment community particular like thank sir peter walters mr john young retire nonexecutive director group deliver commitment support glaxosmithkline conclusion company annual community globally glaxosmithkline continue general meeting invaluable service give play international leadership role increase access board smithkline beecham glaxosmithkline hivaid treatment develop country maintain commitment reduce price government united behalf board corporate executive team nation aid accelerate access initiative announce thank shareholder support company outlined range activity hope proud people achievement improve quality healthcare develop country share enthusiasm tremendous publication call face challenge include extend future prospect glaxosmithkline preferential pricing product country customer include global fund antiretroviral antimalarial offer fix notforprofit price public sector customer nonprofit organisation develop country subsaharan africa additionally gravity hivaid problem subsaharan africa offer preferential price antiretroviral employer provide hivaids treatment staff workplace clinic reconfirm commitment global programme sir richard syke j p garnier eliminate lymphatic filariasis industry chairman chief executive officer large donation programme addition drug donation glaxosmithkline provide extensive programme support partner work prevent disfigure tropical disease message sir richard syke message j p garnier see recent announcement decide behalf board like pay tribute sir richard retire board director effect year annual tremendous contribution glaxo general meeting th time sir christopher hogg glaxo wellcome glaxosmithkline strong currently nonexecutive director glaxosmithkline committed ambassador pharmaceutical industry chairman great champion uk science base wish future time welcome sir christopher new feel right time depart oversee successful chairman look forward benefit wideranging merger glaxosmithkline approach th birthday experience knowledge august wish devote time energy role rector imperial college leave glaxosmithkline great shape future like record thank company employee dedication hard work thank shareholder support yearsglaxosmithkline description business description business discuss activity resourcesandthe operating environment business identifie development achievement follow heading business history development company product operating environment competition regulation operating activity market distribution manufacture supply research development operating resource intellectual property information technology glaxosmithkline people property plant equipment business community performance integrity environmental responsibility access medicine develop world global community partnership corporate donation discussion group management structure corporate governance procedure set corporate governance pagesto remuneration report give detail group policy director remuneration amount earn director senior management page discussion group operate financial performance financial resource give operate financial review andprospect page report glaxosmithkline group mean glaxosmithkline plc subsidiary undertaking thecompany mean glaxosmithkline plcglaxosmithkline share mean ordinary share ofglaxosmithkline plc p report figure quote market size market share market growth rate relate month end th september orlater available glaxosmithkline estimate base onthe recent datum independent external source value sterle relevant exchange rate figure quote product market share reflect sale glaxosmithkline licensee brand name appear italic report trade marks glaxosmithkline plc subsidiary associate company theexception baycola trade mark bayer ag bexxar trade mark corixa corporation inc coreg trade mark roche laboratories inc factive trade mark oflgchemical ltd natrecora trade mark scios inc navelbine trade mark pierre fabre mdicament nicoderm trade mark aventis sa licence group glaxosmithkline description business business history development company glaxosmithkline plc subsidiary associated undertaking constitute major global healthcare group engage creation discovery development manufacture marketing pharmaceutical consumer healthrelated product glaxosmithkline corporate head office london area great west road brentford middlesex tw gs england tel glaxosmithkline operational headquarters philadelphia pa research triangle park nc usa operating company country product sell country principal research development rd facility uk usa japan italy belgium product currently manufacture country major market group products usa japan theuk france germany italy glaxosmithkline plc public limited company incorporate thdecember english law th december company acquire glaxo wellcome plc smithkline beecham plc english public limited company way scheme arrangement merger company glaxo wellcome smithkline beecham major global healthcare business st october glaxo wellcome plc change glaxosmithkline services plc historical reference glaxo wellcome plc document change business segment glaxosmithkline operate principally industry segment pharmaceutical prescription pharmaceutical vaccine consumer healthcare overthecounter medicine oral care nutritional healthcaredescription businessglaxosmithkline product pharmaceutical therapeutic area trade mark compound mechanism indication vary country cns disorder seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety inhibitor wellbutrin bupropion noradrenaline reuptake inhibitor depression imigranimitrex sumatriptan ht agonist migraine cluster headache naramigamerge naratriptan ht agonist migraine lamictal lamotrigine sodium channel modulator epilepsy requip ropinirole dopamine agonist parkinson disease zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction respiratory flixotideflovent fluticasone propionate inhale antiinflammatory asthma bronchial condition serevent salmeterol xinafoate bronchodilator bronchial asthma bronchitis seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma propionate flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis ventolin salbutamolalbuterol bronchodilator bronchial asthma bronchitis becotidebeclovent beclomethasone dipropionate inhale antiinflammatory bronchial asthma bronchitis beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis antibacterial augmentin amoxicillin broad spectrum oralinjectable common infection anti malarial clavulanate potassium antibiotic zinnatceftin cefuroxime axetil oral antibiotic common infection fortumfortaz ceftazidime injectable antibiotic severe life threatening infection amoxil amoxicillin broad spectrum oralinjectable common infection antibiotic malarone atovaquoneproguanil electron transport system inhibitortreatment prophylaxis malaria zinacef cefuroxime injectable antibiotic surgical infection antiviral trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaid abacavir combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaid epivirtc lamivudine reverse transcriptase inhibitor hivaid retrovirazt zidovudine reverse transcriptase inhibitor hivaid ziagen abacavir reverse transcriptase inhibitor hivaid agenerase amprenavir protease inhibitor hivaid valtrexzelitrex valaciclovir dna polymerase inhibitor shingle genital herpe zovirax aciclovir dna polymerase inhibitor herpe infection shingle chicken pox cold sore zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection heptodinepivir hbv relenza zanamivir neuraminidase inhibitor influenza treatment metabolic avandia rosiglitazone ppargamma agonist type diabete gastrointestinal zantac ranitidine hydrochloride antisecretory duodenal ulcer stomach ulcer reflux dyspepsia vaccines havrix hepatitis engerixb hepatitis b twinrix hepatitis b infanrix diphtheria tetanus acellular pertussis oncology zofran ondansetron ht receptor antagonist nausea vomit cancer emesis therapy hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast cancer cardiovascular coreg carvedilol alphabeta blocker congestive heart failure lanoxin digoxin cardiac antiarrhythmic congestive heart failure cardiac arrhythmia flolan epoprostenol inhibitor blood clot primary pulmonary hypertension lacipil lacidipine calcium channel blocker hypertension pritor telmisartan angiotensin ii antagonist hypertension arthritis relafen nabumetone non steroidal antiinflammatory osteoarthritis rheumatoid arthritis glaxosmithkline description business product pharmaceutical therapeutic area antibacterial antimalarial augmentinis broadspectrum antibiotic suitable treatment glaxosmithkline principal pharmaceutical product presently wide range common bacterial infection particularly direct major therapeutic area analysis salesby effective respiratory tract infection new augmentin es therapeutic area description principal product extra strength suspension specifically design treat child setout recurrent persistent middle ear infection sale therapeutic area zinnatis oral antibiotic primarily communityacquire central nervous system infection lower respiratory tract fortumand zinacefare respiratory hospitalbase injectable antibiotic market antibacterial malaroneis oral antimalarial treatment antiviral prophylaxis malaria cause plasmodium falciparum metabolic gastrointestinal vaccine antiviral oncology emesis combivir combination retrovirand epivir consolidate cardiovascular position reverse transcriptase inhibitor arthritis cornerstone multiple antihiv product regimen physician acceptance clearly demonstrate value place divested product minimise pill burden face patient ziagenis group new reverse transcriptase inhibitor product potency ease use resistance profile allow central nervous system cns disorder play significant role variety highly active tolerate seroxatpaxilis selective serotonin reuptake inhibitor ssri andsimplifie hiv treatment regimen approve depression panic obsessive compulsive disorder triziviris combination combivirand ziagen combine social anxiety disorder approval receive post antihiv therapie tablet twice daily administration traumatic stress disorder generalise anxiety disorder usa uk european markets ageneraseis new protease inhibitor treatment hiv medicine class bring market wellbutrini antidepressant available usa normal glaxosmithkline ageneraseha twice daily dose regiman orsustaine release tablet formulation significant food drink restriction imigranimitrexis ht receptor agonist treatment zeffixha approve marketing usa europe china ofsevere frequent migraine cluster headache market treatment chronic hepatitis b reference product sector naramigamergeis group new migraine product zoviraxis treatment herpe infection chicken pox genital herpe shingle cold sore new lamictalis treatment epilepsy combination antiherpe compound valtrex reinforce group presence product achieve penetration mature inthis market treatment zoster episodic market successful treatment severe case longterm suppression genital herpe requipis specific dopamine dlike receptor treatment ofparkinson disease metabolic gastrointestinal avandiais potent insulin sensitise agent act zybanis novel nicotinefree prescription medicine available underlie pathophysiology type diabetes asasustainedrelease tablet treat problem smokingaddiction zantac treatment peptic ulcer disease range ofgastric acid relate disorder continues play major role respiratory treatment number market patent protection sereventis longacting bronchodilator ventolina selective lose pyloridtritecis combination antibiotic shortacte bronchodilator treatment asthma eradication helicobacter pylori causative agent inulcer flixotidefloventand becotidebecloventare inhale steroid treatment inflammation associate bronchial asthma chronic bronchitis seretideadvair combination sereventand flixotide offer alongacte bronchodilator antiinflammatory single inhaler flixonaseflonaseand beconaseare intranasal preparation treatment perennial seasonal rhinitis group respiratory product available wide choice delivery system include diskusaccuhaler dry powder multidose inhalerdescription businessglaxosmithkline vaccine sale include sale block drug product amount glaxosmithkline market range hepatitis vaccine havrix million divest product include divest protect hepatitis engerixbagainst hepatitis b merger glaxo wellcome smithkline beecham twinrixis combine hepatitis b vaccine protect major product disease vaccine available adult paediatric strength category product infanrixis range paediatric vaccine combination infanrix overthecounter medicine provide protection diphtheria tetanus pertussis analgesic panadol whooping cough infanrix penta provide additional protection dermatological oxy hepatitis b polio andinfanrix hexafurther add zovirax protection haemophilus influenzae type b abreva causesmeningitis gastrointestinal tum citrucel additionally glaxosmithkline market priorixa measle respiratory tract contac mump rubella vaccine typherix vaccine protection beecham typhoid fever varilirix vaccine varicella smoking control nicorette chicken pox nicoderm cq niquitin cq oncology emesis nicabate zofrani prevent nausea vomiting associate vitamin natural abtei chemotherapy radiotherapy cancer available oral care aquafresh bothoral injectable form approve use corega prevention treatment postoperative nausea vomit drb hycamtinis second line treatment ovarian cancer macleans forsmall cell lung cancer odol polident cardiovascular poligrip coregis alphabeta blocker prove sensodyne effective intreate mild moderate severe heart failure nutritional healthcare horlick lucozade arthritis ribena relafenis nonsteroidal antiinflammatory drug treatment arthritis overthecounter medicine lead product panadol widely available nonaspirin analgesic nicorettegum nicodermniquitincqand category include group principal dermatological nicabaterange smoking cessation patch tum calcium product betnovate thehigher potency dermovateand new base antacid citrucellaxative contacfor treatment cold cutivateare antiinflammatory steroid product treat skin influenza abtei natural medicine vitamin range disease sucha eczema psoriasis oxyacne treatment zoviraxand abreva treatment cold sore divest product accordance agreement regulatory approval oral care merger glaxo wellcome smithkline beecham lead oral care product aquafresh macleansand odol product kytril treatment chemotherapy toothpaste mouthwash range toothbrush sell radiotherapy induce nausea vomit famvir aquafreshand dr bestnames acquisition block antiviral treatment shingle herpe divest drug january add sensodynetoothpaste range indecember denture care product available principally polident poligripand coregabrand name product consumer healthcare glaxosmithkline principal consumer product presently nutritional healthcare directedto major area analysis sale area lucozadeglucose energy sport drink ribenablackcurrant isset base juice drink rich vitamin c horlick range milkbase malt food chocolate drink lead product category overthecounter medicine oral care nutritional healthcare divest product glaxosmithkline description business operating environment competition pharmaceutical antibacterial antimalarial major product compete glaxosmithkline semisynthetic pharmaceutical industry highly competitive glaxosmithkline penicillin antiinfective include limited principal competitor large international pharmaceutical generic brand cephalosporin increase degree company substantial resource company particularly japan quinolones augmentinhas experience major product mention increase competition usa particularly pfizer pharmaceutical subject competition different zithromax bayer cipro johnson johnsons levaquin therapy period patent protection lose patent protection country europe patent generic version manufacturer generic success augmentinhas target generic product typically donot bear research development cost manufacturers usa glaxosmithkline consequently areable offer product considerably lower continue respond appropriately note financial price thebrande competitor research development statement legal proceeding amoxilha patent base pharmaceutical company normally seek achieve protection number year subject competition sufficiently high profit margin sale volume period generic brand malarone safety profile convenient dose patent protection repay original investment fund regiman helped product strong position versus research forthe future competition generic product mefloquine follow recent launch malaria prophylaxis generally occur glaxosmithkline patent major market expire antiviral glaxosmithkline pioneer role hiv market glaxosmithkline undertake range activity include retrovirand epiviracte cornerstone combination introduce innovative product market possible therapy available combivirin single tablet launch accelerate process new product bring ziagen ageneraseand trizivirhave broaden thegroup portfolio tomarket hiv product valtrexha helped strengthen company increase brand recognition customer position antiherpe area zoviraxface competition generic aciclovir ultimately glaxosmithkline believe competitive position dependent discovery development new product metabolic gastrointestinal effective marketing exist product major competitor avandiais takeda chemicals actos pharmaceutical industry introduction new product copromote eli lilly usa gastrointestinal process competitor affect pricing level result market zantacface significant competition omeprazole product replacement assurance proton pump inhibitor generic ranitidine hydrochloride glaxosmithkline product outmoded notwithstanding patent trademark protection addition vaccine increase government pressure physician glaxosmithkline major competitor vaccine market include patient use generic pharmaceutical brandname aventis pasteur merck wyeth engerixband havrixcompete medicine increase competition product go vaccine produce merck comvax recombivax hb patent hepatitis b vaqta hepatitis infanrixsmajor competitor aventis pasteur tripedia trihibit wyeth acelimune cns disorder tetramune major competitor paxilin selective serotonin reuptake inhibitor ssri market prozac eli lilly generic fluoxetine competition consumer healthcare available august zoloft pfizer forest laboratory celexa success seroxatpaxilhas major competitor consumer healthcare market target generic manufacturer glaxosmithkline major international company procter gamble colgate continue respond appropriately note financial palmolive american home product unilever johnson statement legal proceeding johnson addition large small company compete glaxosmithkline select market imigranha grow glaxosmithkline lead product address previously unmet need migraine usa major competitor product overthecounter sufferer company launch compete otc medicine tylenol cold cold remedy clearasil acne product new formulation imigransuch nasal spray treatment pepcid indigestion private label smoking cessation introduction naramighave help glaxosmithkline product uk major competitor product lemsip cold retain lead competitor migraine market remedy nurofen anadin analgesic nicotinell smoking maintain growth cessation remedy oral care colgatepalmolive procter gamble unilever respiratory major international competitor combine performance glaxosmithkline flixotide serevent recently launch seretideadvair continue drive nutritional healthcare major competitor horlicksare growth market establish product ventolin ovaltine milo malt food chocolate drink competitor becotidehave face generic competition year ribenaare primarily local fruit juice product lucozade maintain significant sale major competitor compete energy drink glaxosmithkline respiratory product usa singulair glaxosmithkline hold lead global position key merck consumer product area second large company worldwide otc medicine oral care fifth large company worldwide nutritional healthcaredescription businessglaxosmithkline regulation pharmaceuticals usa debate reform healthcare system result increase focus pricing international pharmaceutical industry highly regulate currently government price control private sector purchase national regulatory authority administer panoply law usa federal legislation require pharmaceutical manufacturer andregulation govern testing approval manufacturing pay prescribe rebate certain drug enable label marketing drug review safety eligible reimbursement medicaid healthcare programmes andefficacy pharmaceutical product regulatory requirement major factor determine substance pharmaceutical market worldwide continue develop marketable product experience increase pressure pricing reimbursement time expense associate development government healthcare provider nonprice factor new product high volume principally drive particular importance requirement country growth pharmaceutical expenditure product authorise register prior marketing authorisation registration maintain subsequently europe historically affect government regulation pricing reimbursement pharmaceutical industry continue national regulatory authority jurisdiction include experience pressure price range measure usa european union japan australia high include acrosstheboard price cut link price lowcost standard technical appraisal consequently introduction country price referencing delay agree reimbursement new pharmaceutical product generally entail lengthy increase pressure generic substitution approvalprocess country crossborder import fromlowprice market exert european union procedure obtain commercial pressure incountryprice marketing authorisation medicinal product japan discussion ongoing new price centralise procedure application direct reimbursement control government introduce theeuropean medicine evaluation agency lead authorisation valid member state compulsory value money product derive biotechnology optional new increasingly necessary demonstrate value activesubstance innovative medicinal product formoney new product particular impact drug mutual recognition procedure applicable budget expenditure burden disease majority conventional medicinal product operate mutual treat market need satisfy healthcare purchaser recognition national marketing authorisation value money additional hurdle product agreement reach resolve procedure acceptance regulatory test ofsafety efficacy bind arbitration quality delay bring effective improve medicine market reduce effective patent grant marketing authorisation afford company datum protection time protection period competitor rely confidential datum regulatory file basis market increasingly difficult significant marketing authorisation datum protection period begins improve therapy obtain premium price exist thedate authorisation grant european union medication philosophy found valuebase pricing andexpire year authorisation grant difficult follow circumstance usa centralised procedure year authorisation possible price product reflect value grantedvia mutual recognition procedure depend onthecountry concern future development possible predict extent international market ie country outside usa europe groupsbusiness affect future legislative regulation regulatory environment continue regulatory development relate specific pharmaceutical extremely varied challenging product pricing product glaxosmithkline anticipate introduction new product continue require substantial effort time expense regulation consumer healthcare comply regulatory requirement consumer healthcare industry subject national regulation testing approval manufacturing labelling price control marketing product country high standard addition form regulation refer technical appraisal entail lengthy approval process new manycountries price pharmaceutical product control product launch law national regulatory authorisation require approve government influence price pharmaceutical switch product prescription otc requirement product control national healthcare organisation include longterm experience quality safety efficacy bear large cost supply product oftheproduct wide patient population datum confirm consumer thatthe relevant condition selflimite easily country france japan prices individual diagnose bythe consumer product regulate uk price control reference limit overall profitability measure rate return capital employ sale product supply national healthservice glaxosmithkline description business operating activity marketing distribution directtoconsumer dtc advertise major component product marketing usa dtc advertisement glaxosmithkline sell product worldwide primary source information patient request specific brand extensivenetwork subsidiary licensee distributor product physicians usa gross profit margin earn sale pharmaceutical outside usa dtc prohibit limited product generally higher earn sale rolein inform patient european union canada consumer product reflect risk uncertainty dtc currently prohibit australia government allow dtc inherent develop marketing pharmaceutical risk advertise pharmacyonly product subject certain safeguard include high level research development expenditure new zealand dtc allow selfregulated industry require discover test obtain patent protection new collaboration advertising standard agency product competition new generic product market allow dtc date impact limit glaxosmithkline worldwide business subject number addition direct marketing product subsidiary risk inherent conduct business certain country include glaxosmithkline enter agreement withother possible nationalisation expropriation restrictive pharmaceutical company comarkete copromotion government action capital regulation addition currency product market fluctuation change economic condition occur time time favourable unfavourable marketing distribution consumer healthcare effect trading income glaxosmithkline regard factor deterrent expansion international principal market consumer healthcare otc medicine operation company closely review method usa uk germany australia argentina italy mexico operation particularly develop country develop japan canada france nutritional drink business strategy respond change economic political condition particularly strong uk ireland india range product available market principal market marketing distribution pharmaceutical oral care product germany uk analysis total pharmaceutical sale include otc oral care product primarily distribute divested product geographic region set pharmacy mass market outlet directly wholesaler nutritional healthcare product distribute similar sale geographic region extensive retail wholesale network usa europe manufacture supply rest world glaxosmithkline large portfolio product range asia pacific tablet toothpaste inhaler complex capsule japan different pack size presentation latin america middle east africa manufacture medicine begin development canada therapeutic active ingredient bulk active select formulation global manufacture supply gms develop manufacturing process scale volume production active compound glaxosmithkline sell prescription medicine primarily primary manufacturing site convert active compound wholesale drug distributor independent chain retail finish dosage formulation responsibility secondary pharmacy physician hospital clinic government entity manufacturing site institution product ordinarily dispense follow merger glaxo wellcome smithkline public pharmacy prescription write physicians beecham december gms operate single global usa world large pharmaceutical market network site country employ pressureto contain healthcare cost encourage growth people year gms produce tonne bulk manage care organisation pharmacy benefit manager active billion pack package intermediary use range method low cost include deliver sale country world substitution generic product cheap therapy support approximately new product line extension brand product prescribe doctor glaxosmithkline contract launch year manage care sector increase importance gms focus deliver supplier healthcare community secure source supply high quality product market glaxosmithkline deploy salesforce compliance regulatory requirement customer representative support medical staff promote expectation prescription product medical prescriber healthcare good class cost purchaser personal visit lead edge practice performance site promotion glaxosmithkline product supplement procurement global function scientific seminar advertise medical journal television advertising provision sample direct mailing ofprinte material information contain company site world wide webdescription businessglaxosmithkline organisation network rationalisation plan production cease gms operation structure supply chain region site seven country include hungary sri lanka taiwan disposal closure site antibiotic supply chain announce year global organisation site spread country total staff employ external supplier site broad range antibiotic product procurement global function support function area manufacture package glaxosmithkline business manufacture large area billion spend external supplier actives supply chain year include purchase active ingredient chemical active ingredient nonantibiotic product produce intermediate finish finish product gms take site network locate australia india ireland appropriate step protect supply chain disruption singapore uk usa approximately staff result interrupted external supply appropriate stock employ manufacturing supply active ingredient level contract alternative register supplier secondary pharmaceutical site region research development pharmaceutical european region global biological pharmaceutical research site european region spread seven development rd function glaxosmithkline responsible country employ people total discover develop registering commercialise support european site manufacture nearly major effective marketing innovative prescription medicine vaccine pharmaceutical product market globally glaxosmithkline delivery system treatment prevention human wide variety finish dosage form disease north america region fundamental goal thorough understand pharmaceutical site north america region disease investigation increasingly involve pioneer work locate puerto rico canada usa site employ ingenetic predictive medicine traditional staff research discipline pharmacology medicinal chemistry addition work create new medicine vaccine international region extensive effort gain clear understanding international region comprise manufacture site unmet need patientsand healthcare provider payer country spread distinct area employ contribution overall direction rd people site middle eastafrica site glaxosmithkline invest billion spread asia pacific area site china japan pharmaceuticals rd approximately staff involve seven latin america biological pharmaceutical rd activity site worldwide include vaccine supply chain vaccine production locate principally rixensart belgium uk beckenham brentford cambridge dartford dresden germany site employ staff greenford harlow stevenage tonbridge ware vaccine production operate separate network welwyn garden city usa bristol tennessee philadelphia upper merion consumer healthcare supply chain upper providence pennsylvania research triangle consumer healthcare manufacturing site spread park north carolina country employ staff seven site belgium rixensart add result january acquisition block drug canada mississauga incorporate supply organisation france les ulis evreux consumer healthcare supply chain diverse include italy verona manufacture supply otc medicine oral care nutritional japan tsukuba science city takasaki healthcare smoking cessation product spain tres cantos madrid year merger integration rd undergone glaxosmithkline integration significant change despite progress portfolio glaxo wellcome strategic master plan smp maintain range product therapeutic smithkline beecham global supply initiative gsi programme area deliver market extensive focused improvement overall site network programme regulatory submission market worldwide consolidate glaxosmithkline programme continue progression portfolio development cycle addition unprecedented inlicense initiative long term integrate change programme call global strengthen pipeline particularly later stage practical supply network gsn structured deliver benefit management portfolio compound development major stream activity focus ensure glaxosmithkline rd invest resource project achieve optimum value reduction site infrastructure cost procurement initiative continue network rationalisation logistic improvement operational excellence lean sigma improvements glaxosmithkline description business product development pipeline product development pipeline set show considerable breadth depth end glaxosmithkline pharmaceutical vaccine project development clinic key date submission date regulatory approval maa eu approval letter al approvable letter compound type indication phase maa nda antimicrobial host defence sb antifactor ix monoclonal antibody severe sepsis septic shock stroke augmentingranule beta lactam antibiotic respiratory tract infection na incl penicillinresistant pneumoniae modify release granule formulation augmentin beta lactam antibiotic respiratory tract infection incl penicillinresistant pneumoniae daily formulation gr phospholipid antiendotoxin emulsion sepsis ii sitamaquine unknown treatment visceral leishmaniasis iii na tafenoquine sb aminoquinoline malaria prophylaxis adult iii lapdap antifolate treatment uncomplicate malaria iii na oxibendazole polymerase inhibitor treatment adult paediatric helminth iii na intestinal infection augmentin es beta lactam antibiotic acute otitis medium incl penicillinresistant iii na pneumoniae highdose chewable tablet augmentin xr beta lactam antibiotic respiratory tract infection incl penicillinresistant submit sdec sdec pneumoniae modify release formulation factive broad spectrum fluoroquinolone antibiotic respiratory urinary tract infection oral formulation submit sfeb sdec antiviral gw hiv integrase inhibitor hiv infections ii ziagenepivir reverse transcriptase inhibitor hiv infection combination tablet iii gw protease inhibitor agenerase prodrug hiv infection iii valtrexzelitrex nucleoside analogue hsv suppression immunocompromise patient iii na valtrexzelitrex nucleoside analogue prevention hsv transmission iii valtrexzelitrex nucleoside analogue cold sore submit na snov epivir reverse transcriptase inhibitor hiv infection daily dosing approve anov saug zeffix reverse transcriptase inhibitor paediatric hepatitis b approve sjun aaug cardiovascular urogenital gw peroxisome proliferatoractivator receptor dyslipidaemia ppar agonist gw ppar agonist dyslipidaemia sb antifactor ix monoclonal antibody stroke severe sepsis septic shock sb lppla inhibitor atherosclerosis gw thrombin inhibitor prevention stroke secondary atrial fibrillation ii prevention treatment venous thrombosis gw angiotensin convert enzymeneutral hypertension ii endopeptidase inhibitor talnetant sb tachykinin nk antagonist urinary incontinence irritable bowel syndrome ii copd cough schizophrenia sb indirect thrombin inhibitor prevention stroke secondary atrial fibrillation ii prevention treatment venous thrombosis sb ht antagonist atrial fibrillation ii sb potassiumcalcium channel blocker cardiac arrhythmia ii dutasteride gi alpha reductase inhibitor alopecia bph ii natrecornesiritide recombinant betatype natriuretic peptide acute heart failure iii na pritortelmisartan angiotensin ii antagonist hypertension combination hydrochlorothiazide submit sapr na vardenafil pdev inhibitor erectile dysfunction submit sjan ssep dutasteride alpha reductase inhibitor benign prostatic hyperplasia alopecia approve ssep anov coreg beta blocker severe heart failure approve na anov metabolic musculoskeletal gi ccka agonist obesity gw beta adrenergic agonist type diabete sb beta adrenergic agonist type diabete obesity gw u noradrenaline reuptake inhibitor obesity attention deficit hyperactivity disorder ii tbd ibandronate bisphosphonate rd generation postmenopausal osteoporosis iii avandiametformin ppar gamma agonist plus metformin type diabete combination tablet avandia ppar gamma agonist type diabete combination insulin submit alfebdescription businessglaxosmithkline compound type indication phase maa nda neurology gastrointestinal sb corticotropin releasing factor crfr irritable bowel syndrome anxiety depression antagonist sb tr dual alpha integrin antagonist vla multiple sclerosis ms inflammatory bowel disease asthma ra gw adenosine antagonist neuropathic pain migraine sb p kinase inhibitor inflammatory bowel disease ra talnetant sb tachykinin nk antagonist irritable bowel syndrome urinary incontinence copd cough gw cox inhibitor second generation pain include inflammatory pain sb ht antagonist alzheimer disease sb yh reversible proton pump antagonist gastroesophageal reflux disease sb endothelin antagonist haemorrhagic ischaemic stroke ii sb benzodiazepine inverse agonist alzheimer disease vascular dementia ii carabersat sb benzopyran epilepsy migraine ii imigranimitrex ht agonist migraine needlefree injection ii requip nonergot dopamine agonist parkinson disease control release formulation ii requip nonergot dopamine agonist restless leg syndrome iii lotronex ht antagonist irritable bowel syndrome submit na sdec snda imigranimitrex ht agonist adolescent migraine nasal formulation submit sfeb sdec oncology sb recombinant human interleukin immunologicallysensitive cancer melanoma renal cell immunomodulator gw erbb egfr dual kinase inhibitor solid tumour sb grot cxc chemokine prevention chemotherapyinduce cytopaenia gw multidrug resistancebreast cancer solid tumour resistant protein inhibitor sb tumour activate prodrug colorectal cancer second line therapy pancreatic maytansineantibody conjugate cancer line therapy repifermin keratinocyte growth factor mucositis wound care inflammatory bowel disease ii ethynylcytidine sb selective rna polymerase inhibitor solid tumours ii hycamtin topoisomerase inhibitor small cell lung cancer line therapy ii hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation hycamtin topoisomerase inhibitor ovarian cancer line therapy iii navelbine vinca alkaloid nonsmall cell lung cancer oral therapy iii na bexxar iradiolabelle antib monoclonal nonhodgkin lymphoma submit na ssep antibody psychiatry gw noradrenalinedopamine reuptake depression bipolar disorder inhibitor talnetant sb tachykinin nk antagonist schizophrenia urinary incontinence irritable bowel syndrome copd cough sb corticotropin releasing factor crfr anxiety depression irritable bowel syndrome antagonist gw glycine antagonist smoking cessation gw nk antagonist depression anxiety sb ht antagonist schizophrenia alzheimer disease ii vilazodone sba ssri ht partial agonist depression ii emd lamictal sodium channel inhibitor bipolar disorder acute treatment iii na lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis iii wellbutrin xl bupropion aminoketone depression cr formulation daily dose iii seroxatpaxil cr selective serotonin reuptake inhibitor premenstrual dysphoric disorder pmdd iii tbd control release formulation seroxatpaxil cr selective serotonin reuptake inhibitor panic disorder control release formulation submit tbd afeb seroxatpaxil selective serotonin reuptake inhibitor posttraumatic stress disorder ptsd approve asep adec glaxosmithkline description business compound type indication phase maa nda respiratory inflammation sb p kinase inhibitor rheumatoid arthritis ibd gw alpha integrin antagonist inhale asthma upper respiratory inflammatory disease urid sb osteoclast vitronectin antagonist rheumatoid arthritis sb tr dual alpha integrin antagonist vla asthma rheumatoid arthritis ms ibd gw adenosine agonist asthma chronic obstructive pulmonary disease ii copd urid talnetant sb tachykinin nk antagonist copd cough urinary incontinence ii irritable bowel syndrome schizophrenia mepolizumab sb antiil monoclonal antibody asthma atopic dermatitis ii ariflo pde iv inhibitor copd iii flovent inhale corticosteroid asthma daily dosing submit na soct flixotideflovent inhale corticosteroid copd approve asep smay noncfc meter dose inhaler propellant gr serevent beta agonist asthma copd iii flixotideflovent inhale corticosteroid asthma copd approve aapr sfeb seretideadvair beta agonistinhale corticosteroid asthma approve ajun aloct diskusaccuhalerdry powder inhaler seretideadvair beta agonistinhale corticosteroid adult paediatric asthma daily dose iii seretideadvair beta agonistinhale corticosteroid copd submit ssep smay seretideadvair beta agonistinhale corticosteroid asthma line therapy submit sjun sapr serevent beta agonist copd submit smay ventolin beta agonist asthma approve adec aljul hepatitis vaccine hepatitis e recombinant hepatitis e prophylaxis ii extra strength hepatitis b recombinant extra strength hepatitis b prophylaxis iii tbd poornonresponder twinrix dose recombinant combine hepatitis b prophylaxis childadolescent submit sjun paediatric vaccine rotarix live attenuate oral rotavirus prophylaxis ii n meningitidis ac conjugate meningitis prophylaxis ii meningitis b cuba subunit meningitis b prophylaxis ii tbd pneumoniae paediatric conjugate pneumoniae disease prophylaxis child iii mmrvaricella live attenuate measle mump rubella varicella prophylaxis iii tbd infanrix pentahepbipv recombinant diphtheria tetanus pertussis hepatitis b inactivated polio prophylaxis approve aoct sjul infanrix hexahep b conjugatedrecombinant diphtheria tetanus pertussis hepatitis b approve aoct tbd ipvhib inactivated polio prophylaxis haemophilus influenzae type b prophylaxis vaccine new influenza subunit influenza prophylaxis new delivery hiv recombinant hiv prophylaxis pneumoniae elderly conjugate pneumoniae disease prophylaxis epsteinbarr virus recombinant ebv prophylaxis ii malaria recombinant malaria prophylaxis ii human papilloma virus recombinant prophylaxis hpv infection ii simplirix recombinant genital herpe prophylaxis ii boostrix subunit adolescentadult booster diphtheria tetanus approve aoct pertussis pharmaccine gwpowderject recombinant hepatitis b treatment sb recombinant treatment chronic hepatitis b ii sb recombinant treatment lung cancermelanoma ii joint venture shionogi license agreement scios inc copromotion bayer ag codevelopment copromotion roche content drug development portfolio change time new compound progress discovery development development market owe nature drug development process unusual compound especially early stage investigation terminate progress development competitive reason new project preclinical development disclose project type identifieddescription businessglaxosmithkline compound progress phase clinical development discovery project list table progress nonclinical safety testing early phase clinical development compound continue rigorous nonclinical clinical commercial assessment lead proof concept decision month compound mechanism indication sb p kinase inhibitor rheumatoid arthritis asthma exacerbation inflammatory bowel disease gw adenosine aa agonist intranasal upper respiratory inflammatory disease gw noradrenalinedopamine reuptake inhibitor unipolar depression bipolar disorder sb lipoproteinassociate phospholipase inhibitor atherosclerosis sb interleukin melanoma carcinoma gw adenosine agonist migraine neuropathic pain gw alpha integrin antagonist asthma inhale upper respiratory inflammatory disease gw peroxisome proliferator activator receptor agonist dyslipidaemia sb corticotropinrelease factor antagonist unipolar depression anxiety irritable bowel syndrome augmentin betalactam antibiotic betalactamase inhibitor oncedaily treatment bacterial infection carabersat gap junction modulator epilepsy migraine prophylaxis product approval submission approval receive number new product include significant new indication formulation exist product summarise table countryregion product approval date description alkeran usa reformulate tablet cytotoxic melphalan cancer augmentin es usa june paediatric high dose mgml suspension formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor acute otitis media becotide europe july noncfc metereddose device inhalation delivery corticosteroid treatment asthma boostrix european country combine diphtheria tetanus acellular pertussis vaccine january november booster indication coreg usa november betablocker carvedilol treatment severe heart failure deroxat seroxat france selective serotonin reuptake inhibitor treatment social anxiety disorder dutasteride usa november alpha reductase inhibitor benign prostatic hyperplasia epivir europe november daily presentation reverse transcriptase inhibitor lamivudine hiv flixonase europe intranasal formulation corticosteroid fluticasone propionate treat sinus pain pressure influenza vaccine europe july august influenza vaccine strain prevalent malarone europe april combination atovaquone proguanil malaria prophylaxis paxilseroxat usa april selective serotonin reuptake inhibitor treatment generalise european country anxiety disorder incl uk marchsept paxilseroxat european country selective serotonin reuptake inhibitor treatment posttraumatic incl uk februaryjuly stress disorder usa december seretide europe januaryjune combination salmeterol fluticasone propionate noncfc meter dose inhaler treat asthma twinrixadult usa combine hepatitis b vaccine adult ventolin usa april noncfc metereddose inhaler formulation bronchodilator salbutamol treat asthma zeffix usa august reverse transcriptase inhibitor lamivudine treatment hepatitis b paediatric use glaxosmithkline description business number significant regulatory submission set product region description ambirix europe combine hepatitis b vaccine twodose treatment regimen dutasteride europe alpha reductase inhibitor benign prostatic hyperplasia dutasteride usa alpha reductase inhibitor year datum benign prostatic hyperplasia epivir usa lamivudine reverse transcriptase inhibitor daily treatment hiv flovent usa fluticasonepropionate inhale corticosteroid daily dose asthma flovent usa treatment chronic obstructive pulmonary disease myleran usa new tablet formulation busulphan cancer seretideadvairdiskus europe usa combination salmeteroland fluticasonepropionate diskusas line therapy asthma seretideadvair diskus europe usa treatment chronic obstructive pulmonary disease serevent diskus usa salmeterolfor treatment chronic obstructive pulmonary disease telmisartan hydrochlorthiazide europe fixeddose combination telmisartan angiotensin ii antagonist hydrochlorthiazide diuretic hypertension ultiva europe remifentanil shortacting opioid use anaesthetic intensivecare unit valtrex usa valaciclovir nucleoside analogue treatment cold sore zeffix europe usa lamivudine reverse transcriptase inhibitor paediatric treatment hepatitis b inlicense establish joint venture shionogi complete focus identify compound joint venture exclusive right develop commercialise enhance exist future franchise create innovative select compound contribute company initial collaboration ensure glaxosmithkline regard compound provide shionogi gw partner choice large small company follow hiv integrase inhibitor hiv infection phase ii compound subject inlicense copromotion deal sb benzodiazepine partial inverse agonist alzheimer disease vascular dementia phase ii sb endothelina receptor antagonist treat sba mixed selective serotonin reuptake inhibitor haemorrhagic ischaemic stroke phase ii hta receptor partial agonist phase ii depression sb ampanmda antagonist stroke head license merck kgaa injury preclinical development grx phospholipid antiendotoxin emulsion phase ii sepsis inlicense sepsicure sb kinesin spindle protein inhibitor treatment controlledrelease formulation bupropion wellbutrin cancer inlicense alliance cytokinetic phase iii development oncedaily treatment depression centre therapeutic target mitotic kinesin inlicense biovail agreement sign tanabe seiyaku broad ibandronate bisphosphonate phase iii development range global collaboration research development osteoporosis codevelopment copromotion commercialisation series tanabe preclinical compound hoffmanla roche covering range potential therapeutic area include vardenafil selective phosphodiesterase inhibitor male psychiatry neurology urology diabete erectile dysfunction copromoted bayer ag nesiritide natrecor btype natriuretic peptide phase iii research development collaboration drug treatment acute heart failure inlicense europe delivery system dd division initiate formulate novel scios inc drug fight respiratory disease asthma chronic obstructive pulmonary disease copd addition broad collaborative initiative complete provide inlicensed compound agreement reach inex pharmaceutical corporation develop targeted cancer drug encapsulate glaxosmithkline sign worldwide development glaxosmithkline proprietary camptothecin anticancer agent commercialisation agreement neurocrine bioscience inside inexs drug delivery technology call transmembrane corticotropin releasing factor receptor antagonist crfr carrier system drug develop inex crfr entirely new class compound treat psychiatric hycamtin neurological gastrointestinal disease include anxiety depression mood disorder irritable bowel syndrome neurocrine lead crfr antagonist sb currently phase developmentdescription businessglaxosmithkline rd process discovery commercialisation delivery regard integrate new product development function combine responsibility clinical regulatory commercial activity necessary bring new medicine marketplace similarly creation new product supply organisation bridge traditional divide development manufacturing taking responsibility scaleup production centre genetic preclinical subsequent manufacture physical product research excellence development new important step glaxosmithkline rd japan future medicine prove fully integrate company global development drug discovery discovery new product value commercialisation process order eliminate work duplication research development cedd speed regulatory filing plan rationalise discovery work japan tsukuba site development takasaki facility agree continue focus optimise operational effectiveness rd glaxosmithkline complete sale affymax drug discovery operation base santa clara california syndicate venture capital firm rd close site renne france acquire bioproject milan intellectual property validate target drug product italy location nikem research new company lead create demerger local glaxosmithkline medicinal chemistry group rd process line glaxosmithkline strategic intent early research role genetic indisputable leader industry rd set goal early stage find new medicine require essentially productive rd organisation industry component target show affect mechanism important pathological process human disease ie target glaxosmithkline rd measure productivity compound typically small molecule include number innovativeness product create macromolecule protein therapeutic vaccine able value commercial value measure product ability modulate behaviour target glaxosmithkline heritage address unmet need healthcare customer include smithkline beecham glaxo wellcome genomics patient healthcare professional budget holder regulator genetic research mean company wellplaced select perspective constitute valuable human genome subset therapeuticallyrelevant new product rd position ensure generate target focus earlystage research effort right information respond different perspective ie safety efficacy quality information data target validation process glaxosmithkline aim demonstrate overall reduction healthcare utilisation identify gene relevant common disease large result use new medicine increase length quality unmet medical need asthma noninsulin dependent life increase workplace productivity diabetes migraine osteoarthritis metabolic syndrome depression chronic obstructive pulmonary disease early onset heart disease order implement operationally drive product value alzheimer disease disease arise complex primary objective rd glaxosmithkline interaction number gene variant environmental implement rd process devise merger factor challenge involve unravel picture planning period especially design eliminate underestimate identify gene traditional barrier successful rd successful predispose patient particular disease understand commercialisation allow value asset role disease progression lead identification new way maximise consistent prioritisation strategic direction intervene disease earliest stage rd product launch subsequent lifecycle management discovery research key glaxosmithkline rd organisation development purpose discovery research dr identify lead design philosophy enable leverage critical compound form basis new drug discovery effort mass area research clinical development centre excellence drug discovery cedd investment create strategic advantage focus agile structure dr focus improve quality number drug discovery commensurate entrepreneurial approach lead compound produce end rd begin build new ensure efficient rapid validation lead candidate automation facility tre canto harlow preclinical testing proof concept criterion complete plan facility upper providence conduct pharmacological exploration effect new compound similar speed capacity degree automation challenge substantive progress implement high throughput biology plan new discipline help determine relevant therapeutic application new drug modulate pathological mechanism underpin different disease glaxosmithkline description business crucial success rd capacity embrace preclinical development develop new technology streamline drug discovery process scientific technical activity support work establishment new technology development discovery research cedd new product development organisation rd abreast emerge technology collect preclinical development grouping advance creation new medicine evaluate encompasse discipline develop understanding technology provide investment knowledge compound absorb body pharmacokinetic require develop select technology good advantage pharmacology metabolise rd generate modify technology focus establish probability shortterm longterm glaxosmithkline internal goal maximise toxicological effect additionally chemical development return rd asset sale spinout outlicense division responsible definition efficient synthesis mechanism candidate molecule minute quantity centres excellence drug discovery require initial testing appropriate scale support crucial step convert lead compound drug commercialisation pharmaceutical development final candidate optimise lead potency selectivity dosage form testing establish optimum quality standard efficacy safety intrinsic characteristic molecule storage condition experience world ii demonstrate validity therapeutic hypothesis perform organisation early clinical trial result candidate molecule efficient delivery rapid worldwide uptake new merger glaxosmithkline establish innovative product closely link ease manufacture issue cedd responsibility lead optimisation scaleup manufacturing technology consider proof therapeutic concept focus specific disease early stage product development process move area cedd design nimble entrepreneurial smallscale production experimental material early largely autonomous matrix team range skill scale clinical study largescale industrial manufacturing resource require drive midstage development project product supply fast efficient responsibility key decisionpoint major investment new product supply partnership rd global fund largescale phase iii clinical trial manufacturing supply partnership ensure disease responsibilitie usa base cedds development organisation deliver product align order increase focus increase optimise term largescale commercial manufacturing efficient use resource new product development cardiovascular urogenital disease centre upper merion provide focus development commercialisation metabolic viral disease centre research triangle park process proceed unison major functional microbial musculoskeletal proliferative disease include component medical regulatory product strategy cancer centre upper merion upper providence integrate single management organisation cedd complement europe crossfunctional therapeutic area strategy team cover group disease neurology centre harlow uk psychiatry centre verona italy cardiovascular urogenital metabolic respiratory inflammation respiratory pathogen centre infectious disease include develop world disease stevenage uk neurology gastrointestinal oncology musculoskeletal inflammation cedd autonomy include freedom select new psychiatry compound internal external source respiratory reinforce close integration glaxosmithkline inlicense function business development rd organisation matrix team responsible maximise worldwide cedd responsible select optimal candidate development opportunity product remit series similar chemical compound ensure work ensure alignment regional marketing candidate safe animal model develop need clinical commercial information generate technical perspective achieve cedd new product develop team collaborate responsible proving compound safe efficacious early stage cedd define target product profile patient proofofconcept provisionofconfidence decision new molecule integrate technical development point decision basis information manufacturing function ensure rapid effective launch generate date progress compound late stage drug delivery product development necessary largescale clinical trial genetic research highly informative stage conduct successfully register commercialise product drug candidate enter clinical trial launch point responsibility project pass crossfunctional extensive use bring research team lead member new product development elucidate genetic basis underpin variable response glaxosmithkline major response challenge regard therapeutic efficacy sideeffect see disease affect develop world microbial musculoskeletal medicine know enable healthcare provider proliferative disease cedd responsibility new drug prescribe medicine accurately safely discovery unit base tre canto spain dedicated find new medicine treat diseasesdescription businessglaxosmithkline discontinuation animal research research development carry risk failure commensurate ethical regulatory scientific reason research animal extension scientific knowledge compound remain small vital research development effect lead compound identify possess new medicine vaccine animal positive activity validate target prove safe alternative available glaxosmithkline constantly aim introduce human feasible manufacture reduce number glaxosmithkline strive exceed commercial scale glaxosmithkline rd endeavour ensure industry standard care welfare animal use far possible risk ameliorate extensive predictive laboratory animal usually breed specifically research testing early possible development process care life qualified train staff number new activity genetic research discovery animal research unnecessary pain suffer research preclinical development initiate establish isscrupulously avoid validate leadingedge predictive toxicology enable glaxosmithkline actively engage research develop optimisation early portfolio inform decision validate experimental method provide well make prior largescale investment effort resource alternative use animal research despite effort ultimate test product remain point administer large number patient glaxosmithkline acknowledge use animal research disease purpose subject enormous sensitivity rightly command high level public interest glaxosmithkline public review datum phase iiia trial tranilastshowed policyposition care ethical use animal research benefit placebo development compound isavailable public company internet site place wwwgskcomtomorrowanimalshtm request review datum gi peroxisome proliferator activate company secretary receptor ppar agonist phase iii clinical trial treatment type diabete indicate meet target profile research development consumer healthcare establish development product principal centre consumer healthcare research diabetes terminate work ongoing development uk usa focus rd indication identification rapid development novel product latestage project terminate bring significant health benefit consumer otc oral care development micronise preparation nonsteroidal nutritional healthcare market consumer healthcare liaise antiinflammatory drug nabumetone treat osteoarthritis closely pharmaceutical maximise group asset pain therapeutic antigen disabled infection single cycle prescription product find application otc vaccine treatment herpe nebuliser formulation marketplace flixotide inhale corticosteroid fluticasone propionate acute paediatric asthma research collaboration glaxosmithkline enter number agreement party codevelop comarket certain compound arrangement range milestone payment party acquire right intellectual property joint venture develop commercialise specify compound agreement group obligation payment future specify milestone achieve financial commitment summarise note financial statement commitment vaccine rd worldwide vaccine rd conduct biological team locate principally rixensart belgium pharmaceutical sector team follow essentially similar approach development vaccine glaxosmithkline description business operating resource intellectual property lamictal patent active ingredient lamotrigine expire usa virtue paediatric glaxosmithkline regard intellectual property key business exclusivity bin europe asset effective legal protection intellectual property key element ensure effective return investment retrovirbasic patent active ingredient zidovudine rd intellectual property protect patent trade mark expire patent cover pharmaceutical formulation contain register design copyright domain registration zidovudine medical use expire glaxosmithkline regard patent trade mark rights usa europe particularly valuable epivirthe patent active ingredient lamivudine expire usa bin europe patent glaxosmithkline policy obtain patent protection combivirthe patent specific combination lamivudine significant product discover develop rd zidovudine expire usa activity patent protection new active ingredient available bin europe significant market addition protection obtain valtrex patent active ingredient valaciclovir new pharmaceutical formulation manufacturing process expire usa bin europe new medical use special device administer product ziagen patent active ingredient abacavir expire usa bin europe glaxosmithkline continue patent protection form key pharmaceutical product major market zofran patent active ingredient ondansetron addition obtain patent anticipate patent expire usa bin europe protection grant new product patent use emesis expire glaxosmithkline development initiate legal action patent generic manufacturer patent position respect significant product follow seretideadvairthe patent specific combination active paxilseroxatthe patent protect commercial form ingredient salmeterol fluticasone propionate paxilseroxatis expire major market expire usa bin europe glaxosmithkline initiate patent infringement litigation usa europe number generic avandiathe patents active ingredient rosiglitazone maleate manufacturer attempt launch version expire usa bin europe product prior patent expiry serevent patent active ingredient salmeterol xinafoate augmentinthe basic patent key active ingredient potassium expire bin europe b france clavulanate expire market usa bin italy usa italy patent provide protection common company glaxosmithkline currently legal challenge court routinely engage legal dispute defence patent right flixotidefloventand flixonaseflonasein usa patent product note financial statement legal active ingredient fluticasone propionate expire proceeding protection expect extend virtue paediatric exclusivity european country patent trade mark expire b glaxosmithkline pharmaceutical product protect register trade mark major market general mark wellbutrin sr andzybanpatent basic active ingredient product market world expire formulation patent protect currently local variation example united states trade market sr formulation late expire mark paxili instead seroxatand advairis instead usa patent legal challenge seretide uscourts europe regulatory datum exclusivity additionally provide protection trade mark protection generally extend long country trade mark renew necessary glaxosmithkline trade mark pharmaceutical product generally zinnatceftin patent active ingredient cefuroxime assume increase importance patent product axetil generally expire expire expire particular country generic version european country patent extend product available patent specific amorphous form glaxosmithklineproduct expire consumer healthcare business trade mark particularly glaxosmithkline initiate legal action important business brand orientate patent generic manufacturer usa products patent protection imigranimitrex patents active ingredient sumatriptan glaxosmithkline routinely engage legal dispute defence expire usa bin europe trade mark right take action company find infringe version product include extension term b include extension term supplementary protection certificatedescription businessglaxosmithkline information technology enhance business performance virtually glaxosmithkline major business process rely heavily information technology play strategic role use information technology major programme glaxosmithkline capture key information source electronic form facilitate communication access information available require global basis improve quality potential value molecule support key business process local regional discovery development key aim rd functional global level develop webbase tool provide chemist biologist enable transformation extension key business information need candidate medicine activity information target molecule computer infrastructure hardware software test result obtain unique organisation responsible voice video technology molecule molecule similar monitoring business technology trend characteristic way earlyphase rd team draw impact glaxosmithkline prepare company short list molecule consideration possible treatment risk associate modern information technology specific disease fast confidence quality shortlist area rd play year focus help business unit important role highthroughput biology laboratory automation achieve merger synergy establish network image electronic datum capture document knowledge system new company possible clinical datum management legacy company system select glaxosmithkline combination complete critical system integration work begin extend manufacturing enterprise resource meet synergy target remain high priority planning solution year ability theshortterm consolidate mission critical operation way reflect grow availability reliability global data network consumer healthcare integration block drug ensure glaxosmithkline compliant system place business glaxosmithkline system achieve common process sixmonth acquisition lead cent reduction combine cost usa way identify improve speed datum delivery vendor streamline datum process financial data system european country adopt reduce cent time taken provide retail euro base currency convert readiness prescription datum report business result sale january introduction representative manager able fast well inform decision communication access information importance glaxosmithkline internet internal transforming extend business activity intranet continue grow internal website allow information insight gain genomic proteomic transforming share company global basis support way disease target identify validate information search engine analogous externally obtain variety external source need integrate internet ability provide share access information internally generate information rapid flexible manner enable grow use virtual team work rely heavily information technology support analysis collaboratively span multiple geography time zone database require significant amount process subject stringent time constraint glaxosmithkline power take advantage advance computer technology intranet adopt portal strategy order assist employee choose receive information need access information regulatory agency clinical opinion leader healthcare professional patient public information exchange electronically broad array enhance number market step take reduce supplier customer partner protection reliance paper base process clinical trial registration unauthorised access information asset grow risk new medicine use wireless handheld technology pose computer viruse major issue internet telephone video conference familiar aspect business life complement computerbase glaxosmithkline people collaborative work screensharing tool help team glaxosmithkline people fundamental current future respond practical challenge pose operate global success business skill intellect key organisation enable glaxosmithkline knowledge worker component successful implementation sound business productive key goal standard desktop strategy glaxosmithkline human capital maximise adopt globally assist support employee use potential group scientific commercial financial asset software efficiently outcome effective human resource policy glaxosmithkline solid reputation international employer choice employer choice group initiate candidate care commitment seek acquire good employment candidate reflect diversity background experience perspective contribute success glaxosmithkline glaxosmithkline description business performance reward executive development programme design identify importance people translate employment practice prepare talent require grow business worldwide demonstrate value individual compensation programme develop skill area key future business benefit package glaxosmithkline totalreward competitive success entrepreneurialism strategic insight global mindset innovative global local orientation depend crossfunctionalcultural collaboration competitive intelligence well drive business performance reward individual innovative base peer interaction idea exchange contribution contribute strategy deployment compensation philosophy programme development underscore human resource service information system glaxosmithkline commitment performance culture human resource service information deliver performancebase pay base variable share award share low cost highly effective channel easy job option performance development planning evaluation candidate employee retire access information contribute retention key talent superior performance employment compensation benefit policy programme accomplishment business target glaxosmithkline human resource delivery strategy design commitment flexible work flextime teleconferencing technology available today deliver valuable remote working flexible work schedule recognise information employee convenience allow employee work good environment help integrate return work quickly comprehensive content core work personal life transaction deliver intuitive personalise webbase tool available employee location example communication involvement usa employee support employee response extensive range communication programme stimulate center stateoftheart centre provide information involvement glaxosmithkline goal progress include service presentation business result groupwide magazine site newspaper video record voice mail message senior property plant equipment executive officer access glaxosmithkline intranet glaxosmithkline operating establishment country tool facilitate successful integration geographical spread group activity indicate company company note financial statement principal group company share ownership scheme encourage participation owner glaxosmithkline conduct research development business increase awareness short longterm business site manufacture product site objective global local employee opinion survey allow country refer research development pharmaceutical employee opportunity express view perspective manufacture supply important company issue glaxosmithkline invest billion property acarrying value financial statement billion diversity billion carrying value invest plant equipment company wide diversity strategy focus create glaxosmithkline invest billion new andrenewal inclusive work environment benefit employee customer property plant equipment property mainly heldfreehold stakeholder approach aim enhance employee new investment finance exist group liquid resource innovation productivity valuing draw st december group contractual commitment differ knowledge perspective experience style resident future expenditure million operate global community diversity initiative lead lease commitment million corporate executive team jack ziegler president consumer healthcare sponsor key objective create glaxosmithkline business sciencebase technologyintensive communicate diversity strategy measurably improve employee highly regulate governmental authority glaxosmithkline attraction development retention allocate significant financial resource renewal maintenance property plant minimise risk glaxosmithkline remain committed employment policy interruption production achieve compliance discriminate potential exist staff regulatory standard research development ground colour race ethnic national origin gender marital manufacture active pharmaceutical ingredient require use status religious belief disability ofchemical hazardous material glaxosmithkline observe stringent procedure use specialist skill manage leadership development talent management environmental risk activity environmental issue comprehensive leadership development opportunity available date operation modify discontinued employee level opportunity target help reference environmental responsibility leader meet challenge face global economy note financial statement legal proceeding matrixed organisation ensure glaxosmithkline leadership motivate enable team individual good work glaxosmithkline believe facility adequate development planning key element overall performance current need integration glaxo wellcome smithkline planning year beecham operation involve series announcement rationalisation potential disposal number site property consider changesdescription businessglaxosmithkline business community performance integrity integrate environment health safety planning decision make manufacturing process package design product time glaxosmithkline produce social labelling help differentiate product protect extend environmental review entitle performance integrity life incorporate information press issue core business generate significant interest global corporate citizen glaxosmithkline demonstrate external shareholder include medicine develop responsibility implement global standard guideline target world community investment environment health management system auditing report publicly safety performance integrity available openly performance seek dialogue external secretariat company head office company web stakeholder consider view develop approach site wwwgskcom information available ehs management web site constitute document glaxosmithkline operation achieve legal compliance ehs regulation continuously improve performance particularly environmental responsibility area accident prevention waste minimisation environment health safety ehs section performance emission reduction seek align business process ensure integrity incorporate information group ehs incorporate planning decisionmake environmental responsibility cover issue programme budget training communication performance group make ongoing capital expenditure environmental protection equipment cash expenditure environment health safety management site remediation operation maintenance successful management environment health safety high environmental facility anticipate expenditure priority glaxosmithkline company year material impact group capital expenditure primary focus create management organisation cash flow management system integrate concept feature high standard practice heritage company objective metric target represent systematic approach alignment establish broad goal environment health safety international standard start comprehensive ehs policy establishment organisation framework management policy approve glaxosmithkline system new company establish year policy support standard foundation baseline year establish performance level eh management system establish basic requirement intensive consultation process follow establish target operation comply ensure compliance local accomplished end base law regulation guideline give detailed information feasible improvement project specific site opportunity recommend way meet standard development improvement target set individual site roll follow additional technical information training form overall company target result complete framework eh programme associate documentation environment health safety audits glaxosmithkline perform audits select site assess stakeholder dialogue status environment health safety program group extensive internal stakeholder dialogue ehs development glaxosmithkline ehs standard audits programme initiative include target setting process conduct standard establish engage major contributor develop concrete plan heritage company audit protocol follow new improvement group environmental profile standard develop implement glaxosmithkline work key external stakeholder form basis explore iso certification ensure approach ehs meet expectation injury illness environment health safety strategy glaxosmithkline aspire work environment environment health safety consideration integral result injury illness employee target set injury way glaxosmithkline business ehs strategy align illness improvement reduce rate cent business driver embrace principle continuous year baseline end result improvement support corporate social responsibility rate low pharmaceutical industry vital protect health safety employee contractor visitor affect company important issue operation group design facility process conduct issue important glaxosmithkline risk assessment provide training order eliminate work global significance issue relate safety health hazard specific group impact issue include climate change air emission use material resource efficiency process glaxosmithkline product carefully design create company generate handle dispose waste biological change patient result potential ehs risk profile contract manufacturer key supplier public impact lifecycle apply principle issue pharmaceutical environment glaxosmithkline product stewardship organisation deliver positive commitment issue cover webbase social ehs benefit minimise risk principle apply environmental review performance integrity contract manufacturer key supplier glaxosmithkline description business access medicine develop world preferential pricing arrangement glaxosmithkline understand need price reflect far healthcare develop country press problem possible ability purchase offer sustainable widely acknowledge poverty root cause large preferential pricing arrangement develop country part population develop country subsaharan africa vaccine year secure regular access food clean water let hivaid medicine group longterm healthcare services glaxosmithkline vital role play commitment contribution world health develop suitable product make available sustainable preferential price set preferential price encourage support commercially viable level sustain long play company patient need treatment mandate expertise resource address underlie problem exist sector global society government work partnership international agency private sector work significant barrier stand way access improve healthcare develop world medicine develop world tackle share effort backed fund massive scale responsibility sector global society glaxosmithkline welcome creation global glaxosmithkline continue engage stakeholder working fund fight aid tb malaria gfatm look forward access medicine develop world include time provide appropriate funding maximise nongovernmental organisation ngo company benefit patient companys preferential pricing offer consult work government develop focus debate access medicine develop world un patents glaxosmithkline believe patent restrict investment community continue constructive dialogue access medicine contrary true patent stimulate organisation share aim try improve access fundamentally underpin framework medical medicine develop world advance depend lead sustained investment glaxosmithkline make vital contribution improve health research development rd effective intellectual property care develop world group continue legislation mechanism enforce essential effort focus area difference maintain rd new well medicine include help find innovative way make medicine disease prevalent develop world available accessible develop country glaxosmithkline take innovative responsible holistic approach care company publish sustainable approach address healthcare challenge social environmental review expand group develop world june company publish face approach progress address issue access challenge report set principle commitment medicine develop world contribution improve healthcare develop world key area company contribute global community partnership corporate donation continue investment rd disease particularly glaxosmithkline community investment charitable donation affect develop world offer sustainable preferential pricing total million equivalent cent arrangement take lead role partnership group profit tax community activity promote effective healthcare programme longterm commitment help rd disease develop world bring sustain change donation continued investment research disease affect number year group community investment activity develop world essential improvement focus follow area disease program regional health people live region community initiative education product donation employee challenge drug resistance poor patient compliance involvement lack funding healthcare mean commercial market product glaxosmithkline disease programme frequently work partnership share expertise cost risk global alliance eliminate lymphatic filariasis rd develop world disease viable glaxosmithkline key member global alliance scale glaxosmithkline commitment substantial eliminate lymphatic filariasis lf unique partnership glaxosmithkline company currently involve research include world health organization ministries health development prevention treatment endemic country ngo communitybase organisation priority disease world health organization academic institution international organisation private malaria tuberculosis hivaid company numerous sector glaxosmithkline support alliance donate anti rd project medicine large programme research parasitic drug albendazole help coalitionbuilde vaccine disease prevalent develop world planning training communication initiative glaxosmithkline glaxosmithkline recognise importance work commit donate albendazole require investing effort basic research centre achieve goal eliminate lf anticipated year life tre canto spain establish site research drug programme year programme disease develop world approximately million tablet ship country number expand programme extend billion people risk countriesdescription businessglaxosmithkline positive action hivaid donate total british retinitis positive action glaxosmithkline longterm international pigmentosa society marie curie institute mental health programme hivaid education care community support foundation parkinson disease society research age programme glaxosmithkline work partnership support medical research donation network people live hivaid community group equip laboratory bristol interactive exhibition international agency nongovernment organisation combine science nature art government intensify community response hivaid glaxosmithkline international impact award recognise diverse array partner reflective community identify need work voluntary community healthcare organisation winner requirement respond effectively hiv epidemic receive award unrestricted requirement include implementation initiative deliver group donate noahs ark appeal hiv education prevention psychosocial care support help kickstart fund build children hospital alleviate stigma discrimination positive action support capacity wale group support red cross gateway project building programme provide organisation advocacy scotland donate help young people disability fund raise strategic management leadership communication live independent life skill promote right improve quality live people live hivaid example company sponsor american sublime exhibition tate britain february work exhibition positive action partner international council see uk aids service organisation implement programme dialogue care treatment infrastructure issue royal botanic garden kew redevelop extensive community mobilisation project twoyear programme collection grass world display advance community discussion infrastructure issue garden donation company hivaid care treatment strengthen community europe base response hivaid programmes europe focus child health total centre african family study initiative support fund million support range longterm programme organisational development people live hivaid include africa glaxosmithkline fund pilot programme reach young europe programme run increase participation communitybase group befrienders international umbrella organisation network people live hivaid local national samaritan movement worldwide help child denmark international hivaids policy discussion programme lithuania develop stress cope skill enable participate organisation deliver effective service include home base care extend project hope run programme russia ukraine combat substance abuse paediatric positive action support community attendance regional rehabilitation programme bosnia international hivaids conference support include barretstown gang camp ireland france community scholarship programme support meeting area provide therapeutic recreation seriously ill child exclusive people live hivaid implementation europe receive respectively community orientation session support enable individual underresourced community attend conference share north america experience particular address discrimination stigma programme north america focus improve access violation human right home country well healthcare partnership funding million allocate positive action main supporter community north america community partnership team attendance conference trinidad thailand million invest regional community activity addition million donation new york city community malaria programme disaster fund july announce malaronedonation programme establish end september threeyear grant million support completion pilot phase donation programme children health fund referral management initiative rmi prove efficient effective use resource grant ensure continuity care medically underserved achieve objective reduce suffer death malaria highrisk child homeless company commit focus resource allocate annual share award recognise communitybased malaronedonation programme new community partnership programme meet need racially ethnically malaria initiative announce culturally diverse elder total million award distribute threeyear period award administer regional community initiative university pennsylvania institute aging united kingdom threeyear partnership exist ovarian cancer glaxosmithkline charitable donation million uk national alliance heighten awareness ovarian cancer charity uk corporate donation committee woman physicians manage care organisation project science education medical research carter center rosalynn carter fellowship mental health healthcare art environment fund journalism year programme promote long addition glaxosmithkline company uk provide term systemic change american public belief million community investment purpose give combined perception mental illness total million support project uk glaxosmithkline description business glaxosmithkline year grant united way concern child trust charity establish promote southeastern pennsylvania create effective healthcare health wellbee child pakistan specific delivery united way member agency glaxosmithkline focus preventive primary healthcare education international impact award acknowledge reward excellence glaxosmithkline provide fund healthcare nonprofit healthcare community great philadelphia screen education immigrant child lowincome area winner receive area karachi glaxosmithkline facility north carolina community health education mother major childhood killers relation staff work address issue affect employee programme complete final year family community glaxosmithkline support glaxosmithkline provide year programme health education art civic affair country initiative aim provide mother develop country basic information need recognise major promising practice support prevention treatment childhood killers chronic disease affect lowwealth community receive year education school link glaxosmithkline support education contribution education programme glaxosmithkline work inkind donation volunteerism support nc range partner develop young people knowledge business committee education education foundation understand technical personal skill number area governor entrepreneurial school award particular focus science programme include playmaker repertory company educational matinee series bring science world international educational art classroom glaxosmithkline provide programme encourage communication share learn different culture habitat humanity receive construction annual health matter european school awards home lowwealth family glaxosmithkline employee introduce student importance health issue today volunteered build habitat home society develop teamworke investigation research glaxosmithkline investment volunteer excellence communication skill provide grant qualify nonprofit organisation base support royal institution christmas lecture employeepartner volunteer time grant total provide opportunity young people learn science glaxosmithkline employee volunteer hour eminent scientist active science new web resource pupil age plus finally north carolina glaxosmithkline foundation people medicine new webbase resource support advancement education science health endow science student age selffunde organisation operate separate entity foundation publish annual report available glaxosmithkline local site participate actively promote request use asset base support math science learn education local community health education north carolina product donation international glaxosmithkline donate essential product humanitarian relief glaxosmithkline international community partnership project effort donation request government address health education mobilisation provide partnership major charitable organisation product fund million programme include inventory nongovernmental organisation complete need assessment order product need international support phase initiative personal hygiene community ensure right product reach right sanitation education kenya uganda nicaragua peru person right time total value group phase provide hygiene sanitation education school child international product donation exclude lfprogramme aim reduce diarrhoearelate disease death million wholesale acquisition cost allocate health improvement programme indigenous population communities australia employee involvement glaxosmithkline employee encourage contribute provide fund new hivaids clinic masoyi local community employee volunteer scheme tribal area mpumalanga south africa clinic support varie world includes pay time threeyear glaxosmithkline programme provide donation charity employee complete voluntary quality continuum care region work match give glaxosmithkline match infect affected hivaid personal cash contribution employee qualify institution glaxosmithkline rural nursing excellence programme matching gift programme usa thailand sponsors female high school graduate rural glaxosmithkline match employee gift area complete year nursing degree glaxosmithkline value million donate year train nurse march addition special disaster relief fund establish help see graduate programme victim tragedy take place usa th september total gift totalling glaxosmithkline match giftsglaxosmithkline corporate governance section discuss glaxosmithkline management structure governance procedure board corporate executive team governance policy dialogue shareholder annual general meeting accountability audit combine code glaxosmithkline corporate governance b board sir peter job age cg nonexecutive director sir peter nonexecutive sir richard syke aged director glaxo wellcome plc chief executive nonexecutive chairman sir richard chairman glaxo reuters group plc nonexecutive director schroders wellcome plc completion merger plc shell transport trading company plc tibco software inc formglaxosmithkline plc rector imperial college instinet group llc science technology medicine doctorate microbial f biochemistry bristol university doctor science degree john mcarthur aged university london fellow royal society sit nonexecutive director mr mcarthur nonexecutive number government scientific committee receive director glaxo wellcome plc dean harvard knighthood services pharmaceutical industry business school nonexecutive director bce inc cabot nonexecutive director rio tinto plc corporation rohm haas company springs industries inc df aes corporation sir roger hurn age fh nonexecutive deputy chairman sir roger appoint donald mchenry age nonexecutive director glaxo wellcome plc deputy nonexecutive director mr mchenry non chairman nonexecutive chairman prudential plc executive director smithkline beecham plc nonexecutive director cazenove group plc distinguish professor practice diplomacy school chairman court governor henley management foreign service georgetown university president centre irc group llc nonexecutive directorship include bd cocacola company fleetboston financial corporation att sir peter walters age corporation previously serve ambassador nonexecutive deputy chairman sir peter non permanent representative united nations executive director smithkline beecham plc b chairman completion merger sir ian prosser aged chairman institute economic affairs nonexecutive director sir ian nonexecutive director smithkline beecham plc chairman dr jeanpierre garnier aged continents plc nonexecutive deputy chairman bp plc chief executive officer dr garnier appoint executive chairman executive committee world travel director smithkline beecham plc serve tourism council member cbi presidents committee chairman pharmaceutical appointment chief operating officer chief executive officer dr ronaldo schmitz aged april nonexecutive director united technologies nonexecutive director chairman audit committee corporation member board trustee dr schmitz nonexecutive director glaxo eisenhower exchange fellowship hold phd pharmacology wellcome plc nonexecutive director legal general university louis pasteur france mba group plc member board directors rohm stanford university usa haas company cabot corporation member board executive director deutsche bank ag john coombe age h chief financial officer mr coombe executive dr lucy shapiro aged director glaxo wellcome plc responsible nonexecutive director dr shapiro nonexecutive finance investor relation member uk director smithkline beecham plc professor accounting standard board code committee uk department developmental biology director takeover panel beckman centre stanford university school medicine f hold phd molecular biology albert einstein college paul allaire aged medicine nonexecutive director mr allaire nonexecutive e director smithkline beecham plc nonexecutive director john young age lucent technologies inc sara lee corporation pricelinecom nonexecutive director chairman remuneration inc chairman ford foundation chairman nominations committee mr young formerlynonexecutive xerox corporation mr allaire succeed mr young chairman vice chairman smithkline beecham plc non remuneration nominations committee executive appointment include directorship chevrontexaco fh corp lucent technologies inc affymetrix inc perlegen sciences dr michle barzach aged inc ciphergen biosystems fluidigm grassroots enterprise nonexecutive director dr barzach nonexecutive agere system director glaxo wellcome plc chairman external advisory panel health nutrition population world sir richard syke sir peter walters mr young retiring bank director board international aids vaccine board annual general meeting initiative consultant health strategy french minister health family membership board committee indicate follow bd symbol sir christopher hogg aged nonexecutive director sir christopher chairman member nonexecutive director smithkline beecham plc non audit b executive chairman reuters group plc st march finance c allied domecq plc anonexecutive director air remuneration nomination e f liquide sa chairman royal national theatre board corporate social responsibility g hcorporate governanceglaxosmithkline corporate executive team howard pien president jp garnier pharmaceutical international chief executive officer work abbott laboratories merck mr pien join chief executive officer smithkline beecham dr garnier smithkline beecham hold commercial position join smithkline beecham president uk asia president pharmaceuticals pharmaceutical business north america chairman responsibility commercial operation worldwide pharmaceutical appointment chief pharmaceutical vaccine business operating officer elect smithkline beecham board directors david stout president rupert bondy pharmaceutical senior vice president general counsel mr stout president pharmaceuticals north america mr bondy join smithkline beecham senior counsel smithkline beecham join senior vice corporate appoint head corporate legal president director sale market secretarial group join smithkline beecham president schering laboratory responsibility include lawyer private practice mr bondy responsible legal matter pharmaceutical operation worldwide manufacture glaxosmithkline tim tyson ford calhoun president senior vice president global manufacturing supply information technology mr tyson join glaxo appoint senior vice dr calhoun join smithkline french faculty president director worldwide manufacture supply glaxo mount sinai school medicine doctoral training wellcome previously vice president general microbial genetics postdoctoral training biomathematic manager business operation marketing glaxo wellcome computer science notable accomplishment smithkline inc member glaxo wellcome executive committee beecham bioinformatics drug development process collaborative computing healthcare information product chris viehbacher internet product service president pharmaceuticals europe john coombe regional director europe mr viehbacher member chief financial officer glaxo wellcome executive committee addition role join glaxo group financial controller mr coombe chairman chief executive president directeur general glaxo appoint board executive director wellcome france director continental europe responsible finance investor relation later add join wellcome responsibility group finance director glaxo wellcome plc tachi yamada chairman bob ingram research development chief operating officer president smithkline beecham dr yamada appoint chairman pharmaceutical operation research development pharmaceutical previously mr ingram chief executive glaxo wellcome plc president smithkline beecham healthcare service chairman glaxo wellcome inc subsidiary join join smithkline beecham nonexecutive member board glaxo inc merck appoint board director glaxo wellcome chief executive glaxo wellcome jennie young senior vice president james palmer corporate communication community partnership senior vice president mrs younger appoint current post december new product development pharmaceutical rd join glaxo wellcome director investor relation dr palmer responsible glaxosmithkline new product year british gas head investor relation development include worldwide responsibility medical mrs young financial analyst kleinwort benson regulatory product strategy hold similar position glaxo barclays de zoete wedd wellcome member glaxo wellcome executive committee physician training join glaxo jack ziegler president dan phelan consumer healthcare senior vice president mr ziegler appoint president consumer healthcare human resource smithkline beecham join smithkline beecham mr phelan join smithkline beecham manager head north american consumer healthcare division labour relation vice president director president north america division personnel pharmaceutical appoint senior appoint executive vice president vice president director human resource glaxosmithkline corporate governance governance policy corporate social responsibility committee consist entirely nonexecutive director provide board level forum board executive regular review external issue potential director list board appoint impact group business reputation rd serve date board glaxosmithkline plc responsible group corporate executive team system corporate governance ultimately accountable executive management group responsibility group activity strategy financial performance chief executive officer senior manager form corporate executive team meet time year board comprise executive nonexecutive director member corporate executive team responsibilitie role nonexecutive director bring independent judgement list corporate executive team board deliberation decision sir richard syke nonexecutive chairman dr jeanpierre remuneration director garni chief executive officer information remuneration director give remuneration report sir roger hurn sir peter walters nonexecutive deputy chairman dialogue shareholder sir richard syke employ glaxosmithkline services plc company announce financial result quarterly glaxo wellcome plc executive chairman completion merger nonexecutive director company report formally shareholder twice year consider board independent give halfyear fullyear result announce report nonexecutive deputy chairman appoint andor summary review issue shareholder chief independent company consider necessary executive officer chief financial officer presentation appoint senior independent director final year end result institutional investor analyst medium london new york addition company hold board process teleconference release second board meet regularly year formal quarter result institutional investor analyst medium schedule matter reserve decision access company web site delegate specific responsibility board committee describe annual general meeting company take place london board works agree agenda review key formal notification send shareholder month activity business receive paper presentation advance meeting business presentation enable effectively minute board committee shareholder director able attend available formally remuneration nomination committee place meeting informally question agenda board detail annual general meeting set company secretary responsible board available section annual general meeting individual director respect board procedure company chief executive officer chief financial officer maintain secretary simon bicknell dialogue institutional shareholder company plan objective programme regular meeting board committee speak regularly external conference presentation audit committee review financial internal reporting process system internal control management risk company investor relation department office external internal audit process committee consist london philadelphia act focal point contact entirely nonexecutive director meet time year investor year chief executive officer chief financial officer general company internet site wwwgskcom give access counsel head internal audit corporate compliance current financial business information group external auditor attendance information available web site constitute finance committee review approve major financial document security transaction company dividend result announcement business annual general share buyback programme meeting committee consist chief executive officer october company announce plan invest chief financial officer nonexecutive director meet billion buying share market programme cover time year additional meeting hold time purchase company employee trust relate share option grant share base incentive cover remuneration nomination committee determine term purchase company share cancellation accordance service remuneration executive director authority give shareholder company annual corporate officer consider appointment director general meeting total billion spend corporate officer committee consist entirely non executive director meet time year company authorise purchase maximum necessary chief executive officer attend meeting million share million share purchase remuneration consider cancellation detail give note financial statement share capital share premium account exact time offuture purchase determine company dependent market condition factorscorporate governanceglaxosmithkline annual general meeting company identify number area significant risk subject regular reporting company annual general meeting hold pm th queen elizabeth ii conference centre broad intellectual property sanctuary westminster london swp ee specific risk include maintain enforce intellectual property right compliance relevant legislation infringement director party intellectual property right protection inlicense mr allaire dr barzach retire offer product technology election board article company article association biographical detail give litigation legal board normal course business glaxosmithkline subject proceeding legal action claim matter auditor subject risk uncertaintie outcome resolution propose reappoint pricewaterhousecooper predict level certainty nature risk auditor authorise director determine discuss note financial statement legal remuneration proceeding special business information technology company seek renew authority protect glaxosmithkline electronic asset increasingly complex donation eu political organisation incur eu business partnership extend network system electronic political expenditure datum party dependency internet director authority disapply preemption right communication increase ensure proper system validation allot new share certain circumstance electronic record signature key regulatory issue maximum cent current issue share capital matter potential risk company similarly web system obtain authority purchase ordinary share accessible public comply legal regulatory maximum cent current issue requirement share capital area potential risk include use personally identifiable datum electronic record retention outsource business application accountability audit potential susceptibility virus outside incursion board recognise responsibility present balanced understandable assessment group position prospect human resource discussion follow set procedure legal requirement discrimination harassment accountability control operate glaxosmithkline integrity workforce control use contractor temporary staff risk inherent company internal control framework employee company operate attach importance clear principle procedure design achieve accountability control corporate ethic compliance programme appropriate sciencebase business operate multinationally group operate complex legal regulatory environment highly regulate business sector central direction span globe inconsistencie jurisdiction resource allocation risk management key functional cornerstone group compliance effort activity commercial strategy research development diligence prevent detect misconduct legal manufacture information system human resource financial noncompliance promote ethical behaviour compliance practice commercial financial responsibility clearly delegate law regulation corporate responsibility level local operating unit support regional management effective compliance system structure product safety principle design provide environment central pharmaceutical product bring benefit risk leadership local operating autonomy framework effect intent pre exercise accountability control group key clinical clinical trial conduct development functional activity management sector represent potential product determine safety efficacy corporate executive team product use human follow approval regulatory ongoing process identify evaluate body spite effort drug introduce manage significant risk affect business marketplace unanticipated adverse effect occur policy procedure risk manage process operation year manufacturing review continue operate date approval loss manufacturing site key production product report process accord guidance internal control important glaxosmithkline significant risk group policy issue turnbull committee assessment manufacturing conduct accordance applicable group risk review update annually similarly law regulation corporate standard operate level business unit require process exceed requirement failure meet legal regulatory identifying evaluate manage risk significant requirement number risk result close business specialist team review report compliance asite critical supply important product glaxosmithkline corporate governance environment safety audit committee board employee injury change health occupational condition audit committee board responsibility review plant management potential impact plant behalf board effectiveness system internal environment risk company address control management risk process monitor comprehensive architecture set target provide guidance compliance law regulation ethical code practice result achieve audit committee receive regular report area significant risk company relate internal control follow financial risk appraisal consideration report committee report annually risk surround group ability forecast board overall framework effectiveness control future uncertainty ability meet financial target set budgeting process group invest new product addition audit committee keep review scope venture base assumption success result audit independence objectivity effort prove inaccurate addition risk external auditor committee review nature extent group treasury operation include tax liability nonaudit services external auditor provide order transfer pricing possibility trading loss ensure fee service significant counterparty fraud extensive financial control procedure question independence group selfassessment exercise audit measure review board consider audit committee report group internal auditor place minimise effect effectiveness control believe system internal risk control provide reasonable absolute assurance financial risk management process material misstatement loss comprehensive planning system annual budget approve control mitigate eliminate risk addition director result operating unit report area company business necessary monthly compare budget forecast prepare risk order achieve satisfactory return shareholder regularly year company announce result case company objective apply expertise quarterly basis prudent management elimination risk risk oversight compliance council rocc director review relate company subsidiary rocc responsible coordinate internal control extend material associate undertaking joint risk management activity company ensure venture investment company cent assignment designate manager manage significant risk interest quest diagnostics inc quest account membership comprise member cet head associate company activity quest department internal control risk management audit andor company core business competency interest compliance responsibility term reference include quest hold investment company ensure regular gap analysis carry identify gap review quest system internal control internal control provide report audit committee addition report provide separate internal control combine code audit compliance department company rocc company seek uphold report compliance support corporate compliance department good practice corporate governance combined code principle good governance code good practice corporate social responsibility committee csrc combine code issue uk list authority csrc committee board chair sir richard combined code comprise recommendation good practice syke comprise nonexecutive director term control reporting function board committee advise board social ethical environmental company combine code set principle issue potential seriously impact glaxosmithkline heading business reputation director committee meet formally twice year additional ad director remuneration hoc meeting consultation require glaxosmithkline relation shareholder executive functional responsibility business area accountability audit relate issue involve risk control interface external stakeholder attend meeting provide input prescribe detailed provision respect principle committee committee activity feed internal specifically provision require director report annual control framework help board ensure group account complie combine code corporate governance director remuneration director responsibility account go concern internal control compliance director report compliance combine code report accordance provision combine code set director statement responsibility pageglaxosmithkline remuneration report remuneration report set remuneration policy operate glaxosmithkline remuneration policy describe process policy programme take effect completion merger th december director remuneration set remuneration earn director glaxosmithkline interest share option share incentive plan director senior management set interest director glaxosmithkline shares glaxosmithkline plc contract information provide aggregate remuneration interest director senior management glaxosmithkline reference glaxosmithkline share adss mean respectively ordinary share glaxosmithkline plc p american depositary share glaxosmithkline plc ad represent glaxosmithkline share glaxosmithkline remuneration report remuneration policy glaxosmithkline remuneration policy special defer bonus recognition extraordinary effort corporate lead global healthcare company glaxosmithkline aim executive team cet integrate successfully remuneration policy programme enable legacy company time deliver improve recruit retain motivate calibre executive talent business performance rn committee decide award need compete international market place special defer bonus member cet include glaxosmithkline believe remuneration policy executive director provide bonus equivalent programme represent competitive advantage good practice salary st december cet member heavy emphasis pay performance risk treat notionally invest glaxosmithkline compensation executive longterm incentive plan share th february receive bonus cet design align executive reward shareholder member require leave company voluntarily interest particular creation enhance shareholder value th february payment equivalent value share notionally acquire remuneration nomination committee february plus dividend reinveste period convert share company committee board remuneration nomination rn defer payment way fully align executive interest committee develop company policy executive director shareholder act strong retention tool remuneration approval board determine defer bonus pensionable change control remuneration package executive director rn company automatically trigger payment defer committee consist exclusively independent nonexecutive bonus addition annual bonus director current members committee mr john agree deferred bonus committee hold individual young chairman mr paul allaire dr michle barzach sir roger performance multipli ipm normal annual bonus plan hurn mr john mcarthur mr donald mchenry mr allaire cent cet member succeed mr young chairman committee exception dr garnier ipm hold cent remuneration company nonexecutive director give individual achievement considerably determined glaxosmithkline board receipt pay absence special defer bonus advice external consultant longterm incentive policy remuneration executive director comprise share option participation performance share plan link reward shareholder value long rn committee advice lead firm medium term respectively describe compensation benefit consultant aim provide package incentive reward competitive reference share option global healthcare company multinational share option allow holder buy share future date company consider similar glaxosmithkline term size price determine reference open market price share geographical spread complexity business time grant share option grant manager glaxosmithkline include executive director construct review remuneration package emphasisis link pay performance reward effective vest option grant executive director subject management individual achievement mix tothe performance condition earning share growth apackage design align personal reward enhance exclude currency exceptional item shareholder value short long term ninepercent increase uk retail price index executive director remuneration consist component threeyear measurement period respect future grant rn committee review performance condition salary market condition performance bonus longterm incentive performance share plan benefit participation performance share plan grant approximately executive company include salary executive director designate target number share reflect executive director experience responsibility eachparticipant vest award plan subject market value toa performance condition apply year measurement period performance condition consist performance bonus twopart apply cent award base annual performance business team demand financial target individual accomplishment objective bonus subject upper limit target business performance bring total compensation line competitor panel compensation rise target performance exceed executive total compensation fall level compensation competitor target achieve option invest bonus glaxosmithkline share inwhich case bonus enhance cent share hold minimum yearsremuneration reportglaxosmithkline condition compare glaxosmithkline director service contract totalshareholder return tsr period tsr executive director employ service contract ofcompanie uk ftse index period glaxosmithkline require year notice termination ifglaxosmithkline rank ftse executive director require month notice inrelation tsr performance cent sharessubject performance condition vest dr garniers contract specifie compensation pay iftheranke th position ftse company termination employment include centofthe share vest glaxosmithkline rank immediate payment year salary bonus dr garni thposition share subject entitle continue participate company longterm performance condition vest th th incentive plan month follow notice position vest occur slidingscale termination company dr garniers notice period reduce year year dr garnier receive second performance condition require year pension accrual termination certain glaxosmithkline earning share growth exclude currency circumstance year accrual andexceptional item cent theincrease uk retail price index threeyear mr coombes contract specifie compensation pay performance period condition meet share event redundancy event notice termination subject performance condition vest give case redundancy mr coombe condition meet share subject require mitigate loss earning result ofthe performance condition vest executive director service contract contain garden leave benefit noncompetition nonsolicitation confidentiality clause executive director participate glaxosmithkline senior executive rn committee believe year contract pension plan define benefit plan uk cash bein good interest glaxosmithkline regard offering balance plan usa benefit payable age aglobally competitive overall remuneration package secure cash balance plan provide pension payable fund maximum protection intellectual property right contribution tenpercent earning pay interest accrue base treasury bill rate bonuse pensionable nonexecutive director glaxosmithkline service participate employee plan include executive contract director payment nonexecutive director glaxosmithkline executive director participate legacy glaxo wellcome share smithkline beecham employee share plan uk usa glaxosmithkline plan replace enhance link director shareholder arrangement dr garnier receive cent basic pay glaxosmithkline require nonexecutive director receive form glaxosmithkline share ukarrangement significant fee form share allocate mr coombe member sharesave plan november share account offer opportunity invest join employee sharereward plan contribute balance fee share account share pay month buy share number share buy month directors retirement board later date match company onthe basis dividend reinveste interim benefit healthcare provide line practice market executive employ share ownership guideline align executive interest shareholder executive director require hold share company chief executive officer require hold share value time base pay executive director glaxosmithkline require hold share value time base pay purpose requirement share adss hold smithkline beecham bonus deferral plan vest defer award longterm incentive plan include yearend dr garniers total shareholding basis adss mr coombe share result director exceed share ownership guideline glaxosmithkline remuneration report director remuneration table set remuneration earn director glaxosmithkline plc comparative amount represent remuneration earn director glaxo wellcome plc smithkline beecham plc statutory disclosure respect director remuneration attributable director glaxosmithkline plc relation service company subsidiarie th st december set note financial statement annual compensation annual total total fee emolument defer annual fee emolument annual salary benefit bonus compensation salary benefit bonus compensation note executive director dr j p garnier ae mr j coombe total nonexecutive director sir richard syke cf sir roger hurn dfg sir peter walters fgh mr p allaire fh dr barzach df mr c bonham df sir christopher hogg fh sir peter job dfg mr j h mcarthur dfg mr f mchenry fh sir ian prosser fgh dr r schmitz dfg dr l shapiro fghi mr j young fgh total total compensation dr garni executive director smithkline beecham salary fee include company match compensation defer b mr coombe executive director glaxo wellcome include bonus company match defer bonus addition bonus show mr coombe receive award respect second half pay c sir richard syke executive chairman glaxo wellcome remunerate executive director andreceive annual performance bonus st january remunerate nonexecutive chairman glaxosmithkline addition sir richard receive bonus award respect second half pay nonexecutive director glaxo wellcome mr bonham resign nonexecutive director glaxosmithkline stmay e bonus include special defer bonus payable describe f share adss automatically allocate follow nonexecutive director fee sir richard syke share sir roger hurn share sir peter walters share mr p allaire adss dr barzach share mr c bonham shares sir christopher hogg share sir peter job share mr j h mcarthur adss mr f mchenry ads sir ian prosser share dr r schmitz shares dr l shapiro adss mr j young adss share allocate account include director interest g follow nonexecutive director elect receive balance fee form share adss sir roger hurn sir peter walters sir peter job mr j h mcarthur sir ian prosser dr r schmitz dr l shapiro nil mr j young share allocate account include director interest h nonexecutive director smithkline beecham additional remuneration award nonexecutive director pay form smithkline beecham share adss sir peter walters share mr p allaire adss sir christopher hogg share mr f mchenry ads sir ian prosser shares dr l shapiro adss mr j young adss share allocate account include director interest glaxosmithkline share dr shapiro member glaxosmithkline scientific advisory board receive addition fee show fee form adssremuneration reportglaxosmithkline share option lapse grant average average option adss grant price exercise number grant price number grant price dr j p garnier lapsed grant average average option share grant price exercise number grant price number grant price mr j coombe sir richard syke director interest option company share glaxosmithkline intend grant share option director senior manager annual basis november initial grant follow completion merger march measurement period option grant march commence st january measurement period option grant november commence st january march november grant dr garni receive ad option mr coombe receive share option consequence merger option grant prior merger exercisable exception option grant mrcoombe option option grant mr coombe dr garnier exercisable vary time february november option lapse exercise vary time november director hold option share option plan refer note financial statement employee share scheme share price thmarch glaxosmithkline share glaxosmithkline ad connection merger circular list particular send shareholder july time holder option glaxo wellcome smithkline beecham share adss offer opportunity exchange option option glaxosmithkline share director elect exchange outstanding glaxo wellcome smithkline beecham options applicable new option glaxosmithkline share glaxo wellcome smithkline beecham share option plan participant elect exchange option receive additional benefit cash sum equal cent exercise price original option additional benefit give new option exercise provide exercise second anniversary effective date merger case sir richard syke cessation executive employment early highest low price year end st december glaxosmithkline share respectively high low price glaxosmithkline adss year st december respectively market price glaxosmithkline share st december st december glaxosmithkline ad st december grant market option exercise adss date number price price dr j p garni grant market option exercise share date number price price sir richard syke gain option exercise director year st december comprise relate drgarnier relate sir richard syke compare gain exercise option year st december comprising relate dr garnier relate sir richard syke glaxosmithkline remuneration report incentive plan adss adss performance share plan adss lapse award grant dr j p garni plan plan share share performance share plan share lapse award grant mr j coombe plan plan performance share plan psp mediumterm incentive scheme introduce psp replace longterm incentive plan midterm incentive plan operate respectively glaxo wellcome smithkline beecham term psp number share actually vest determined follow end relevant measurement period year dependent glaxosmithkline performance period usually award share november year precede start year measurement period initial grant follow completion merger march measurement period relate share award march commence st january end st december share award november measurement period commence st january end st december share exercise average money market price value share exercise exercise share share longterm incentive plan share number vest mr j coombe sir richard syke longterm incentive plan ltip share award scheme operate glaxo wellcome plan close new entrant completion merger grant award mr coombe march february vest march february respectively award march february sir richard syke vest sir richard leave executive office completion merger award ltip lapse exercise month vest performance condition lapse completion merger share ltip award atnominal cost recipient vest vested defer defer unvested participation participation unvested participation participation participation lapse award participation midterm incentive plan adss dr j p garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant connection merger performance condition respect grant lapsed final award employee resign end relevant measurement period final award share receipt award defer director dr garnier defer receipt award deferred award additional adss subsequently receive dividend reinvestment arenot include director interest table technically retain mtip pay average stock appreciation right sar adss grant price exercise grant dr l shapiro dr shapiro member glaxosmithkline scientific advisory board sab dr shapiro member smithkline beecham sab completion merger glaxo wellcome member sab receive annual grant smithkline beecham sars general vest year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision account accrue gain sar date grant connection merger previously grant sar immediately exercisableremuneration reportglaxosmithkline pension pension benefit accrue follow director define benefit scheme accrue annual benefit individual director retirement set change year net inflation age dr j p garnier mr j coombe sir richard syke dr garni member smithkline beecham allemployee pension plan entitlement spouse children pension surrender pension early retirement pension reduce factor relate age service apply employee dr garnier case receive additional year service retire glaxosmithkline certain circumstance year accrual pension increase grant discretionary basis transfer value payable leave theplan dr garni member money purchase scheme contribution pay scheme mr coombe sir richard syke member glaxo wellcome uk pension plan spouse provide pension twothird executive pension event death event decide early retirement pension reduce cent year age retire company agree procure sir richard syke pension age calculate basis salary st december remain fulltime employment th birthday pension guarantee increase payment rate increase uk retail price index rpi maximum cent year discretionary increase pay addition allowance discretionary increase transfer value leave glaxosmithkline remuneration report director senior management director interest follow beneficial interest director company show register maintain company accordance company act share adss th march december december th march december december note dr j p garnier mr j coombe ab sir richard syke ce sir roger hurn e sir peter walters e mr p allaire e dr barzach e sir christopher hogg e sir peter job e mr j h mcarthur e mr f mchenry de sir ian prosser e dr r schmitz e dr l shapiro e mr j young e glaxosmithkline ad represent glaxosmithkline share include share purchase glaxosmithkline sharereward plan totalling share st december nil share th march b include nonbeneficial interest trust hold share st december share th march c include nonbeneficial interest trust hold share st december share th march addition interest show mr mchenry interest defer fee plan relate period mrmchenry director smithkline beckman priorto merger beecham group defer fee index total return glaxosmithkline share payable seven year follow mr mchenrys retirement total accumulate value defer fee st december restate reflect merger equivalent glaxosmithkline adss fully provide e include share adss receive fee describe footnote f g h annual compensation table director remuneration dividend receive share adss convert share adss st december include director interest interest abovementione director thmarch reflect change end financial year thmarch director beneficially own cent issue share capital company director interest contract describe end financial year director connect person material interest contract significance relation group business group company director senior management report purpose necessary provide information compensation interest director senior management asagroup group purpose disclosure group define director member corporate executive team company secretary th march numbering person glaxosmithkline aim provide package incentive reward competitive reference global healthcare company multinational company consider similar glaxosmithkline term size geographical spread complexity business remuneration group consist salary performance bonus longterm incentive form share option participation performance share plan benefit respect financial year total compensation pay group aggregate increase accrue pension benefit aggregate payment define contribution scheme thmarch group own share adss constitute cent issue share capital company group hold date option purchase share adss issue pursuant executive share option plan describe note financial statement group award share adss glaxosmithkline performance share plan th march hold share adssglaxosmithkline operate financial review prospect operate financial review prospect discuss operate financial performance group financial outlook financial resource group follow heading financial trend ratio year result year st december compare year st december financial position resource st december outlook risk factor additionally accordance requirement year result year st december compare year st december select financial datum ukus gaap result accounting principle result year compare primarily result precede year reference quarterly halfyearly trend result exchange group multinational business operate countriesand earn revenue incur cost currency result group report sterling affect bymovement exchange rate sterling overseascurrencie company use average exchange rate prevail period translate result cash flow overseas group subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation usdollar euro japanese yen order illustrate underlie business performance exclude theeffect exchange rate movement translation group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate totranslate result overseas company sterling remain unchanged previous period discussion review term cer state glaxosmithkline operate financial review prospect financial trend ratio business performance total cer total cer total cer sale pharmaceutical consumer healthcare total cost sale sell general administration research development trading profit retain business trade profit divest business trade profit total profit taxation earning earning share penny p p p research development business performance pharmaceutical consumer healthcare total business performance primary performance measure management present exclude merger item integration restructuring cost disposal subsidiary management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement include consolidated statement profit loss page prepare accordance ukgaap total result include nonrecurre item total result profit taxation earning earning share penny p p p interest net interest payable interest cover time time time interest cover calculate total profit interest divide net interest payable tax rate business performance total result borrowing net debt gearing ratio gearing ratio calculate net debt percentage shareholder fund net debt minority interestsoperate financial review prospect glaxosmithkline year world economy world market pharmaceutical characterise sharp deterioration global global pharmaceutical sale increase cent economic outlook sort downturn softlande billion rate growth unequivocally emerge second real magnitude slowdown apparent move world market value growth geographic region bn total factor contribute significant investment especially technology significant usa impact energy cost high oil price temper europe consumer demand weakness japan economy germany tragic event usa september leave france economy world uncertainty italy uk usa asia region affect downturn japan gdp growth decelerate swiftly cent latin america cent strong exposure technology asia pacific excess capacity euroarea begin year middle east africa able weather slowdown well canada economy start decelerate significantly particularly total germany japan continue laggard trap deflation bad credit problem soar public debt market remain buoyant represent cent year emerge market hit turmoil turkey global prescription pharmaceutical market compare argentina contagion effect relatively limit far cent decade ago compare previous crisis glaxosmithkline hold second position world pharmaceutical background economic policy response market market share cent exclude product remarkable usfederal reserve act swiftly begin divest result merger pfizer market year half cent interest rate cut follow share cent aggressive stance overall ease cent european central bank reduce rate glaxosmithkline product world product cent japan bank japan move avandia augmentin flixotide imigran serevent quantitative ease monetary policy continue generally seroxatpaxil wellbutrin zofran ineffective problem nonperforme loan affect banking system difference monetary policy reflect world market value growth therapeutic class bn total different degree slowdown deep usa shallower cardiovascular europe development currency market central nervous system dollar reach high level past year alimentary tract metabolic event september hit global economy hard antiinfective bacterial head recession create disruption viral fungal exclude vaccine specific sector particularly transport insurance severely respiratory hit confidence collapse world global trade continue decline month year note datum base month th september business consumer confidence stabilise preseptember level bode recovery exchange significant injection liquidity global level fiscal policy remain stimulatory inventory cycle turn strongly euro jpy jun favourable global economy set rebound doubt pace recovery rise unemployment high degree leverage corporate consumer level overhang global spare capacity real gdp growth likely moderate pharmaceutical market generally show consistent growth year price remain pressure legislator regulator world large wealthy economy introduce propose legislative jun dec jun dec jun dec jun dec jun dec jun dec measure cut price andor slow rate growth spend medicine average sterling exchange rate weak dollar euro strong yen compare aggregate currency movement compare net favourable effect sterling result cent respect sale cent respect business performance earning share glaxosmithkline operate financial review prospect pharmaceutical sale application eu registration seretidefor treatment chronic obstructive pulmonary disease copd submit total pharmaceutical sale million compare september january fda advisory committee million increase cent like recommend approval advairand floventfor treatment like basis sale product divest copd associate bronchitis flixotideand sereventa regulatory approval merger glaxo wellcome individual agent approve country smithkline beecham exclude sale grow cent treatment copd million approximately cent overall growth come price increase expect sale flixotidefloventand sereventdecline market increase momentum seretideadvair glaxosmithkline exist portfolio sale new product sale flixonaseflonase treatment perennial launch major market year rhinitis grew strongly account cent total sale grow cent million sale establish franchise product old respiratory product ventolinand becotidecontinue amount million represent cent total sale decline patient convert new product growth cent compare year old product actively promote million account antibacterial cent total sale sale product decline seven overall sale antibacterial show little growth cent broadspectrum antibiotic augmentinis high selling product group portfolio achieve cent pharmaceutical sale growth fourth quarter growth worldwide augmentin esextra strength cent million sale usa contribute launch usa october treatment child million growth cent wholesaler recurrent persistent middle ear infection submission buying pattern distort product sale total report fda approval augmentin xrextende release sale growth line underlie demand indicate submit extra data information request prescription datum europe sale improve cent fda million rest world sale improve cent million overall sale old product zinnatceftin fortumand amoxilcontinue decline sale zinnatceftingrew pharmaceutical sale therapeutic area central eastern europe cent central nervous system antiviral major therapeutic area glaxosmithkline portfolio record glaxosmithkline continue expand leadership hivaid sale growth cent seroxatpaxiland wellbutrindrove current global market share cent sale growth antidepressant sector cent april paxilwa approve food drug administration trizivir glaxosmithkline new triple combination medicine fda treatment generalise anxiety disorder gad hivaids available tablet key driver growth december treatment posttraumatic stress disorder hivaid franchise launch number key market ptsd seroxatpaxilis approve country year include europe usa canada treatment gad countrie treatment ptsd sale combivir combination epivirand retrovir wellbutrinsale drive sale growth cent grow cent major growth market japan asia result increase awareness physicians efficacy pacific middle east latin america africa favourable effect profile nonanxious depressed patient sale ziagenincrease cent approval receive migraine sector successful launch japan imigran paediatric indication october use eu ziagenis tablet treatment previously available approve country worldwide injection help imigranimitrexsale grow cent treatment hivaid adult lamictalfor treatment epilepsy grow strongly sale requipfor parkinson disease zybanthe smoking cessation sale zeffix hepatitis b grow market region product launch france usa zeffix market epivirhbv approve treatment child year old august respiratory performance herpe treatment valtrexand zovirax successful launch asthma treatment seretideadvair produce combined sale growth cent usa usa number countries europe valtrex sale helped dtc advertising campaign rest world help boost sale growth product approval usa shorter threeday course therapy combination flixotidefloventand serevent available recurrent genital herpe decline zoviraxin region country worldwide sale seretideadvairexceede world result transfer new valtrexproduct billion usa million prescription generic competition write month follow launch april speed patient adopt seretideadvairin usa make successful pharmaceutical product launch seretideadvair glaxosmithkline large product europe sale million operate financial review prospectsglaxosmithkline pharmaceutical sale therapeutic area total usa europe row therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil c wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sale continue business divest product total pharmaceutical sale cer represent sale growth constant exchange rate sterling growth calculate figure give analysis sale quarter give financial record page glaxosmithkline operate financial review prospect metabolic gastrointestinal usa avandia glitazone treatment type diabetes group earn cent total pharmaceutical revenue key driver growth metabolic gastrointestinal therapy usa year recording growth cent area usa avandiasale benefit increase acceptance advairseretide launch midapril achieve sale revolutionary class drug record growth cent million launch slow sale growth avandia launch china italy currently approve constituent product flixotidefloventand serevent combine country file marketing approval japan sale product amount million december growth cent sale zantachave continue decline face generic cns therapeutic area seroxatpaxil launch generalised competition anxiety disorder april grow strongly wellbutrincontinue good growth record product benefit vaccine grow antidepressant market usa lamictalindicate infanrix glaxosmithkline combination vaccine diphtheria epilepsy grow cent tetanus pertussis whoop cough drive total vaccine sale antibacterial sector augmentinreflecte gain share growth cent strong growth priorix adult paediatric market growth bolster tritanrixand typherixmore offset decline hepatitis launch es extra strength formulation indicate portfolio twinrix havrixand engerixb subsequent year treatment child acute otitis medium middle ear end glaxosmithkline announce discontinuation lymerixin infections usa result poor demand product combination treatment trizivirwa launch market oncology emesis late sale financial year amount continued sale growth zofran management million help produce cent sale growth nausea vomiting associate chemotherapy hivaid sector antiviral antiviral market valtrex radiotherapy cancer treatment benefit oncology emesis herpe show strong performance therapy area grow cent overall sale hycamtin approve treatment recurrent ovarian cancer decline europe cent principally result adverse wholesaler buy europe region contribute cent pharmaceutical sale pattern usa large market france show strong growth good growth record major market include italy spain cardiovascular central eastern europe seretidewa major sale driver sale coreggrew cent november fda give region usa affect sale constituent approval treatment severe heart failure coregis product seretideadvairis large product europe betablocke agent indicate increase survival mild moderate sale million severe heart failure patient glaxosmithkline exclusive cns area seroxat couple launch zybanin right market coregin usa markets contribute growth launch trizivir help produce cent growth hivaid sector therapeutic area sale relafenfor arthritis fall reflect generic competition metabolic gastrointestinal zantacsale continue decline usa face increase generic competition partially offset performance avandiawith launchesin number regional analysis market include uk germany pharmaceutical sale geographic area antibacterial decline cent reflect generic competition augmentinand amoxil vaccine show growth region cer major market total growth decline hepatitis market germany sale improve european country principally uk spain italy usa europe oncology area growth attributable strong france sale zofranin france germany offset decline uk hycamtinsales european country italy germany spain rest world central cent sale growth rest world region reflect eastern europe strong growth major market region europe market growth japan drive number therapeutic rest world area launch tablet form imigranin august asia pacific seroxatin late key driver switch becotideto japan latin america new product flixotideand zoviraxto new valtrex middle east africa contribute sale growth new product lead canada decline old product canada significant growth achieve seretideand cer represent sale growth constant exchange rate sterling growth calculate avandia launch march therapeutic figure give analysis sale quarter give financial record area trizivirfor hiv treatment launch november page sale present retain product basis exclude divest product sale market europe adjust effect parallel tradeoperate financial review prospectsglaxosmithkline seven cent total sale derive asia pacific area oral care principally australia sale growth cent acquisition block drug add number significant brand meter dose inhaler seretidewas launch market oral care business sensodyne polidentand poligrip sale zybangrew successful launch late exclude block drug oral care sale grow cent reflect strong growth europe partly offset strong competitive latin america report cent sale growth reflect strong pressure aquafreshin market growth mexico cent area predominately benefit seretidesereventflixotide market grow nutritional healthcare cent hivaids vaccine market show good nutritional healthcare business grow seven cent reflect return antibacterial decline generic competition strong performance lucozadeand horlick middle east africa area follow trend market growth seretide avandiaand hivaids trading profit business performance market vaccine area record growth cent illustrate glaxosmithkline business performance zofranin oncology area drive growth cent analysis trading profit subsequent discussion subsaharan south africa key driver growth exclude merger item integration restructuring cost antiviral vaccine disposal subsidiary management believe exclusion nonrecurre item provide well comparison business consumer healthcare sale performance period present accordingly information cer provide supplement contain consolidated statement profit loss page prepare otc medicine accordance ukgaap analgesic dermatological gastro intestinal growth cer respiratory tract sale smoking control vitamin natural cost sale oral care sell general nutritional healthcare administration research total sale continue business development divest product trading profit total consumer healthcare sale cost sale acquisition block drug company inc complete cost sale increase percentage sale loss january add million sale purchase add highmargin product divest december inclusion sensodynetoothpaste brand range denture care brand low margin block drug product high stock provision worldwide significant addition otc medicine largely partly offset benefit merger manufacturing usa block drug business integrate restructuring saving glaxosmithkline result acquisition glaxosmithkline sell general administration number company globally oral care add sell general administration sga cost benefit significant extra scale business particularly north america merger saving principally general administration expenditure japan europe inclusion block drug cost distort year year comparison exclude estimate block drug expense growth otc medicine sga expense cent sga express report sale otc medicine grow cent percentage sale cent low million primarily result acquisition block drug exclude block drug otc medicine decline cent research development reflect private label competition smoke control research development expenditure broadly level market sluggish growth global otc market year saving merger expenditure research development plan increase future june glaxosmithkline reach agreement taisho merger saving begin reinveste area establish partnership introduce nicotine replacement product japan trading profit significant new product introduction otc medicine include business performance trading profit growth cent niquitin lozenge effective otc product launch reflect improved trading margin trading margin improve tohelp smoker quit eumovate topical steroid cent cent result cost saving glaxosmithkline switch prescription otc major merger integration partly offset divestment certain high new extension panadolanalgesic fast act formula margin product require regulatory authority condition market actifast slow release product target merger persistent pain introduce scandinavia extend glaxosmithkline operate financial review prospect profit taxation business performance merger item restructuring cost disposal business analysis discussion profit taxation relate key item discuss business performance merger cost arise integration glaxo wellcome operating incomeexpense smithkline beecham business unify glaxosmithkline royalty income business refer merger integration cost amount operate expense million cost primarily include consultancy fee severance asset writeoff share option retention incentive income equity investment manufacturing restructuring cost million incur implement previously operate income significantly lower announce glaxo wellcome smithkline beecham plan low sale equity investment low product restructure manufacturing activity disposal high cost relate product withdrawal million charge respect postmerger restructuring activity cost include consultancy fee severance profit disposal interest associate asset writeoff group sell million share quest diagnostic inc year realise gain million st december block drug company inc share split quest share sale glaxosmithkline acquire block drug january cost glaxosmithkline hold million share incur acquire integrate business million comprise professional fee severance share profitslosse joint venture associate asset write off undertaking share profit associate arise principally group disposal business hold inquest diagnostic inc loss disposal business primarily arise sale affymax charge include million writeoff goodwill previously eliminate reserve net interest payable interest payable taxation investment income business performance share interest payable associate merger restructure disposal subsidiary total taxation net interest payable lower low average level net debt low interest rate business performance taxation charge taxation business performance profit amount profit taxation million represent effective tax rate cent operating incomeexpense disposal tax rate benefit low rate tax applicable interest inanassociate add million profit manufacturing operation singapore puerto rico ireland taxation compare million reduction onetime profit plan improve overall transfer pricing issue inevitable global business quality group earning take account contribution glaxosmithkline integrate nature group worldwide associate comprise share profit share ofinter operation involve significant investment research strategic thegroup net interest payable business performance manufacture limited number location consequential profit tax million compare million crossborder supply route numerous endmarket give rise increase cent complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit fall tax individual territory resolution issue continue factoflife glaxosmithklineoperate financial review prospectsglaxosmithkline usa number years glaxosmithkline significant critical accounting policy open issue relate transfer pricing issue affect year consolidated financial statement prepare accordance present concern number product ukgenerally accept accounting principle follow account significant relate success zantacin policy approve board describe note respect claim internal revenue service irs financial statement management require estimate substantially exceed group estimation taxation liability assumption affect amount asset liability revenue irs claim continue subject discussion expense report financial statement actual amount uk tax authority competent authority provision result differ estimate follow double tax convention country consider critical accounting policy adopt discussion wide variation view uk tax authority exceptionally unable legal dispute settle dispute event uk tax authority glaxosmithkline provide anticipate settlement cost reach agreement matter resolve litigation associate expense arise legal dispute glaxosmithkline use good advice determine transfer group reasonable estimate likely pricing methodology seek manage transfer pricing issue outcome dispute possible reasonable satisfactory conclusion basis external professional estimate provision advice continue believe adequate provision outcome claim legal proceeding matter liability likely arise open assessment glaxosmithkline involve predict certainty director take appropriate legal advice merger restructuring expect group ultimate liability matter take credit taxation merger restructuring item account provision tax benefit insurance material amount million reflect estimate actual tax adverse effect financial condition result operation rateapplicable transaction territory cash flow theyarise earning intangible asset intangible asset acquire glaxosmithkline earning party cost acquisition capitalise licence compound earning share p p development amortise estimate useful life earning ad exceed year estimate useful life review annually adjust earning impairment review undertake event occur adjust earning share p p question carry value asset adjust earning ad brand acquire business capitalise independently weight average number share million separable long term value group brand amortise estimate useful life exceed adjust earning adjust earning share year end useful economic life glaxosmithkline arepresente order illustrate business foresee brand amortise subject annual performance primary measure management impairment review discuss early future event cause value intangible asset adjust earning increase cent cer adjust earning significantly impaired adverse effect share increase cent cer weight average future result group number share purpose earning share decrease slightly topurchase share employee impairment fix asset share ownership trust satisfy future exercise share option carry value fix asset subject amortisation share purchase cancellation offset exercise share review impairment indication value option year asset impaired impairment determine reference high net realisable value value use measure reference discount cash flow future event cause assumption impairment review change consequent adverse effect future result group glaxosmithkline operate financial review prospect financial position resource cash flow group purchase share market cancellation amount million summary group cash flow set preference share classify nonequity minority interest amount million redeem exist group resource quarter total operating cash flow dividend joint venture major product divest obtain regulatory approval net interest minority merger generate proceed million december preference share dividend total net debt increase nearly billion billion tax payment free cash flow future cash flow net capital expenditure group expect future operating cash flow sufficient net cash operation fund operate debt service cost satisfy normal level dividend share capital expenditure meet obligation exist licensing business acquisition agreement meet routine commitment include business disposal tax dividend subject risk factor discuss page sale purchase equity investment sale purchase interest associate subsequent year group expect cash purchase share share option outflow integrate operation glaxo wellcome use share exercise share option smithkline beecham unify glaxosmithkline business share issue exercise share option cash outflow continue implementation purchase share cancellation manufacturing restructuring plan redemption preference share issue subsidiary group plan complete billion share buyback product divestment programme announce october exact movement include exchange timing purchase depend market condition increasereduction net debt fund group exist resource th march share purchase cancel net cash inflow total operating activity cost million million increase million group time time additional demand merger restructuring item million net interest finance acquisition group access payment minority preference share dividend tax source liquidity bank financial institution payment free cash flow represent cash flow addition cash flow operation forsuch need discretionary spending amount million increase million financial position capital expenditure tangible intangible fix asset summarise reclassify presentation group balance sheet amount million million set disposal realise million million group acquire block drug cash consideration million include business acquisition dispose goodwill interest quest diagnostic inc sum intangible fix asset million tangible fix asset investment total million million realise work capital sale purchase investment equity share debtor creditors rd october glaxosmithkline announce plan invest provision billion buying share market programme taxation cover purchase company employee share ownership defer taxation trust esot relate share option grant share net operating asset base incentive cover purchase company share share cancellation programme billion dividend propose spend net debt group fund purchase esot share net assets glaxosmithkline plc satisfy future exercise option shareholder fund award employee share incentive scheme total cost minority interest million million atotal million million receive employee exercise finance net asset share option exercise satisfied share previously purchase esot yield million million exercise satisfied issue new share yield million millionoperate financial review prospectsglaxosmithkline book value net asset decrease million net debt increase million primarily stdecember million st december purchase block drug cash consideration million decrease million reflect redemption restructuring merger cost million purchase million nonequity minority interest purchase share company cancellation esot share cancellation share share buyback programme option commitment total million effect net asset exchange rate movement partly offset retain profit million provide shareholder fund dividend summary movement equity shareholder fund set intangible fix asset intangible fix asset st december million st december million include fair value beginning year brand acquire million acquisition block drug profit year remain increase intangible asset reflect acquisition dividend licence patent knowhow marketing right partially offset share issue exercise share option amortisation expense impairment loss share issue cancel exchange movement overseas net asset investment goodwill write glaxosmithkline investment st december end year carry value million st december million investment mainly equity share hold equity shareholder fund decrease million derive directly group business arise st december million st december business divestment connection research collaboration primarily retain profit share purchase access biotechnology development potential interest cancellation write reserve goodwill glaxosmithkline equity investment include current asset regard available sale include commitment contingent liability fix asset market value investment st financial commitment summarise note financial december approximately billion st december statement commitment contingent liabilitie billion market value volatile obligation respect short long term debt set note contingent liability note net debt share st december esot hold million share payment policy company option commitment employee share incentive plan date million share group company responsible monitoring manage million exercisable work capital term sale collection supplier payment reflect local commercial practice debtor creditor increase net creditor year reflect increase uk company uk subsidiary operate accrual legal dispute inlicense technology procedure ensure supplier pay time particular staff compensation uk company seek settle term payment supplier agree provision term transaction group carry provision million st december ensure supplier aware agree term respect estimate future liability ofpayment million relate pension postretirement abide term payment benefit employee provision legal dispute indemnify disposal liability cost procedure include arrangement accelerate payment manufacturing restructuring merger integration extent small supplier balance sheet date actual constructive obligation exist case merger integration manufacturing payment performance restructure majority remain cost expect st december average number day purchase recognise end represent trade fix asset creditor company nil day nil day respect company uk net debt subsidiary aggregate day day group net debt st december comprise company see deterioration payment performance result integration system expect improve cash liquid investment borrowing repayable year borrowing repayable year net debt glaxosmithkline operate financial review prospect treasury policy liquid asset surplus immediate operating requirement group company invest manage centrally corporate glaxosmithkline plc ukbased business report sterling treasury requirement group company operate finance pay dividend sterling profit meet possible central resource role corporate treasury glaxosmithkline manageand external borrowing mainly manage centrally corporate monitor group external internal funding requirementsand treasury comprise portfolio long mediumterm instrument financial risk support group corporate objective treasury shortterm finance activity govern policy procedure approve board monitor treasury management group glaxosmithkline hold issue derivative financial glaxosmithkline maintain treasury control system procedure instrument trading purpose group treasury policy monitor foreign exchange interest rate liquidity credit specifically prohibit activity transaction financial financial risk instrument undertake manage risk arise underlie business activity speculation liquidity group operate globally primarily subsidiary company fund maturity counterparty risk establish market group trade group invest centrally manage liquid asset primarily nature group business patent protection government bond shortterm corporate debt instrument ofthe product group portfolio group product minimum shortterm credit rating ap standard compete largely product efficacy price selling poor moodys respectively margin sufficient cover normal operating cost group manage net borrowing requirement group operating subsidiary substantially cash generative portfolio long mediumterm borrowing include bond operate cash flow fund investment research shortterm finance commercial paper development new product routine outflow capital programme group mediumterm borrowing mature date expenditure tax dividend repayment mature debt longdate sterling bond mature group time time additional demand finance share purchase acquisition glaxosmithkline longterm debt rating aa standard december billion fix rate year bond poor aa moodys agencies shortterm rating issue new billion european medium term paper issue group commercial paper programme programme addition usbillion commercial paper p respectively programme sign december programme replace premerger funding programme flexibility interest rate risk management group fund option glaxosmithkline policy interest rate risk management require net borrowing fix rate increase glaxosmithkline operate low level net debt addition ratio forecast net interest payable trading profit tothe strong positive cash flow normal trading activity additional liquidity readily available commercial sensitivity analysis consider sensitivity group net debt paperprogramme back committed line credit hypothetical change market rate assume variable remain constant base composition net debt treasury operation st december cent increase decrease average objective treasury activity manage posttax net interest rate result negligible change group costincome financial operation benefit group annual interest expense earning corporate treasury operate profit centre foreign exchange risk management glaxosmithkline use variety financial instrument include glaxosmithkline foreign currency transaction exposure arise derivative finance operation manage market risk normal trade flow respect external intragroup operation trade hedge glaxosmithkline policy minimise financial instrument comprise cash liquid resource exposure overseas operating subsidiary transaction risk borrowing spot foreign exchange contract bymatche local currency income local currency cost forthispurpose intragroup trading transaction match glaxosmithkline use number derivative financial instrument centrally intragroup payment term manage reduce manage market risk treasury operation derivative risk exceptional foreign currency cash flow hedge selectively instrument principally comprise forward foreign currency management corporate treasury contract interest rate currency swap corporate treasury swap borrowing liquid asset currency base composition net debt st december require group purpose manage exposure market cent appreciation sterle major currency risk change foreign exchange rate interest rate result reduction group net debt approximately million cent weaken sterle major glaxosmithkline balance use borrowing liquid asset currency result increase group net debt regard cash flow operating activity approximately million thecurrencie earn tax cost intragroup distribution currency business asset denominate posttax cost borrowing compare totheposttax return liquid assetsoperate financial review prospect glaxosmithkline high proportion group borrowing include commercial company obtain shareholder approval annual paper programme dollar benefit liquidity general meeting market purchase share denominate capital market certain rd october glaxosmithkline announce share borrowing swap currency require group repurchase programme esot share purchase programme purpose group seek denominate borrowing billion announcement date st december currency principal overseas asset borrowing denominate glaxosmithkline purchase million share cancellation swap foreign currency match investment total cost million overseas group asset treat hedge relevant net asset european monetary union glaxosmithkline european company preparation derivative financial instrument hedge policy introduction single currency st january group use limited number currency swap interest country europe directly affect preparation rate swap redenominate external borrowing intothe currency include conversion information system datum financial interest rate coupon require group purpose duration process training staff local implementation swap match duration theprincipal instrument team support central coordination team experience group manage centrally shortterm cash surplus introduction euro begin borrowing requirement subsidiary company use forward show conversion information system datum contract hedge future repayment originate financial process successful currency contract year duration shortterm company expect cost derivative instrument account hedge relevant benefit introduction euro material effect asset liability group trading performance equity risk management group use derivative financial instrument manage equity risk equity investment classify current asset available sale group manage disposal meet overall business requirement arise financial asset liabilitie analysis net debt give note financial statement analysis financial asset liability carry value fair value reconciliation net debt give innote discussion derivative financial instrument quantitative disclosure market riskin accordance requirement financial reporting standard group net debt increase nearly billion st december st december primarily impact acquisition block drug merger restructuring cost group purchase share market redemption preference share classify nonequity minority interest group continue benefit strong positive cash flow group financial asset liability st december representative treasury policy strategy glaxosmithkline apply consistently year significant change policy year esot share purchase share purchase cancellation group fund market purchase employee share ownership trust share glaxosmithkline plc amount million million share hold employee share ownership trust satisfy future exercise option award group share option award scheme proportion purchase respect option rule scheme require company satisfy exercise market purchase issue new share purchase represent opportunity acquire share satisfy future exercise price exercise price purchase match option grant diminish dilutive effect new share issue shareholder capital earning glaxosmithkline operate financial review prospect outlook risk factor outlook generic drug manufacturer seek market generic version number group important product include improve pharmaceutical sale growth exist product augmentin paxiland wellbutrin prior expiration seven cent cer cent group patent product future cent key driver glaxosmithkline current effort involve challenge validity patent business performance company expect launch assertion alternative compound infringe advair forcopd infanrix pentadutasteride vardenafil group patent group successful maintain merger saving million achieve exclusive right market major product manufacture restructuring saving excess particularly usa group high margin million group expect deliver total annual merger sale country patent protection period manufacture restructuring saving rd group revenue margin adversely affect reinvestment billion saving note financial statement legal proceeding measure project level expenditure discussion patentrelate proceeding group forecast glaxo wellcome smithkline beecham involve immediately prior merger country group operate patent glaxosmithkline expect deliver business performance earning protection significantly weak usa share growth midteen lowteen european union addition effort control public health well guidance assume glaxosmithkline crisis develop country south africa brazil successfully defend intellectual property surround recently announce plan substantial reduction augmentinand paxilin usa scope patent protection pharmaceutical product particular country facilitate competition glaxosmithkline engage legal proceeding validity market generic manufacturer infringement group patent relate augmentinand unable introduce compete product number year paxilseroxat discuss risk factor loss patent protection likely affect adversely group note financial statement legal proceeding operate result group net debt billion low relative pharmaceutical product price subject control pressure market capitalisation position advantage market government intervene directly set opportunity arise build business price addition market major purchaser risk uncertaintie inherent business pharmaceutical product governmental agency discuss risk factor private health care provider economic power exert substantial pressure price group predict risk factor exist control increase new control introduce reduce group margin affect adversely ability risk uncertaintie relevant group business introduce new product profitably factor list group think cause group actual result differ materially expect example usa group high margin historical result factor list sale country pricing pressure significantly adversely affect group increase proposal consideration reform medicare federal state programme control group operate highly competitive business cost pharmaceutical adopt medicare programme pharmaceutical business face competition provide outpatient pharmaceutical coverage proprietary product large international manufacturer beneficiarie government enormous purchasing producer generic pharmaceutical significant product power programme demand discount innovation technical advance intensification price implicitly create price control prescription drug additionally competition competitor adversely affect group number state propose implement scheme operating result continue consolidation pharmaceutical control price senior citizen drug programme industry adversely affect group competitive position include importation country bulk purchasing continue consolidation group customer drug growth number patient cover increase pricing pressure large manage care institution usa likely particular group face intense competition increase medicare reform increase pricing pressure manufacturer generic pharmaceutical product group product trend adversely affect major market generic product enter market group revenue margin sales usa expiration patent datum exclusivity period group group comply broad range regulatory control product introduction generic product typically lead test approval manufacturing marketing dramatic loss sale reduce group revenue pharmaceutical consumer healthcare product margin proprietary product expiration date country include usa european union patent group major product set regulatory control increasingly demand increase description business patent cost product development time require reach market uncertainty successfully group expect trend continue expand countriesoperate financial review prospectsglaxosmithkline strict regulatory control heighten risk withdrawal group control change inflation interest regulator approval previously grant reduce rate foreign currency exchange rate control revenue result product recall product liability economic factor affect business possibility lawsuit addition case group voluntarily political unrest legal regulatory change nationalisation cease marketing product face decline sale base jurisdiction group operate factor concern efficacy safety scientifically materially affect group future result operation justify absence regulatory action effective tax rate group earning benefit continue development commercially viable new product fact portion earning tax favourable rate critical group ability replace sale old product jurisdiction outside united kingdom change tax decline expiration exclusive right increase overall law application respect matter transfer sale develop new product costly lengthy uncertain pricing note financial statement taxation process new product candidate fail stage relate portion group earning tax process latestage product candidate fail favourable rate increase group effective tax rate receive regulatory approval new product candidate appear adversely affect net earning promise development significant investment fail new revise accounting standard rule promulgate reach market limited commercial success time time uk international accounting standardsetting result efficacy safety concern inability obtain necessary board material adverse impact group regulatory approval difficulty excessive cost manufacture report financial result infringement patent intellectual property right group currently defendant number lawsuit include class action involve substantial claim damage governmental investigation lawsuit include product liability claim relate group pharmaceutical product antitrust action number lawsuit class action include claim punitive damage unfavourable resolution similar future proceeding material group result operation cash flow group material provision relate legal proceeding reduce earning recent insurance loss experience include pharmaceutical product liability exposure increase cost insurance coverage group order contain insurance cost group adjust coverage profile accept great degree selfinsurance note financial statement legal proceeding discussion proceeding group currently involve environmental law jurisdiction impose actual potential obligation group remediate contaminate site group identify potentially responsible party comprehensive environmental response compensation liability act number site remediation cost relate group use ownership site note financial statement legal proceeding discussion environmentalrelate proceeding group involve group currently product million billion annual global sale product augmentin paxilseroxatand wellbutrin group currently defend intellectual property right usa group major product subject problem loss patent protection unexpected effect regulatory proceeding publicity affect doctor patient confidence pressure competitive product new effective treatment introduce impact group revenue operating result significant group conduct substantial portion operation outside united kingdom fluctuation exchange rate sterling currency especially dollar euro materially affect group revenue operating result glaxosmithkline operate financial review prospect year accordance ussec disclosure requirement follow rhinitis sector growth flixonaseflonasewas similarly offset discussion compare result year st december decline old product beconase overall group result year st december product sector grow cent support dtc advertising usa exchange antibacterial average sterling exchange rate weak sale antibacterial product increase cent dollar yen strong european growth augmentinoffset flat sale zinnatceftinand currency aggregate currency movement amoxiland decrease fortum net favourable effect sterling result compare cent respect sale cent respect sale reach billion augmentincontinue perform business performance earning share strongly usa sale grow cent market share nearly quarter solid growth achieve latin america pharmaceutical sale south east asia europe sale affect generic competition glaxosmithkline pharmaceutical sale amount million compare million increase zinnatceftindecline seven cent large market cent exclude sale divest product product usa offset growth emerge market divest fulfil regulatory condition approval middle east africa latin america asia pacific glaxo wellcomesmithkline beecham merger sale growth continue business cent growth substantially antiviral volume increase minor net increase price growth antiviral sale cent reflect strong growth hiv franchise group market range reverse pharmaceutical sale therapeutic area transcriptase inhibitor rtis recently launch protease inhibitor agenerase steady growth sale herpe product central nervous system continue uptake new product viral disease antidepressant sector sale billion achieve strong growth seroxatpaxiland wellbutrincontribute sale rtis increase cent combiviragain grow growth cent important market paxilwas strongly reflect conversion patient constituent single support successful directtoconsumer dtc campaign product epivirand retrovir aggregate product promotional effort enable wellbutrinto increase achieve real growth cent market share product benefit overall growth group herpe treatment new valtrexand antidepressant market old zovirax grow combine rate cent valtrex migraine portfolio imigranimitrexand naramigamerge continue protect group franchise area strong grow cent reflect return growth usa increase region successful launch japan august account quarter sale dtc market zeffix chronic hepatitis b achieve sale million campaign migraine awareness programme instrumental launch asia pacific area perform strongly increase sale europe sale stable strong growth chinese south korean market france offset decline market relenza new influenza treatment double sale sale lamictal epilepsy treatment grow strongly worldwide million follow launch japan december particularly usa great market penetration available major market achieve expand market requip treatment parkinson disease increase sale cent smoking metabolic gastrointestinal cessation market zybans growth cent reflect rollout avandia glaxosmithkline new treatment type diabete european market follow european union approval april achieve sale approach half billion pound majority initial sale particularly strong uk germany usa launch april fda approve avandiain combination sulphonylurea respiratory previously approve monotherapy combination flixotidefloventsale increase cent notably usa metformin august avandiareceive positive dtc promotion expand market lead recommendation uk national institute clinical cent increase sale europe group new excellence nice combination product seretide launch market sale flixotidewere maintain despite seretide success zantaccontinue decline face competition generic sereventgrew cent growth particularly product alternative antiulcerant treatment rate strong market decline slow cent zantacs large market japan sale remain stable seretide new combination flixotideand sereventgenerate sale million significant new market lotronex treatment irritable bowel syndrome launch include spain italy australia uk germany usa march generate sale million seretidehad available year continue withdraw november follow discussion strong gain market share fda interpretation datum relate gastrointestinal effect company disagree total antiasthmacopd sale grow cent reflect fdas assessment safety profile lotronex agree strong performance flixotide sereventand seretide offset withdraw market withdraw decline sale old asthma product ventolinand regulatory submission worldwide becotide patient convert new productsoperate financial review prospectsglaxosmithkline pharmaceutical sale therapeutic area total usa europe row therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg dermatological arthritis relafen total sale continue business divest product famvir kytril total pharmaceutical sale cer represent sale growth constant exchange rate sterling growth calculate figure give glaxosmithkline operate financial review prospect vaccine strong growth sale augmentinand amoxiloffset decline vaccine sale reach million increase cent ceftinand fortum enable sale antibacterial area hepatitis franchise engerixbdecline cent outperform market growth augmentinbenefite increase low sale usa havrix hepatitis grow slightly prescriber awareness effectiveness bacteria resistant twinrix combine hepatitis b vaccine adult antibiotic paediatric strength grow cent million minor impact sale growth product disposal infanrix glaxosmithkline range combination vaccine anaesthesia portfolio dermatological range diphtheria tetanus pertussis whooping cough grow october cent october european commission approve infanrix penta provide additional protection hepatitis b europe polio infanrix hexawhich add protection sale europe represent cent group haemophilus influenzae typeb disease pharmaceutical sale grow cent france glaxosmithkline large market region sale oncology emesis grow strongly reflect growth hiv portfolio zofran emesis wellestablishe product leader asthma franchise major market italy germany spain sector benefit market growth usa seretidewas key contributor growth uk market benefit third sale generate increase sale seretideand successful launch zyban overall sale decline slightly generic competition therapeutic area parallel trade cardiovascular sale stable cent growth coreg recent launch pritorfor hypertension european market success seretidecontribute cent growth offset decline old product future sale benefit asthmacopd range growth lamictaland launch new datum show coregs effectiveness treat severe zybancontribute cent increase total cns sale sale heart failure hiv product increase cent combination solid growth establish product range uptake recently disposal anaesthesia franchise usa end launch ziagen sale infanrix combination vaccine contribute fall therapeutic area cent child grow recent approval infanrix october glaxo wellcome company dispose pentaand infanrixhexaoffere potential growth portfolio dermatological product contribute cardiovascular area launch pritorle cent cent decline sector increase sale pharmaceutical sale geographic area offset strong performance decline sale augmentin mild flu season impact generic usa competition uk germany continue decline sale market represent half total group zantac avandiawas launch uk germany late pharmaceutical sale grow cent avandia launch june achieve sale million rest world market leader class benefit overall growth cent reflect mix double digit withdrawal competitor product market growth asia pacific middle east africa canada quarter year slow growth japan latin america respiratory sale increase cent reflect particular asia pacific market principally contribute sale growth increase acceptance inhale steroid treatment australia area large market launch seretide asthma august zybanin november china zeffix launch key factor sale growth cent cns sale increase cent grow anti depressant market dtc campaign focusse social anxiety japan group second large market sale grow disorder help paxilto grow cent migraine cent sale asthma product grow quarter launch portfolio growth cent reverse decline see paxilin november relenzain december add previous year reflect promotional effort million sale offset decline sale overall expansion market lamictal antibiotic small product contribute significantly growth sale latin america sale growth cent affect increase cent difficult condition brazil exclude brazil sale region antiviral sector hiv sale grow cent reflect grow cent mexico group large market continue growth establish product uptake region sale grow cent good performance new product ziagen ageneraseand initial sale trizivir therapeutic area particularly vaccine brazil sale affect generate million sale approval government drive promote generic product market trizivirwas receive november herpe impact hiv contract repeat sector strong sale valtrexbenefite convenience middle east africa region grow cent oncedaily dosage form wide usage long notable increase hiv product antibiotic term herpe suppression therapy canada sale grow cent reflect strong growth paxiland recent launch seretideand avandia rest asthmacopd range wellbutrinalso contribute growth zybandecline centoperate financial review prospectsglaxosmithkline consumer healthcare sale cost sale cost sale increase increase sale smithkline cer beecham reflect benefit manufacturing rationalisation otc medicine change product mix benefit newly launch product oral care reduce external royalty glaxo wellcome cost sale nutritional healthcare increase percentage sale reflect low production total sale continue business volume follow stockbuild reduce rate divest product increase second half year manufacture total consumer healthcare sale rationalisation deliver efficiency benefit exchange sell general administration otc medicine sell general administration sga increase line sale growth vitamin natural dermatological sale growth high selling cost particularly support product offset decline category notably smoke control launch avandia seretideand paxil offset saving gastrointestinal sale affect low sale tumsin administration cost competitive market analgesic affect voluntary recall panadolin australia follow tamper threat research development research development rd expenditure increase smoking control sale decline cent reflect competition increase sale pharmaceutical rd million market follow introduction private label nicotine consumer healthcare rd million replacement therapynrt gum patch introduction new glaxosmithkline smoking control product trading profit market clear nicodermpatchand nicorette orange gum trading profit increase cent increase sale prevent inroad private label brand exclude reflect management sga line sale growth low usa smoking control sale grow cent rate increase cost sale rd oral care healthcare service sale aquafreshtoothpaste toothbrush increase healthcare service business divest contributed percent notably usa rest world market trading profit date divestment offset decline oral care brand profit taxation business performance nutritional healthcare strong sale growth achieve nutritional healthcare analysis discussion profit taxation relate range sale lucozadebenefite strong growth lucozade business performance sportin uk operating incomeexpense divest product royalty income divest product product sell operate expense regulatory approval merger income equity investment trading profit business performance illustrate glaxosmithkline business performance analysis trading profit subsequent discussion net operating income low few exclude merger item restructuring cost cost arise disposal old product income equity investment include disposal healthcare service business disposal affymetrix share second half year management believe exclusion nonrecurre item reduce group hold cent provide well comparison business performance period present accordingly information provide disposal associate supplement contain consolidated statement group reduce investment affymetrix inc half profit loss page prepare accordance uk realise gain million account gaap analysis discussion focus retain business disposal interest associate subsequently group pharmaceutical consumer healthcare performance cease significant influence affymetrix time healthcare service dealt separately cease equity account investment disposal share affymetrix second half growth include investment disposal operating income cer sale profitslosse associate joint venture cost sale share profit associate arise principally smithkline sell general beecham hold inquest diagnostic incorporate administration hold august research development trading profit glaxosmithkline operate financial review prospect net interest payable manufacturing restructuring cost million incur glaxo wellcome interest payable million smithkline beecham implementation investment income previously announce plan restructure manufacturing activity share interest payable associate associate cost represent group share restructuring cost net interest payable include group share net interest incur associate quest diagnostic inc associate quest diagnostic inc august apart quest diagnostics inc divest business interest interest payable investment income broadly stable impact disposal healthcare service business compare reflect consistent average level august million million net credit net debt proceed disposal restructuring cost incur healthcare service divest product receive late december million minor benefit net interest payablein taxation profit taxation operating incomeexpense disposal business performance interest anassociate add million profit merger restructure disposal taxation compare million taking subsidiary account contribution associate comprise share total taxation profit share interest thegroup net interest payable profit tax million compare charge taxation business performance profit amount million increase cent million represent effective tax rate cent consistent rate cent expect glaxo merger item restructuring cost divest business wellcome rate cent expect merger smithkline beecham cost effecting merger refer transaction cost amount million cost comprise expense earning fee prepare implement scheme arrangement earning merger include obtain approval shareholder earning ordinary share p p regulatory authority secure admission earning adr glaxosmithkline share official list uk list authority adjust earning cost incur planning arise integration adjust earning ordinary share p p glaxo wellcome smithkline beecham business adjust earning adr unified glaxosmithkline business refer integration cost weight average number share million amount million cost include consultancy fee support integration planning severance cost adjust earning adjust earning sharearepresente recognise arise initial stage integration order illustrate business performance appointment process initial asset writeoff cost glaxosmithkline million recognise smithkline beecham respect adjust earning increase cent cer adjust earning accelerate vest share option share incentive award share increase cent cer reflect low result merger cost recognise glaxo wellcome weight average number share weight average number arise lapse performance condition attach share purpose earning share decrease share incentive award result merger purchase share employee share ownership trust order obtain regulatory approval merger glaxo satisfy future exercise share option wellcome smithkline beecham agree number product divestment significant divestment famvir kytril sell december famvirwas sell novartis kytrilwas sell roche sale kytril roche glaxosmithkline purchase exclusive right coreg usa canadaoperating financial review prospectsglaxosmithkline select financial datum ukus gaap profit loss account amount accordance uk gaap business performance retain business sale operate profit profit taxation earningsnet income business performance primary performance measure management present exclude merger item restructuring cost disposal subsidiary early year exclude divest healthcare service business management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement contain consolidated statement profit loss page prepare accordance ukgaap total result include nonrecurre item total result sale operate profit profit taxation earningsnet income earning share p p p p p weight average number share million dividend glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend glaxosmithkline ad glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline sharead amount accordance gaap total result sale incomeloss operation profitloss tax net lossincome balance sheet amount accordance uk gaap total asset net asset equity shareholder fund amount accordance gaap total asset net asset shareholder equity exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate th march glaxosmithkline operate financial review prospect result accounting principle review discuss result glaxosmithkline plc change shareholder equity year shareholder equity st beginning year december prepare accounting principle net lossincome combination glaxo wellcome smithkline beecham share issue acquisition account merger ukgaap financial share purchase cancel statement glaxosmithkline present share issue share option company combine period present treasury stock usgaap glaxo wellcome determined accounting dividend acquirer smithkline beecham purchase acquisition date th december financial statement end year glaxosmithkline prior merger glaxo wellcome net asset smithkline beecham book value glaxosmithkline glaxo wellcome incorporate smithkline beecham net asset ukgaap basis adjust normal ukusgaap difference principal adjustment result inclusion unamortised goodwill intangible asset glaxos acquisition wellcome glaxo wellcome acquisition summary result smithkline beecham dividend declare propose sale basis treatment share hold employee share trading profit ownership trust treasury stock investment operate profitloss profitloss tax prospect net loss glaxosmithkline publish expectation future growth basic loss share penny earning share ukgaapbasis exclude merger result glaxosmithkline glaxo wellcome restructure item refer outlook sale increase primarily acquisition smithkline glaxosmithkline expect incur cost deliver expense beecham th december block drug january savings synergies integration glaxo wellcome smithkline beecham operation trading profit increase primarily result ukgaap cost expense usgaap certain acquisition smithkline beecham december block cost expense represent drug january trading profit low usgaapbasis adjustment value acquire goodwill uk gaapbasis result primarily charge sfas stockbase compensation amortisation adoption sfa recent fasb pronouncement product right purchase receive company adopt sfas accounting derivative regulatory approval instrument hedge activity st january sfas operate profitloss include significant difference require derivative carry balance sheet fair annual charge amortisation goodwill intangible asset value company record transition adjustment arise glaxos acquisition wellcome glaxo movement derivative instrument adjustment wellcome acquisition smithkline beecham sfas business combination require business intangible asset recognise balance sheet amortise combination st july account profit loss statement usgaap uk purchase method gaap additionally onetime charge million write inprocess research development sfas goodwill intangible asset require acquire acquisition smithkline beecham effect implement effect st january standard charge produce profit tax result reclassification certain intangible asset goodwill million tax minority interest net loss addition goodwill intangible indefinite useful life year million compare loss tax long amortise subject annual impairment million tax minority interest net loss test amortisation expense goodwill intangible million consider indefinite life billion sfas accounting obligation associate shareholders equity st december retirement longlive asset issue august shareholders equity st december ukgaap require implement effect st january respect glaxosmithkline million standard require fair value obligation associate retirement tangible longlived assets acquisition smithkline beecham th december capitalise asset cost finance issuance common stock premium par increase shareholder equity billion considerationi october fasb issue sfas accounting represent billion asset book value impairment disposal longlive asset require gaap basis billion ukgaapbasis billion fair value implement effect st january standard adjustment principally respect intangible asset goodwill develop accounting model longlive asset include value billion ascribe inprocess research discontinue operation dispose sale company development write income statement currently assess impact sfas glaxosmithkline financial statement section comprise director statement independent auditor report financial statement financial statement consist principal financial statement support note additional financial data director statement responsibility independent auditor report financial statement consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement presentation financial statement accounting policy new accounting policy requirement exchange rate merger glaxo wellcome smithkline beecham segment information merger item restructuring cost divest business operate incomeexpense operating profit joint venture associate undertaking net interest payable taxation earning share dividend goodwill intangible asset tangible fix asset fix asset investment equity investment stock debtor creditor provision liability charge contingent liability net debt commitment share capital share premium account nonequity minority interest reserve legal proceeding acquisition disposal financial instrument relate disclosure employee share scheme director remuneration employee cost reconciliation accounting principle principal group company principal financial statement financial record quarterly trend year record glaxosmithkline director statement responsibility director statement responsibility relation internal control tothefinancial statement board audit committee review director assessment risk internal control framework operate glaxosmithkline plc consider responsible ensure maintenance proper accounting effectiveness system internal control operation record disclose reasonable accuracy financial inthegroup year cover report position group time financial date approval board director statement beprepare comply company act combine code require law prepare financial statement financial period true fair view state board consider glaxosmithkline plc apply principle affair company group end combine code asdescribe corporate governance financial period ofthe profit loss period page comply provision responsible ensure operation system combine codewiththeexception provision relate internalcontrol take reasonable step safeguard appointment senior independent director asset group prevent detect fraud company position describe board executive irregularity executive director service contract pensionable bonus financial statement year end st december terminationcommitment company position comprise principal statement support note set describe remuneration report infinancial statement page report chairman remuneration nomination committee unable attend annual general meeting director confirm suitable accounting policy owe business commitment consistently apply preparation financial statement support reasonable prudent judgement estimate require listing rule financial service authority asnecessary applicable accounting standard follow auditor haveconsidere director statement compliance financial statement prepare go relation point combine code concern basis specify theirreview responsibility auditor relation financial annual report statement set independent auditor report opposite annual report year end st december comprising report director financial statement financial statement year end st december additional information investor approve include annual report publish board director sign behalf company hardcopy print form company web site internet director responsible maintenance sir richard syke chairman integrity annual report web site accordance th march uk legislation govern preparation dissemination financial statement access web site available outside uk comparable legislation different director remuneration remuneration report page report describe board policy director remuneration apply glaxosmithkline plc set detail remuneration earn director convenience remuneration report include disclosable information relate director officer interest statutory disclosure respect remuneration attributable todirector glaxosmithkline plc set note financial statement remuneration report complie section b combine code go concern basis make enquiry director reasonable expectationthat group company adequate resource continue operational existence foreseeable future forthis reason continue adopt go concern basis inprepare accountsglaxosmithkline independent auditor report members glaxosmithkline plc audit consolidated financial statement basis audit opinion comprise consolidate statement profit loss conduct audit accordance auditing standard consolidate statement total recognise gain loss issue united kingdom auditing practice board consolidate statement cash flow consolidated balance sheet withauditing standard generally accept united states relate note prepare anaudit include examination test basis evidence relevant historical cost convention accounting policy set amount disclosure financial statement statement accounting policy examine include assessment significant estimate judgement amounts disclose relate emolument share option director preparation financial longterm incentive director form statement accounting policy appropriate remuneration report company circumstance consistently apply adequately disclose respective responsibility director auditor plan perform audit obtain director responsibility prepare annual report information explanation consider necessary consolidated financial statement accordance applicable order provide sufficient evidence reasonable united kingdom law accounting standard set assurance consolidated financial statement free statement director responsibilitie material misstatement cause fraud responsibility audit consolidated financial statement irregularity error form opinion evaluate accordance relevant legal regulatory requirement unite overall adequacy presentation information kingdom auditing standard issue auditing practice board consolidated financial statement list rule financial service authority united kingdom opinion report opinion financial statement true fair view properly prepare opinion financial statement true fair view inaccordance united kingdom company act state affair company group st december wealso report opinion report director profit cash flow group year consistent consolidated financial statement end properly prepare accordance company hasnot keep proper accounting record united kingdom company act receive information explanation require audit information specify law list rule united states opinion director remuneration transaction disclose opinion financial statement present fairly material read information contain annual report respect consolidated financial position group consider implication report aware stdecember result consolidated anyapparent misstatement material inconsistency operation andit consolidated cash flow consolidated financial statement information comprise year period end st december conformity report director joint statement accounting principle generally accept united kingdom chairman chief executive officer operate accounting principle generally accept united kingdom financial review corporate governance statement vary certain significant respect accounting principle review corporate governance statement reflects generally accept united states application company compliance seven provision affect determination consolidate net income combine code specify review list rule express insterle year period end report require consider stdecember determination consolidated board statement internal control cover risk shareholder equity express sterling st december control form opinion effectiveness extent summarise note company group corporate governance procedure financial statement risk control procedure pricewaterhousecooper charter accountant register auditor southwark tower london england th march glaxosmithkline consolidate statement profit loss merger restructuring business disposal performance subsidiary total note turnover include million relate acquisition cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit include million relate acquisition share profitslosse joint venture associate undertaking profit disposal interest associate product divestment merger transaction cost disposal business loss disposal utilisation provision profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning share p adjust earning share p dilute earning share p profit attributable shareholder dividend retain profit item deal arrive business performance operating profit relate continue activity difference profit ordinary activity taxation retain profit state historical cost equivalent consolidate statement total recognise gain loss profit attributable shareholder exchange movement overseas net asset uk tax exchange movement total recognise gain loss consolidate statement profit lossglaxosmithkline merger business performance restructure restructuring business disposal retain divest disposal performance subsidiary total business business total subsidiary total p p p p p p glaxosmithkline consolidate statement cash flow reconciliation operating profit operating cash flow note operate profit depreciation impairment intangible asset write amortisation goodwill intangible fix asset loss sale tangible fix asset profit sale equity investment decreaseincrease stock increase trade debtor increase trade creditor increase pension provision merger transaction cost pay net cash inflow operating activity cash flow statement net cash inflow operating activity dividend joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash outflowinflow management liquid resource finance management liquid resource finance decreaseincrease cash year reconciliation net cash flow movement net debt net debt begin year decreaseincrease cash year cash outflowinflow management liquid resource net increase longterm loan net repayment shortterm loan net repayment ofincrease obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flow return investment servicing finance interest receive interest pay dividend pay minority shareholder dividend pay preference share taxation pay capital expenditure financial investment purchase tangible fix asset sale tangible fix asset purchase intangible asset sale intangible asset product divestment purchase share employee share option award proceed share employee share option purchase equity investment sale equity investment acquisition disposalsnote purchase business cash acquire subsidiary disposal business investment joint venture associate undertaking disposal interest associate financing issue ordinary share capital redemption preference share issue subsidiary ordinary share capital purchase cancellation financing cash flow increase longterm loan repayment longterm loan net repayment shortterm loan net repayment ofincrease obligation finance lease analysis change net debt cash flow acquisition exchange cash repayable demand overdraft debt year commercial paper debt year euro bond mediumterm notes management liquid resource cash balance repayable demand liquid investment net debt glaxosmithkline consolidated balance sheet note goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset call share capital share premium account reserve profit loss account equity shareholder fund nonequity minority interest equity minority interest capital employ approve board sir richard sykeschairman th march reconciliation movement equity shareholder fund note equity shareholder fund begin year total recognise gain loss year dividend ordinary share issue ordinary share purchase cancel exchange movement goodwill write reserve goodwill write equity shareholder fund end year glaxosmithkline company balance sheet note share subsidiary company cost fix asset amount owe group undertaking cash bank current asset taxation dividend propose creditor amount year net asset call share capital share premium account reserve profit loss account equity shareholder fund approve board sir richard sykeschairman th march glaxosmithkline note financial statement presentation financial statement additional information accordance requirement usgenerally accept accounting principle gaap include description business note financial statement note statement glaxosmithkline major global healthcare group difference reconciliation net income shareholder engage creation discovery development manufacture equity uk gaap provide principal marketing pharmaceutical product include vaccine financial statement present accordance gaap overthecounter otc medicine healthrelate consumer andin usgaap format product glaxosmithkline principal pharmaceutical product include medicine follow therapeutic area central merger glaxowellcome plc smithkline beecham plc nervous system disorder respiratory antibacterial antiviral glaxosmithkline plc acquire glaxo wellcome plc smithkline metabolic gastrointestinal vaccine oncology emesis beecham plc way scheme arrangement merger cardiovascular arthritis company effective th december financial period ukgaap financial statement glaxosmithkline plc account cover financial year st january prepare merger glaxowellcome plc smithkline stdecember comparative figure financial beecham plc comparative figure year year st january st december st january st december st december include tost december result glaxo wellcome plc smithkline beecham plc gaap financial statement glaxosmithkline plc composition group prepare acquisition smithkline beecham plc list subsidiary associate undertakings glaxo wellcome plc th december accordingly opinion director principally affect result smithkline beecham period prior date profit net asset group give principal group consolidated company note presentation statement profit loss composition financial statement columnar presentation adopt statement consolidated financial statement draw accordance profit loss order illustrate underlie business performance uk generally accept accounting principle ukgaap primary measure management uk accounting presentation purpose certain item identify separately exclude financial statement comprise business performance comprise merger integration item include product divestment cost relate previously consolidate statement profit loss announce manufacturing restructuring theeffect consolidated statement total recognise gain loss disposal subsidiary consolidate statement cash flow consolidated balance sheet trading profit reflect sale cost sale comprise cost reconciliation movement equity shareholder fund ofmanufacture external royalty sell general company balance sheet administrative expenditure comprise cost sell note financial statement distribution medical support currently market product cost administration cost research permit section company act development create future product sale profitand loss account company present consolidated statement total recognise gain loss accounting convention comprise financial statement prepare historical cost convention realise profit attributable shareholder reflect theconsolidated profit loss account accounting standard unrealise gain loss value group overseas financial statement comply applicable uk accounting net asset relate foreign currency borrowing attributable standard currency movement period reconciliation movement equity shareholder fund accounting principle policy comprise item contribute increase decrease preparation financial statement conformity generally period shareholder fund item include accept accounting principle require management estimate assumption affect report amount total recognise gain loss period asset liability disclosure contingent asset dividend pay propose liability date account report amount proceed share issue period revenue expense report period actual result cost share purchase cancellation differ estimate share buyback programme change goodwill arise acquisition prior financial statement prepare accordance st january set directly reserve company accounting policy approve board describe note company implement new financial reporting standard describe innote note financial statement glaxosmithkline accounting policy foreign currency transaction foreign currency transaction group company book consolidation inlocal currency exchange rate ruling date consolidate account include transaction forward rate hedge forward asset liability result cash flow exchangecontract foreign currency asset liability company subsidiary undertaking include employee translate local currency rate exchange ruling share ownership trust esot balance sheet date forward rate exchange difference group share net asset result joint venture areinclude trading profit associate undertaking revenue account undertaking consolidate revenue recognise profit loss account good st december service supply external customer order undertaking group material interest receive turnover represent net invoice value account subsidiary group exercise dominant deduction discount give point sale product influence joint venture group exercise joint control despatch available collection customer associate group exercise significant accrual estimate future rebate return value add influence esot account subsidiary ground tax sale taxis exclude revenue group de facto control expenditure interest acquire undertaking consolidated expenditure recognise respect good service effective date acquisition interest sell consolidated receive supply accordance contractual term upto date disposal provision obligation exist future liability transaction balance subsidiary undertaking respect past event eliminate profit take sale subsidiary obligation reliably estimate restructuring cost undertaking sale joint venture associate undertaking recognise respect direct expenditure business product sell customer outside group reorganisation plan sufficiently detail advanced appropriate communication goodwill arise acquisition interestsin subsidiary affect undertaken balance sheet date undertaking joint venture associate undertaking represent excess purchase consideration research development group share separable net asset acquire capitalise research development expenditure charge profit asa separate item case subsidiary undertaking loss account period incur tangible cost investment case joint venture fix asset research development depreciate associate undertaking goodwill denominate currency accordance group policy inwhich acquisition finance case acquisition prior goodwill write environmental expenditure reserve subsequent disposal asset acquisition environmental expenditure relate exist condition result related goodwill remove consolidated reserve past current operation current charge consolidated profit lossaccount future benefit discernible charge profit loss group interest joint venture account account group determine liability sitebysite basis thegross equity method group interest associate record liability time probable undertaking account equity method reasonably estimate liability include group portion cost portion potentially defer taxation relief unrealise intragroup profit responsible party cost probable account extent relate taxation effect able satisfy respective share cleanup obligation isexpecte reverse recovery reimbursement virtually certain asset liability overseas subsidiary associate record asset undertaking joint venture include related goodwill translate sterling rate exchange rule balance legal dispute sheet date result cash flow overseas subsidiary provision anticipate settlement cost legal associate undertaking joint venture translate expense associate legal dispute sterling average rate exchange exchange adjustment group reasonable estimate arise open net asset profit theyear likely outcome dispute obligation exist retain overseas subsidiary associate undertaking dispute possible reasonable joint venture translate sterling exchange difference estimate provision cost associate claim arise related foreign currency borrowing take directly group party charge reserve report statement total recognise gain profit loss account incur andlosse translate sterling asset liability result cash flow overseas subsidiary associate undertaking joint venture report currency hyperinflationary economy adjustment aremade reflect current price level loss net monetary assetsis charge consolidated profit loss account glaxosmithkline note financial statement account policiescontinue tangible fix asset tangible fix asset state cost provision pension postretirement benefit depreciation cost acquire develop computer cost provide pension employee postretirement software internal use internet site external use benefit charge consolidated profit loss account capitalise tangible fix asset software site systematic rational basis base actuarial assumption support significant business system expenditure lead period benefit derive employee service creation durable asset difference charge contribution pay include asset liability consolidate balance sheet depreciationi calculate write cost tangible fix asset exclude freehold land equal annual instalment employee share plan expect useful life normal expect useful life incentive form share provide employee major category tangible fix asset share option share award scheme respect award scheme certain share option grant company provide freehold building year finance employee share ownership trust purchase company leasehold land short lease term share open market meet company obligation building year provide share employee exercise option award plant machinery year theexcess purchase price share exercise fixture equipment year price option award charge profit loss erp system software year account periods service respect option computer software year award grant respect share option grant erp system software generally involve significant customisation share option exercise account share issue prior implementation regard useful exercise price additional employer cost respect option economic life seven year maximum year award charge profit loss account period computer software service ondisposal tangible fix asset cost relate cost run employee share ownership trust charge accumulate depreciation remove account profit loss account net proceed take consolidated profit share hold employee share ownership trust account loss account fix asset investment cost accrual cost charge lease goodwill leasing agreement transfer group substantially goodwill state cost provision amortisation benefit risk ownership asset treat amortisation calculate write cost equal annual finance lease asset purchase outright instalment expect useful life useful life asset include intangible fix asset capital element normally expect exceed year leasing commitment show obligation finance lease asset hold finance lease depreciate intangible fix asset short ofthe lease term useful live asset intangible asset state cost provision amortisation interest element lease rental charge profit lease operating lease annual rental acquire licence patent knowhow marketing right charge profit straightline basis lease term amortise estimate useful life equal instalment long year limit reduce impairment fix asset year maximum allow prior period management believe carry value fix asset review impairment well reflect useful economic life asset item indication asset impair capitalise restrict related specific compound firstyear impairment review conduct acquire goodwill product develop commercial application intangible asset certain intangible consider estimate useful life determine amortisation charge anindefinite life amortise intangible review annually andtake account estimate time subject annual impairment test impairment determine takes bring compound product market marketable byreference high net realisable value value use product anydevelopment cost incur group measure reference discount future cash flow areassociate acquire licence patent knowhow provision impairment charge profit marketing right write profit loss account yearconcerne whenincurre brand value independently fair value investment joint ventures associate business acquire party brand value investment joint venture associate undertaking substantial longterm brand carry consolidated balance sheet group share sell separately rest business acquire brand oftheir net asset date acquisition post areamortise estimated useful life long acquisition retain profit loss goodwill year end useful economic life arise acquisition net amortisation brand forseen stock prior acquire minor brand similar intangible stocksare include account low cost include eliminate group balance sheet reserve year manufacturing overhead appropriate net realisable acquisition value cost generally determine basisnotes financial statementsglaxosmithkline accounting policiescontinue new accounting policy requirement taxation company implement financial reporting standard defer taxation calculate liability method accounting policy transitional disclosure requirement account group company taxation defer financial reporting standard retirement benefit frs accelerated reason time difference defer taxation relief update exist standard provide new guidance account onlongterm time difference respect significant effect measurement result ofprovision unfunded retirement benefit taxation defer asset liability company frs adopt market value oraccelerate reason shortterm time difference approach measurement retirement benefit requires account extent probable liability expand disclosure disclosure requirement asset crystallise implement company standard require implementation change measurement approach current asset investment current asset investment state low cost net frs defer tax fall implement company realisable value frs require defer tax account case security acquire significant premium provision basis partial provision basis present discount maturity value intend hold redemption st december effect provision basis cost adjusted amortise premium discount life reduce deferred tax asset approximately million tomaturity security float rate bond state cost interest income take consolidated profit loss account exchange rate receivable basis group use average exchange rate prevail equity investment include current asset regard period translate result cash flow overseas group asavailable sale subsidiary joint venture associate undertaking sterling period end rate translate net asset debt instrument undertaking thecurrencie influence debt instrument state net proceed translation relevant exchange rate adjustedto amortise finance cost debt evenly term debt average rate derivative financial instrument group hold issue derivative financial instrument euro trading purpose yen period end rate derivative financial instrument manage exposure market risk treasury operation principal derivative euro instrument currency swap forward exchange contract yen interest rate swap derivative contract treat inception economic hedge underlie financial merger glaxo wellcome smithkline beecham instrument matching accounting treatment cash flow combination glaxo wellcome plc smithkline beecham plc derivative contract high correlation specific treat merger th december uk gaap financial instrument hedged inception reflect intention respective size merge hedge period derivative instrument long party designate hedge restate market value future change value take directly profit loss account merger accounting share issue glaxosmithkline plc acquire glaxo wellcome smithkline beecham account currency swap forward exchange contract fix par share premium arise share acquire value relate asset liability contract currency glaxosmithkline glaxo wellcome smithkline beecham contract rate accrue profit loss account similarly account nominal value share issue life contract gain loss foreign exchange contract inthe consolidated account glaxosmithkline result designate hedge forecast foreign exchange transaction netasset glaxo wellcome smithkline beecham defer include measurement relate foreign combine book amount subject alignment adjustment currency transaction period occur gain loss balance sheet hedge accrue take directly reserve inview proximity merger date financial yearend forward premiumdiscount recognise interest date relative insignificance business activity life contract th december st december accounting date merger practical purpose take stdecember interest differential interest swap agreement recognise profit financial year consolidated profit loss account adjustment ofinter glaxo wellcome plc smithkline beecham plc wasdeeme expense life agreement relate period prior merger date glaxosmithkline note financial statement segment information analysis turnover profit taxation total asset net asset tangible fix asset geographical business segment areset belowthe business segment consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oralcare otc medicine nutritional healthcare healthcare services clinical laboratory testing pharmacy benefit management thegeographical segment reflect group significant regional market consistent group regional market management reportingstructure adjustment analysis profit tax geographic segment ensure consistency treatment follow sale diversify pharmaceutical service clinical laboratory healthcare service segment long form ongoing business group business segment datum include allocation corporate cost segment intrasegment sale group activity organise global basis geographical segmental figure influence location group operate resource particular manufacture research variation time intragroup trading funding arrangement turnover business sector pharmaceutical consumer healthcare healthcare service external turnover turnover location customer usa europe rest world external turnover profit tax business sector pharmaceutical consumer healthcare healthcare service operating profit share profitslosse joint venture associate undertaking profit disposal associate divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset business sector pharmaceutical consumer healthcare total asset net asset business sector pharmaceutical consumer healthcare net asset block drug business integrate consumer healthcare segment year effect group turnover estimate effect operate profit analysis net asset acquire give note note financial statementsglaxosmithkline segment informationcontinue turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operating profit share profitslosse joint venture associate undertaking profit disposal associate divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset location subsidiary undertaking usa europe rest world total operating asset cash bank liquid investment total asset net asset location subsidiary undertaking usa europe rest world net operating asset net debt net asset glaxosmithkline note financial statement segment informationcontinue plant land equipment computer asset building vehicle software construction total tangible fix asset location subsidiary undertaking usa europe rest world total uk segment information give separately respect uk include group europe market region consider group home segment purpose segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset net operating asset merger item restructuring cost divest business manufacture restructuring cost incur glaxosmithkline implementation previously announce plan restructure manufacturing activity cost incur glaxo wellcome smithkline beecham merger integration cost incur relate integration glaxo wellcomeand smithkline beecham unify glaxosmithkline business cost include consultancy fee respect integration planning severance cost asset writeoff cost relate early vest lapse performance condition share option share incentive award cost programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option integration cost incur relate integration block drug business cost include professional fee severance cost asset writeoff product divestment income arise disposal famvir kytrilandother product require order obtain regulatory approval merger merger transaction cost incur order effect merger cost comprise fee expense incur prepare implement scheme arrangement merger disposal business primarily arise sale affymax include million write goodwill previously eliminate group reserve disposal business relate disposal healthcare service restructuring cost incur healthcare service disposal share associate relate restructure cost incur quest diagnostic restruc disposal merger ture block drug subsidiary total manufacturing restructuring merger integration cost block drug integration cost effect operate profit disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning note financial statementsglaxosmithkline merger item restructuring cost divest business continue restruc disposal merger ture associate subsidiary total manufacturing restructuring merger integration cost effect operate profit share associate product divestment merger transaction cost disposal business loss disposal effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning restruc disposal ture associate subsidiary total manufacturing restructure healthcare service restructure effect operate profit share associate disposal business loss disposal utilisation provision effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning operating incomeexpense royalty income operate expense income equity investment disposal royalty income principally core recur income form royalty outlicense intellectual property operating expense comprise nonrecurre cost relate product liability claim product withdrawal income equity investment disposal arise equity investment sale equity investment writedown adverse market condition product property disposal analyse operating incomeexpense amend follow classification glaxosmithkline note financial statement operating profit follow item charge operating profit employee cost note advertising distribution cost depreciation tangible fix asset own asset lease asset amortisation goodwill amortisation intangible fix asset exchange lossesgain foreign currency depositsloans operate lease rental plant machinery land building audit fee fee auditor work auditor ukfirm auditor overseas firm include audit fee fee relate company audit glaxosmithkline plc include fee auditor work million million relate merger glaxo wellcome smithkline beecham fee relate integration project undertake group particularly human resource information technology global manufacture supply fee person consultancy service amount million joint venture associate undertaking share profitslosse joint venture associate undertaking share profit quest diagnostic inc share lossesprofit associate undertaking goodwill write share turnover joint venture sale joint venture associate undertaking net interest payable interest payable bank loan overdraft loan respect finance lease share interest payable associate investment income interest income provision market value adjustment note financial statement glaxosmithkline taxation taxation charge base profit period uk corporation tax uk statutory rate double taxation relief overseas taxation defer taxation share taxation charge associate reconciliation taxation rate ukstatutory rate taxation defer taxation provide fix asset effect special taxation status manufacturing location net cost different rate taxation overseas undertaking share option deduction usa tax loss rd credit previously recognise difference taxation rate business performance merger restructuring costs taxation rate total group result profit arise manufacturing operation singapore puerto rico ireland tax reduce rate effect reduction taxation charge increase earning share p p p integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit fall tax individual territory resolution issue continue factoflife glaxosmithkline usa number years glaxosmithkline significant open issue relate transfer pricing issue affect year present concern number product significant relate success zantac respect claim internal revenue service irs substantially exceed group estimation taxation liability irs claim continue subject discussion uk tax authority competent authority provision double tax convention country discussion wide variation view uk tax authority exceptionally unable reach agreement settle dispute event uk tax authority reach agreement matter resolve litigation glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing issue satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment save show account provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain st december require way incremental tax arise glaxosmithkline note financial statement taxation continue tax creditor defer tax tax balance st january exchange adjustment acquisition subsidiary chargecredit profit loss account cash pay movement st december potential provide defer taxation assetliability accelerate capital allowance stock valuation adjustment intragroup profit product business disposal pension postretirement benefit manufacturing restructure tax loss time difference category provide defer taxation stock valuation adjustment intragroup profit time difference arecurrent earning share p p p basic earning share adjustment merger item restructuring cost disposal subsidiary merger integration transaction cost product divestment restructuring cost block drug integration cost disposal subsidiary associate adjust earning share dilute earning share earning share calculate divide profit attributable shareholder weight average number ofshare issue period number calculate basic diluted earning share reconciledbelow illustrate business performance primary performance measure management adjust earning adjust earning share present exclude merger item integration restructuring cost disposal subsidiary management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement contain consolidated statement profit loss page prepare accordance ukgaap basic diluted earning share include nonrecurre item net profit period attributable shareholder earning basic diluted adjustment merger item restructuring cost disposal subsidiary adjust earning weight average number share issue million million million basic adjust dilution share option dilute share hold employee share ownership trust excludednote financial statement glaxosmithkline dividend glaxosmithkline plc interim second interim interim fourth interim glaxo wellcome plc interim second interim final smithkline beecham plc interim second interim interim fourth interim dividend state deduct dividend receivable trustee employee share ownership plan trust whereapplicable dividend share p glaxosmithkline plc interim second interim interim fourth interim glaxo wellcome plc glaxo wellcome share p p interim second interim final equivalent dividend glaxosmithkline share dividend glaxo wellcome share smithkline beecham plc smithkline beecham share interim second interim interim fourth interim smithkline beecham plc equivalent dividend glaxosmithkline share interim second interim interim fourth interim glaxosmithkline note financial statement goodwill total cost st january exchange adjustment addition cost st december amortisation st january exchange adjustment provision year amortisation st december net book value st january net book value st december licence intangible asset patent etc brand total cost st january exchange adjustment addition acquisition subsidiary disposal asset write cost st december amortisation st january exchange adjustment provision year asset write amortisation st december impairment st january exchange adjustment impairment loss impairment st december net book value st january net book value st december brand largely comprise portfolio sterling product panadol solpadeineand hedex newly acquire block drug product sensodyne polidentand poligrip consider indefinite life give strength durability brand level marketing support accordingly amortise thevaluation sterling brand review annually year cash flow forecast basis original independent assessment acquire impairment loss calculate discount rate cent valuation block drug brand review annually year cash flow forecast discount rate centnotes financial statementsglaxosmithkline plant land equipment computer asset tangible fix asset building vehicle software construction total cost st january exchange adjustment addition acquisition subsidiary disposal reclassification cost st december depreciation st january exchange adjustment provision year disposal depreciation st december impairment st january impairment loss disposal impairment st december net book value st january net book value st december net book value st december group land building comprise freehold property million st january million property lease year million st january million property lease year million stjanuary million include plant equipment vehicle st december lease asset cost million st january million accumulate depreciation million st january million net book value million st january million impairment loss principally relate reduction forecast cash flow result decision close manufacturing facility andhasbeen measure reference value use discount rate cent joint associate equity fix asset investment venture undertaking investment share total st january exchange adjustment addition charge year impairment transfer current asset reclassification disposal retain profit year goodwill amortisation st december investments joint venture comprise million share gross asset million million share gross liability nil principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange book value st december million million market value million million group own percent quest cent book value include goodwill amortise year amortisation charge million goodwill st december amount million million goodwill million relate continue group interest clinical laboratory asset attribute quest remain eliminate group reserve equity investment comprise list investment million unlisted investment million market value list investment million investment share consist share hold employee share ownership trust detail give note glaxosmithkline note financial statement equity investment st january exchange adjustment additions transfer fix asset investment impairment disposal st december equity investment comprise list investment million million themarket value list investment million million stock raw material consumable work progress finish good debtor amount year trade debtor debtor prepay pension contribution prepayment accrue income amount year debtor prepayment accrue income defer taxation note debtor include trading balance million nilmillion joint venture associate undertaking creditor amount year trade creditor taxation note social security creditor accrual defer income dividend propose amount year taxation note creditor accrual defer income creditor include trading balance nil million joint venture associate undertaking accrual include accrual wage salarie million millionnote financial statement glaxosmithkline provision pension indemnify legal postretirement manufacturing merger disposal liability charge benefit restructure integration liability dispute provision total st january exchange adjustment charge year apply acquisition subsidiary movement st december group recognise cost respect plan manufacture restructuring initiate follow merger glaxo wellcome smithkline beecham acquisition block drug plan implement period cost recognise provision principally respect identify severance site announce manufacturing activity cease expect incur mainly cost asset writedown recognise impairment fix asset group recognise cost respect plan integration glaxo wellcome smithkline beecham business additional cost incur implementation integration follow merger continue cost recognise provision principally respect programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option respect identify severance expect incur provision indemnify disposal liability relate indemnity grant party respect operation dispose prior year include provision indemnity purchase price adjustment respect exit healthcare service business provision legal dispute matter include amount relate antitrust product liability contract termination selfinsurance environmental cleanup property rental amount provide include director good estimate obligation arise quantify unquantified claim base current knowledge take appropriate legal advice outcome legal claim matter glaxosmithkline involve assure final judgement give settlement reach director take appropriate legal advice expect glaxosmithkline liability matter take account provision tax benefit insurance material adverse effect financial condition result operation cash flow glaxosmithkline involve number legal dispute include notification possible claim early stage matter reliable estimate outcome accordingly provision record matter nature group business number matter subject negotiation litigation year large individual amount provide expect settle year discussion litigation issue refer legal proceeding note contingent liability contingent liability comprise warranty discount bill performance guarantee item arise normal course business amount st december million million glaxosmithkline note financial statement net debt liquid investment cash bank loan overdraft year bank loan overdraft commercial paper eurobond mediumterm note obligation finance lease loan loan year bank loan eurobond mediumterm notes loan stock obligation finance lease loan net debt balance sheet date group liquid investment aggregate market value million million loan overdraft year commercial paper comprise billion programme million issue st december st december million back committed facility day duration million renewable annually liquid investment million weight average interest rate commercial paper borrowing st december cent weight average interest rate loan overdraft year st december cent loan year december billion fix rate cent year bond issue new billion european medium term programme loan year repayable period follow year year year year year loan repayable year carry interest effective rate cent cent repayment date range note financial statement glaxosmithkline net debt continue secure loan loan amount million million secure charge fix current asset finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation financial instrument information give note commitment capital commitment contract provide account intangible fix asset tangible fix asset acquisition block drug number commitment licensing agreement principally shionogi neurocrine tanabe bayer roche payment future milestone achieve agreement relate compound early stage development milestone payment continue number year compound successfully development process generally close product marketing approval great possibility success commitment operating lease pay rental year operating lease land building expire year year year operating lease plant equipment vehicle expire year year commitment operating lease pay rental future year glaxosmithkline note financial statement share share capital share premium account redeemable preference share ordinary share p p ccm oi uu nm number number share capital authorise st december st december share capital issue fully pay share capital issue prior scheme arrangement share capital issue scheme arrangement share capital issue share option scheme st december share capital redeem par share capital issue share option scheme share capital purchase cancel st december number number share issuable outstanding option note st december st december number unissue share option st december st december redeemable preference share redeem company st august nominal redeemable preference share convert ordinary share penny result authorise share capital st december billion ordinary share pence rd october glaxosmithkline announce plan invest billion buying share market programme cover purchase company employee trust relate share option grant share base incentive cover purchase company share cancellation total billion spend exact time future purchase determine company dependent market condition factor th march share purchase cancel cost million detail substantial shareholding refer substantial shareholding nonequity minority interest sb holdings corporation sbh corp subsidiary incorporate delaware usa issue million flexible auction market prefer stock flex amp comprise share issue series dividend half share fix issuance seven year period dividend half fix year period end vary predominately prevail interest rate set seven week auction share trade sbh corp issue million auction rate preference stock arp comprise share issue series dividend vary condition similar flex amp describe february march smithkline beecham corporation sb corp subsidiary incorporate pennsylvania usa repay million arp comprise share issue series arp flex amp constitute preference share represent nonequity minority interest smithkline beecham plc certain circumstance guarantee payment dividend declare preference share smithkline beecham plc agree sbh corp certain circumstance provide support sbh corp relation principal guarantee support limit circumstance holder preference share favourable position holder preference share smithkline beecham plc preference share represent longterm nonequity minority interest group balance sheet accordance frs capital instrumentsnote financial statement glaxosmithkline profit reserve reserve loss account total st december goodwill write exchange movement uk tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange st december goodwill write exchange movement uk tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange st december goodwill write exchange movement share purchase cancellation profit attributable shareholder dividend revaluation goodwill exchange st december goodwill arise acquisition st january write reserve amount million include goodwill million previously hold goodwill reserve offset reserve goodwill write relate primarily disposal affymax group hold quest diagnostic inc goodwill denominate local currency subject revaluation amount million st december goodwill acquisition st january capitalise accordance accounting policy set note exchange movement take reserve include loss million loss million gain million foreign currency loan deposit losse million gain million loss million retranslation net asset loss million loss million gain million goodwill eliminate reserve exchange adjustment debit reserve cumulatively million reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million st december million million reserve include capital redemption reserve create result share buyback programme amount million st december nil total reserve amount million st december million million million nil nil relate company million million million relate subsidiary undertaking million million million relate joint venture associate undertakings profit glaxosmithkline plc year million th december st december nil dividend million th december st december nil give retain profit million th december st december nil cost share purchase cancellation million th december st december nil profit loss account reserve st december stand million nil glaxosmithkline note financial statement legal proceeding marketing authorisation issue european country product contain paroxetine hydrochloride group involve legal administrative anhydrate variant group product generic product proceeding consider normal business principally contain anhydrate market germany intellectual property case product liability governmental austria denmark glaxosmithkline believe marketing investigation significant describe paroxetine hydrochloride anhydrate product paroxetine mesylate product party european country infringe intellectual property patent vigorously litigate position action usa number distributor generic drug file european country application food drug administration fda market generic version paxilseroxat paroxetine hydrochloride geneva pharmaceuticals commence action prior expiration group patent paroxetine theus district court eastern district virginia hydrochloride hemihydrate response group file patent recently issue glaxosmithkline cover clavulanic acid action distributor infringement key ingredient augmentinand timentin geneva ask group patent court declare new patent expire invalid august geneva extend complaint cover july glaxosmithkline file action apotex additional patent expire hear genevas district court northern district illinois infringement summary judgement motion challenging validity conclude group patent paroxetine hydrochloride apotex october trial judge issue decision file abbreviate new drug application anda geneva allege suit holder pende anda fda seek approval introduce generic form paxil trial file february novartis subsidiary discovery date set case continue june group file action geneva september teva pharmaceutical file similar action pharmaceutical subsidiary novartis pharmaceutical challenge recently issue patent patent expire district court eastern district pennsylvania december cover augmentin teva action infringement group patent paroxetine hydrochloride consolidated geneva case court set follow notice genevas anda filing case trial date consolidate action december hearing consolidate similar infringement action generic tevas motion summary judgement trial judge rule company subsequently file andas additional infringement bench hold patent expiring december action bring base patent issue subsequent invalid group patent expire invalid original filing case consolidated group teva file second motion summary judgement file action apotex relate certain new invalidity group patent cover augmentinwith expiry patent eastern district pennsylvania party date group continue believe patent consolidated action seek agreement discovery schedule expire valid intend appeal march glaxosmithkline file action pentech ruling contrary district court northern district illinois distributor generic pharmaceutical product file infringement group patent paroxetine hydrochloride anda sustain release bupropion hydrochloride tablet pentech file anda capsule version paxil assert wellbutrin srand zyban usa accompanied case compound presentation infringe group patent certification invalidity group patent group patent invalid fda approve bring suit file party ground pentech anda glaxosmithkline believe pentech patent infringement group file suit andrx capsule substitutable paxiltablet discovery pharmaceutical file anda district court continuing case southern district florida february district october glaxosmithkline file action synthon court judge grant andrxs summary judgement motion district court middle district north carolina rule product infringe group patent infringement group patent paroxetine hydrochloride group appeal decision action file paroxetine mesylate synthon file b application watson pharmaceuticals district court paper nda fda paroxetine mesylate southern district ohio eon labs manufacture different salt form paroxetine market district court eastern district new york impax form paxil fda approve synthon application laboratorie district court northern district glaxosmithkline believe synthon compound california excel district court new jersey substitutable paxil trial date set district watson case settle remain case intheir early stage follow expiration datum exclusivity period europe marketing authorisation issue synthon regulatory group file action infringement patent authority denmark paroxetine mesylate different salt cefuroxime axetil active ingredient group ceftinanti form paroxetine hydrochloride market infective product ranbaxy pharmaceutical form seroxatpaxil authorisation grant district court new jersey preliminary injunction grant european country mutual recognition process favour glaxosmithkline august court assessment group initiate appeal vacate injunction remand case litigation challenge approval danish medicine agency district court trial merit january ground authorisation grant ranbaxy announce fda approve ranbaxys abridge procedure paroxetine mesylate application generic version essentially similar seroxatnote financial statementsglaxosmithkline legal proceeding continue ppa product withdrawal group receive numerous personal injury class action lawsuit file state federal group file similar action apotex second court allege personal injury increase risk injury use distributor generic pharmaceutical product district product contain ppa unfair deceptive business practice court northern district illinois case plaintiff seek remedy include compensatory punitive earlystage damage medical monitoring refund federal case august group commence action district consolidated multidistrict litigation proceed court new jersey reddycheminor dr reddys district court district washington lawsuit laboratory allege infringement patent early stage determination ondansetron active ingredient zofrantablet lawsuit permit proceed class action defendant file anda food drug august bayer ag withdraw baycolcerivastatin sodium administration fda approval anda stay worldwide light report adverse event include death early january resolution patent infringement involve rhadomyolysis glaxosmithkline participate litigation case early stage market baycolin usa pursuant copromotion agreement bayer licence holder product liability manufacturer product follow withdrawal bayer food drug administration aware glaxosmithkline receive numerous lawsuit file state report cardiac valvular problem individual federal court usa behalf individual putative fenfluramine dexfenfluramine combination class baycoluser number suit allege phentermine prescribe regimen weight plaintiff suffer personal injury include rhadomyolysis reduction request voluntary withdrawal fenfluramine use baycol claim person take baycol dexfenfluramine market report cardiac injure risk future injury valvular problem subsequent withdrawal product suffer economic damage purchase baycol market spawn numerous product liability lawsuit file plaintiff seek remedy include compensatory punitive manufacturer distributor fenfluramine statutory damage creation fund medical monitoring dexfenfluramine phentermine number federal case consolidate multidistrict litigation manufacturer phentermine group defendant proceed district court district minnesota numerous lawsuit state federal district court lawsuit early stage usa file class action determination lawsuit permit lawsuit seek relief include combination compensatory proceed class action punitive damage medical monitoring refund purchase drug judicial panel multidistrict follow voluntary withdrawal lotronexin usa litigation issue order consolidate transfer federal november number lawsuit file action district court eastern district pennsylvania group state federal district court include individual court approve global settlement propose defendant personal injury action purport class action assert product wyeth sell fenfluramine dexfenfluramine liability consumer fraud claim plaintiff seek remedy settlement subsequently confirm circuit court include compensatory punitive statutory damage appeal include phentermine defendant action early stage tentative trial date include group individual plaintiff elect opt case set class settlement pursue claim individually wyeth glaxosmithkline number pharmaceutical continue settle individual state court case trial company name defendant number group continue dismiss lawsuit settle purport class action individual personal injury lawsuit wyeth state federal district court usa allege thimerosal glaxosmithkline receive purport class action preservative vaccine cause neurodevelopmental lawsuit file state federal court usa allege disorder injury plaintiff seek remedy include paroxetine active ingredient paxil addictive cause compensatory punitive statutory damage cost dependency withdrawal reaction plaintiff seek remedy fund medical monitoring research lawsuit include compensatory punitive damage cost early stage determination fund medical monitoring lawsuit early stage purport class action permit determination proceed class action lawsuit permit proceed class action government investigation decade litigation glaxosmithkline receive subpoena attorney manufacturer prozac ssri products homicidal office boston massachusetts request production suicidal behaviour exhibit user product group document period present relate receive claim lawsuit respect paxil repackage relabelle private label arrangement purport class action glaxosmithkline discuss thirdparty customer follow report yale haemorrhagic stroke project period issue civil criminal investigation suggest association use phenylpropanolamine price charge party glaxosmithkline ppa decongestant haemorrhagic stroke group product count medicaid good price purpose manufacturer voluntarily withdraw consumer healthcare group provide document response subpoena product ppa active ingredient glaxosmithkline note financial statement legal proceeding continue follow district court decision antitrust claim allege glaxosmithkline receive letter center competitive injury overcharge file teva medicare medicaid services cms state cmss position pharmaceuticals generic manufacturer nabumetone certain price include medicaid purport class direct purchaser payer respectively good price request glaxosmithkline retroactively result allege fraudulent procurement patent adjust good price report quarter prior july wrongful listing patent fda orange book include price prosecution sham patent infringement litigation case file district court district massachusetts glaxosmithkline respond subpoenas office eastern district pennsylvania december inspector general department health human january early stage service department justice states texas california connection allegation pharmaceutical commercial matter company include glaxosmithkline violate federal fraud otsuka pharmaceutical co ltd initiate arbitration proceeding abuse law federal false claim act december concern group unilateral withdrawal respect texas california comparable state law result grepafloxacin raxarvaxar october safety reason ofthe way certain drug price way medicare otsuka allege product withdrawal simultaneous public medicaid programme reimburse drug announcement constitute material breach licence quarter nevada montana state attorney general supply agreement group believe underlying product file civil lawsuit state court glaxosmithkline withdrawal consistent term agreement drug company action claim behalf valid defence exist claim answer serve state payer behalf instate patient consumer quarter damage restitution base defendant price undefined set pharmaceutical product addition private sbcl indemnity payer class action lawsuit file glaxosmithkline connection sale smithkline beecham clinical federal district court action laboratory sbcl quest diagnostic inc group early stage agree indemnify quest diagnostic aftertax basis november federal trade commission staff advise respect certain liability arise conduct sbcl group staff conduct nonpublic investigation business prior closing include governmental private claim determine group violate section arise government investigation sbcls bill federal trade commission act monopolize attempt marketing practice monopolize market paroxetine hydrochloride prevent generic competition paxiland request group submit environmental matter certain information connection investigation glaxosmithkline notify potential responsibility group cooperate staff investigation relate past operation past waste disposal practice certain site primarily usa matter follow public reference ftc investigation purport subject litigation include proceeding initiate consumer class action file allege group federal state government waste disposal site remediation monopolise market paxil treble damage seek cost tort action bring private party glaxosmithkline allege overcharge flow conduct case advise responsible party early stage determination approximately site appear national priority permit proceed class action list create comprehensive environmental response compensation liability act superfund antitrust pharmaceutical business smithkline proceeding seek require operator hazardous waste beecham glaxo wellcome group party number facility transporter waste site generator antitrust suit certain certify class action hazardous waste dispose site clean site institute nation retail pharmacy consumer reimburse government cleanup cost instance state allege conspiracy restraint trade glaxosmithkline involve allege generator hazardous challenging pricing practice group significant waste site glaxosmithkline number pharmaceutical company wholesaler involve current operator facility sue similar litigation action superfund provide defendant jointly severally action pende state court consolidate liable cleanup cost proceeding frequently resolve pretrial purpose district court northern basis nature quantity waste disposed district illinois federal class action component site generator glaxosmithkline proportionate liability include pharmacy represent approximately twothird total cleanup cost substantially determine retail sale volume settle glaxo wellcome site refer smithkline beecham time group glaxosmithkline potential liability vary greatly site site enter settlement satisfactory term group cost investigation study remediation site engage conspiracy admission wrongdoing time substantial glaxosmithkline routinely accrue include final agreement amount related share liability matter august district court district massachusetts rule group patent nabumetone relafen tax matter invalid anticipatory art inequitable conduct group file pende tax matter describe note appeal decision november note financial statementsglaxosmithkline acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture give book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition block drug shionogi joint venture block drug company inc january group acquire block drug cash consideration million net asset block drug incorporate account fair value follow book fair value net asset value adjustment acquire intangible fix asset goodwill tangible fix asset net current asset provision fair value adjustment intangible fix asset million reflect capitalisation brand block drug business integrate group possible separately identify postacquisition cash flow turnover cost sale block drug product estimate sga rd expenditure follow turnover cost sale gross profit sell general administrative expenditure research development expenditure operating profit shionogi joint venture group establish joint venture shionogi develop commercialise number compound contribute party group acquire cent equity share capital cash consideration million commit contribution certain development milestone achieve disposal quest diagnostic inc group disposed million share investment quest diagnostic inc cash proceed million reduce group hold st december cent recognise charge goodwill previously write reserve million profit million recognise affymax group complete sale affymax business affymax inc new hold company million nonvoting preference share affymax inc represent value million million recognise charge goodwill previously write reserve million loss million disposal cost million incur completing sale tagamet february group sell tagamet japan sumitomo pharmaceutical co ltd cash consideration million recognise charge goodwill previously write reserve million loss million recognise quest diagnostic affymax tagamet block drug shionogi total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal glaxosmithkline note financial statement acquisition disposal continue book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition glaxo wellcome sa acquisition minority interest glaxo wellcome sa group acquire cent glaxo wellcome sa polfa poznan sa poland cash consideration million goodwill million capitalise amortise line initial acquisition disposal affymetrix inc group sell million share affymetrix inc cash proceed million realise profit million sb clinical laboratory final cash settlement million million pay october complete sale sb clinical laboratory sb clinical glaxo laboratory affymetrix wellcome sa total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal book fair value net asset cost value adjustment acquire goodwill acquisition acquisition amoun pharmaceuticals industry co sae glaxo wellcome kk quest diagnostic incorporate amoun pharmaceutical industry co sae apic glaxo wellcome egypt acquire cent apic million cash goodwill million capitalise glaxo wellcome kk group complete merger nippon glaxo limit nippon wellcome kk nw form glaxo wellcome kk quest diagnostics inc group acquire cent equity interest quest consideration disposal sb clinical laboratory million goodwill arise million remain eliminate reserve million capitalise disposal diversify pharmaceutical service dps group sell dps million realise loss million provision million sb clinical laboratory group sell sb clinical laboratory quest million cash equity interest quest value million cost million goodwill write reserve million profit loss transaction affymetrix inc group sell million share affymetrix inc cash proceed million realise profit million sb clinical laboratory dps affymetrix apic total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal note financial statementsglaxosmithkline financial instrument relate disclosure fair value financial asset liability table present carry amount uk policy gaap fair value group financial asset discussion group objective policy liability st december st december debtor management offinancial instrument associate risk creditor year exclude include treasury policy financial review fair value financial asset liability include investment atthe instrument exchange group hold number equity investment frequently current transaction willing party force entity group enter research collaboration liquidationsale follow method assumption group seek realise value investment estimate thefair value inpart research collaboration help create equity investment market value base quote market certain investment regard available sale price case list investment market value account foras current asset investment purpose reference quote price case material unlisted ofusgaap investment classify available sale investment group liquid investment represent fund surplus cash bank approximate carry immediate operating requirement account liquid investment base quote market price case current asset investment purpose usgaap marketable security approximates carry investment classify available sale inthe case time deposit short maturity shortterm loan overdraft approximate carry proceed sale investment classify available short maturity instrument saleunder gaap year end stdecember mediumterm loan market value base quote market weremillion proceed include rollover liquid price case eurobond fix rate fund shortterm deposit gross gain loss reflect borrowing approximate carry case consolidated profit loss account respect investment offloate rate bank loan loan classify available sale gaap million forward exchange contract base market price millionrespectively exchange rate balance sheet date currency swap base market valuation balance foreign exchange risk management sheetdate group enter forward foreign exchange contract interest rate instrument base market valuation inorder swap liquid asset borrowing currency balance sheet date require group purpose st december debtor creditor approximate carry group outstanding contract sell purchase foreign provision approximate carry currency total notional principal million stdecember million majority fair value investment share contract period month group st december investment share end year group number currency swap million million fair value inplace respect mediumterm debt instrument million million difference carry fair value represent gross unrealised gain borrowing denominate swap foreign currency million investment exclude financial match investment overseas group asset treat instrument disclosure fair value market value base ahedge relevant net asset exchange gain quote market price loss record reserve share represent purchase employee share ownership trust interest rate risk management satisfy future exercise option award employee manage fixedfloate interest rate profile debt group incentive scheme purchase match option interest rate swap outstanding commercial bank predetermine exercise price gain loss recognise st december measure exercise price market value concentration credit risk credit exposure financialinstrument group believe expose major concentration credit risk group expose creditrelate loss event nonperformance counterpartie financial instrument expect counterpartie fail meet obligation group apply boardapprove limit credit exposure counterparty employ strict minimum credit worthiness criterion choice counterparty glaxosmithkline note financial statement financial instrument relate disclosure continue classification fair value financial asset liability follow table set classification financial asset liability provide reconciliation group net debt note shortterm debtor creditor exclude financial asset liability provision include contractual obligation settle cash carry fair carry fair value value net debt liquid investment cash bank current asset financial instrument sterling note bond dollar note bond note bond swap dollar currency swap note bond swap yen currency swap mediumterm borrowing shortterm loan overdraft total borrowing interest rate swap forward exchange contract purchase forward exchange contract sell total derivative instrument management net debt total net debt fix asset equity investment current asset equity investment debtor year creditor year provision foreign exchange derivative auction rate preference share subsidiary money market preference share subsidiary flexible auction rate preference share subsidiary total nonequity minority interest total financial asset liability total financial asset total financial liability currency swap present alongside underlie principal instrument carrying amount instrument adjust effect currency swap acting hedge difference carry fair value equity fix current asset liquid investment represent gross unrealised gain million million respectivelynote financial statementsglaxosmithkline financial instrument relate disclosure continue currency interest rate risk profile financial liability financial liability take account currency interest rate swap analyse total financial liability comprise total borrowing million million creditor year million million provision million million nonequity minority interest preference share ofmillion million exclude foreign exchange derivative million nil creditor year exclude benchmark rate determine interest payment float rate financial liability table libor fix rate noninterest bearing average average st december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency fix rate noninterest bearing average average st december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency currency interest rate risk profile financial asset total financial asset comprise fix asset equity investment million million current asset equity investment million million liquid investment million million cash bank million million debtor year million million exclude foreign exchange derivative nil million debtor year exclude st december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency st december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency glaxosmithkline note financial statement financial instrument relate disclosure continue currency exposure net monetary assetsliabilitie group currency exposure rise net currency gain loss recognise profit loss account arise principally company sterle functional currency monetary asset liability denominate overseas functional currency andborrowing designate hedge overseas net asset exclude table stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen nonequity finance minority total total debt lease interest maturity financial liability year demand year year year gain loss net hedge unrecognise gain loss begin year gain loss arise previous year recognise year gain loss arise beginning year unrecognised end year unrecognised gain loss arise year total unrecognised gain loss end year expect recognise year expect recognise year total unrecognised gain loss end year commit facility group commit facility commercial paper programme million million day duration renewable annuallynote financial statementsglaxosmithkline employee share scheme group operate share option scheme option grant employee acquire share adss glaxosmithkline plc grant price share award scheme award grant employee acquire share adss glaxosmithkline plc cost subject tothe achievement performance target detail give relate scheme operate glaxosmithkline separately glaxo wellcome smithkline beecham date merger scheme glaxosmithkline merger glaxo wellcome option outstanding date merger convert glaxosmithkline option smithkline beecham share option wasconverte glaxosmithkline share option smithkline beecham ad option convert glaxosmithkline ad option correspond adjustment grant price glaxosmithkline share option scheme group operate share option scheme savingsrelate share option scheme grant share option scheme normally exercisable year date grant grant savingsrelate share option scheme normally exercisable year save option share option scheme normally grant market price ruling date grant accordance uk practice majority option savingsrelate share option scheme grant price market price ruling date grant option outstanding share option share option savingsrelate scheme share scheme adss share option scheme st december weight weight weight number exercise number exercise number exercise price price price th december convert gw option convert sb option option exercise option cancel st december option grant option exercise option cancel st december range exercise price order encourage employee convert option hold glaxo wellcome smithkline beecham share adss glaxosmithkline share adss programme establish additional cash benefit cent exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger option outstanding share option share option savingsrelate scheme share scheme adss share option scheme st december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share grant option share adss grant savingsrelate share option grant change effective exercise price outstanding option year option grant st december th march glaxosmithkline note financial statement employee share scheme continue option exercisable share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price st december gw sb st december gsk st december gsk glaxosmithkline share award scheme group operate performance share plan award grant director senior staff cost percentage award vest base performance glaxosmithkline year measurement period performance condition consist part apply cent award condition compare glaxosmithkline total shareholder return tsr period tsr company ukftse index period second performance condition compare glaxosmithkline earning share growth increase ukretail price index year performance period share adss number share adss issuable number number th december convert glaxo wellcome award convert smithkline beecham awards awards exercise st december award grant award exercise award cancel st december award relate share relate adss exercisable st december employee share ownership trust group sponsor employee share ownership trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee employee share ownership trust purchase share onthe open market finance provide group way loan contribution expect cost obligation deliver share scheme normally spread period service respect award option grant accelerated charge respect outstanding cost provide share award option exercisable solely result merger share hold share award scheme number share nominal value cost amortisation market value share hold share option scheme number share nominal value cost amortisation market value trustee waive right dividend share hold employee share ownership trustsnote financial statementsglaxosmithkline employee share schemescontinue glaxo wellcome share option scheme date merger glaxo wellcome option share option grant savingsrelate share option grant exercisable performance condition applicable lapsed savingsrelate share option scheme share option scheme total weighted weight weight exercise exercise exercise number share issuable outstanding option number price number price number price st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december glaxo wellcome share award scheme glaxo wellcome operate long term incentive plan annual incentive plan long term incentive plan grant award share director senior staff nominal cost percentage award vest base performance glaxo wellcome threeyear period annual incentive plan performance bonus consist basic award ofshare matching award threeyear retention period result merger awards long term incentive plan payable retention period annual incentive plan lapse number share issuable share award scheme number st december award grant award exercise award cancel st december award grant award exercise award cancel convert glaxosmithkline awards st december glaxosmithkline note financial statement employee share schemescontinue smithkline beecham share option scheme date merger smithkline beecham share option exercisable share adss weight weight exercise exercise number share adss issuable outstanding option number price number price st december option grant option exercise option cancel st december option grant option exercise option cancel convert glaxosmithkline option st december smithkline beecham midterm incentive plan smithkline beecham adopt midterm incentive plan mtip participation mtip grant annually senior staff smithkline beecham designate target number share participant base job grade follow threeyear measurement period rn committee review smithkline beecham total shareholder return relative company comprise ftse index final award proportion target number share cent depend performance measurement period end st december cent cent respectively target number share award receipt award defer case share remain mtip result merger outstanding award payable cent target number share end threeyear cycle share adss number share issuable midterm incentive plan number number st december award grant award exercise award cancel st december award grant award exercise award cancel convert glaxosmithkline awards st december option pricing purpose value option arrive stockbase compensation adjustment reconciliation accounting principle note blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year saving relate share option scheme year yearsnotes financial statementsglaxosmithkline director remuneration glaxosmithkline policy director remuneration detail remuneration receive director give inthe remuneration report director appoint board company rd receive remuneration glaxosmithkline plc continue remunerate glaxo wellcome plc smithkline beecham plc service company themergerbetween glaxo wellcome smithkline beecham complete th december point glaxo wellcome smithkline beecham subsidiaries glaxosmithkline plc statutory disclosure respect director remuneration attributable director glaxosmithkline plc relation servicesto company subsidiarie th st december set director compensation salary fee benefit emolument bonus total compensation date appointment st december benefit salary fee emolument bonus total emolument individual director executive director dr j p garnier mr j coombe nonexecutive director sir richard syke sir roger hurn sir peter walters mr p allaire dr barzach mr c bonham sir christopher hogg sir peter job mr j h mcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young total compensation glaxosmithkline note financial statement employee cost wage salary social security cost pension postretirement cost cost sharebase incentive plan severance cost arise integration restructuring activity pension postretirement cost arise integration group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff consequence time take complete merger glaxosmithkline replace need leaver contractor year end level contractor disproportionately high movement compare reflect conversion contract employee permanent employee redundancie merger integration additional employee acquisition block drug number group employee end financial year give financial record pension postretirement cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost pension postretirement cost arise integration pension group undertaking operate pension arrangement cover group material obligation provide pension retire employee thesearrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length ofservice define benefit scheme include define contribution section aredescribe hybrid scheme table majority case contribution define benefit scheme determine accordance advice independent professionally qualified actuary formal independent actuarial valuation group main plan undertake regularly normally year theasset fund scheme generally hold separately administer trust insure pension cost accounting purpose assess accordance independent actuarial advice generally project unit method spread surplus deficit average expect remain service live respective membership certain country pension benefit provide unfunded basis scheme administer trustee company whereasset hold specific purpose matching liability unfunded scheme provision include provision pension postretirement benefit charge profit respect benefit aggregate ofthe increase year intheassesse liability member service net movement provision set pension inpayment liability generally assess annually accordance advice independent actuariesnote financial statementsglaxosmithkline employee cost continue pension arrangement majority glaxo wellcome company smithkline beecham company continue operate separately instance include usa pension arrangement merge accordingly follow information deal set arrangement separately market value asset group fund define benefit pension fund date late actuarial valuation billion sufficient cover cent benefit accrue member allow future salary pension increase uk define benefit pension scheme account approximately cent group plan asset valuation project benefit term define benefit pension scheme account approximately cent group plan asset valuation project benefit term uk uk pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant new uk employee entitle join new define contribution scheme relevant assumption calculate pension cost uk define benefit scheme accounting purpose follow glaxo wellcome smithkline beecham pa pa pa pa rate increase future earning discount rate expect longterm rate return investment expect pension increase uk equity dividend growth regular cost glaxo wellcome pension arrangement million million credit account allowance spread surplus disclose level percentage salary expect future working lifetime exist member year recent triennial actuarial valuation glaxo wellcome scheme funding purpose carry stmarch date asset scheme represent cent actuarial value benefit accrue member allow future salary pension increase trustee uk pension scheme agree company request grant benefit improvement include cent enhancement entitlement beneficiary allowance improvement funding level fall cent follow valuation company contribution scheme remain suspend formal valuation expect remain suspend thetotal market value asset hold scheme st march million regular cost smithkline beecham scheme million increase accounting cost million allowance spread deficit expect future working lifetime current employee scheme year late valuation carry st december date actuarial value scheme asset represent cent actuarial value accrue service liability base assumption total market value asset hold scheme st december million usa usa glaxo wellcome smithkline beecham define benefit hybrid scheme merge year relevant assumption calculate pension cost accounting purpose follow glaxo glaxo smithkline smithkline wellcome beecham pa pa pa rate increase future earning discount rate expect longterm rate return investment equity dividend growth na regular cost scheme million increase accounting cost million allowance spread deficit expect future working lifetime current employee scheme late valuation carry st january date actuarial value scheme asset represent cent actuarial value theaccrue service liability total market value asset hold scheme st january million glaxosmithkline note financial statement employee cost continue frs disclosure group continue account pension arrangement accordance ssap accounting pension cost transitional provision frs retirement benefit certain disclosure require basis valuation methodology adopt frs define benefit scheme fair value pension scheme asset st december compare future pension liability calculate project unit method relevant assumption frs calculation follow rest uk usa world pa pa pa rate increase future earning discount rate expect pension increase na cash balance creditconversion rate na na inflation rate expect rate return asset fair value asset liability uk define benefit scheme aggregate datum define benefit scheme group st december follow uk usa rest world group average expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability net value scheme surplus defer tax liability net value scheme deficit defer tax asset group total uk define benefit scheme define contribution section account balance total million st december uk scheme close new member project unit method value pension scheme liability current service cost increase member scheme approach retirement deficit frs reflect different basis value asset liability compare ssap include immediate impact fair value asset st december result poor stock market performance fair value asset hold uk pension scheme fall approximately cent seven cent respectively year group operate number unfunded postretirement healthcare scheme principal usa liability frs scheme assess assumption pension scheme assumption future medical inflation seven cent reduce cent year cent basis liability usscheme assess million reduce million taking account defer tax valuation basis apply account instead ssap valuation basis effect profit loss account reserve st december take account defer tax follow profit loss account reserve balance sheet pension liability frs pension liability ssap balance sheet postretirement healthcare scheme frs postretirement healthcare scheme provision balance sheet profit loss account reserve include pension postretirement healthcare liability note financial statement glaxosmithkline reconciliation usaccounte principle summary material difference uk gaap financial statement analyse reconciliation present capitalise interest note represent financial information uk gaap group capitalise interest usgaap require generally accept accounting principle gaap require interest incur cost construct fix apply instead ukgaap asset capitalise amortise life asset significant difference uk gaap computer software ukgaap combination glaxo wellcome plc uk gaap company capitalise cost incur smithkline beecham plc account merger acquire develop computer software internal use pool interest usgaap transaction software support significant business system account purchase business combination glaxo expenditure lead creation durable asset gaap wellcome acquire smithkline beecham company apply sop accounting cost computer software develop obtain internal use glaxosmithkline plc form effect scheme restrict category cost capitalise arrangement merger glaxo wellcome plc smithkline beecham plc effective thdecember glaxosmithkline plc goodwill intangible fix asset acquire issue share capital glaxo wellcome plc begin company change accounting policy smithkline beecham plc exchange share forgoodwill intangible asset ukgaap respect glaxosmithkline plcupon completion merger acquisition material difference exist shareholder glaxo wellcome hold approximately cent uk usgaap difference continue exist shareholder smithkline beecham hold respect prior year goodwill intangible asset fully approximately cent issue share capital amortise usgaap goodwill arise acquisition glaxosmithkline plc st january set shareholder fund uk gaap gaap goodwill capitalise amortise combination glaxo wellcome smithkline beecham expect useful economic life charge income account merger ukgaap financial intangible asset recognise st january statements glaxosmithkline ukgaap represent purchase accounting requirement amortise combined financial statement glaxo wellcome smithkline estimate revenue earn life take patent beecham historical basis period present lifeplusfive year gaap business combination qualify uk gaap cost incur integrate pool interest account glaxo wellcome restructure wellcome smithkline beecham block drug determine accounting acquirer purchase acquisition business follow acquisition date thdecember gaap financial respectively charge profit loss account post statement glaxosmithkline prior merger acquisition gaap certain ofsuch cost consider glaxo wellcome allocation purchase consideration affect view proximity merger date financial year end goodwill arise acquisition date relative insignificance business activity ukgaap certain intangible asset relate specific th december st december accounting compound product purchase party date acquisition practical purpose take develop commercial application capitalise stdecember usgaap payment compound product reconciliation consolidated income statement development receive regulatory consolidated statement comprehensive income change approval charge directly profit loss time shareholder equity year end st december receive regulatory approval correspondingly reflect purchase method merger transaction cost accounting theacquisition smithkline beecham glaxo glaxo wellcome incur total mergerrelate transaction cost wellcome income statement present gaap million exclude integration restructuring cost format certain exceptional item ukgaap uk gaap merger transaction cost expense product divestment merger integration cost addition incur usgaap direct acquisition cost writeoff inprocess research development acquire company include portion purchase classify operate profit consideration consolidate balance sheet consolidate statement cash restructuring cost flow usgaap usgaapformat present prior adoption frs provision contingent liability balance sheet st december include fair value andcontingent asset requirement recording provision acquire asset liability smithkline beecham plc restructuring cost prescriptive usgaap prepare usgaap ukgaap accordingly adjustment financial statement reflect purchase method eliminate ukgaapprovision restructuring cost accounting combination glaxo wellcome smithkline notmeet usgaaprequirement beecham material adjustment require usgaap apply instead ukgaap theperiod present summary purchase accounting adjustment usgaap adjustment provide reconciliation profit attributable shareholder equity shareholder fund uk usgaap glaxosmithkline note financial statement reconciliation accounting principle continue foreign currency hedging group enter forward exchange contract marketable security financial instrument ukgaap treat hedge marketable security consist primarily equity security future income matching principle match gain certain liquid investment ukgaap security loss hedge contract foreign currency state low cost net realisable value transaction profit relate gaap gaap securities available sale statement instrument qualify hedge accounting unrealised financial accounting standard sfas accounting gain loss hedge future profit transaction certain investment debt equity security carry value year end market rate recognise net fair value unrealise gain loss net tax report income current year separate component shareholder equity derivative instrument pension postretirement benefit statement financial accounting standard accounting key difference uk ssap usgaap relation derivative instrument hedge activity sfas define benefit pension plan amend sfas sfas interpret ukgaap effect variation cost derivative implementation group adopt group accumulate successive valuation amortise effective st january sfas establish accounting aggregate basis gaap amortisation reporting standard derivative instrument include certain transition asset cost past service benefit derivative instrument embed contract collectively improvement separately track experience gainslosse refer derivative hedge activity sfas deal aggregate basis amortise outside require entity recognise derivative asset cent corridor liability consolidate balance sheet measure instrument fair value sfas prescribe requirement uk gaap allow measurement plan asset liabilitie designation documentation hedge relationship base result late actuarial valuation usgaap ongoing assessment effectiveness order qualify hedge require measurement plan asset liability accounting date financial statement month prior date group evaluate contract embed derivative consider embed derivative bifurcated disclosure require sfas include note separate host contract accordance sfas stockbase compensation requirement embed derivative exist clearly uk gaap share option account equity closely relate host contract account exercise value issuance price usgaap group separately host contract derivative change apply sfas accounting stockbase compensation fair value record current earning relate accounting interpretation accounting option plan group designate derivative qualify require option fair value grant date hedge instrument sfas accordingly record include profit loss vest period option cumulative effect adopt sfas st january result merger certain group option vest represent initial revaluation derivative item immediately require acceleration compensation expense describe tax charge million stockbase compensation expense relate comprehensive income cumulative effect net accelerate vest million disclosure income gain loss relate fair value adjustment require sfas include note additionally derivative instrument classify consolidated statement group entitle receive tax deduction treat income cashflow accordance nature compensation tax rule employee stock option derivative exercise usemployee year ukgaap treat reduction tax expense fair value book value derivative instrument respect usgaap credit equity financial asset liability st december disclose classification fair value financial asset liability employee share ownership trust esot table note uk gaap share group stock hold esot arerecorde cost provision represent difference valuation derivative instrument cost option exercise price account fair value derivative instrument sensitive movement fix asset investment project loss exercise underlie market rate variable group monitor option cover share record profit fair value derivative instrument periodic basis cross loss account life theoption gaap share currency swap value standard valuation model group stock purchase esot account counterparty valuation thirdparty valuation standard shareholder equity cost gainsorlosse arise subsequent valuation model group consider relevant discount issuance share employee satisfy share option rate market yield curve valuation date forward record adjustment toshareholder equity currency exchange rate counterparty risk significant rate variable obtain market source valuation base remain term maturity instrument foreign currency forward value forward rate observe quote price relevant market possible group assume party longterm contract economically viable immediately exercise early termination right economically beneficial right exist contractnote financial statement glaxosmithkline reconciliation accounting principle continue sfas require goodwill long amortise estimate useful life company instead identify value dividend report unit purpose assess annually uk gaap dividend propose provide year potential impairment goodwill allocate reporting unit respect recommend board ofdirector additionally company need reassess useful life approval shareholder usgaap suchdividend exist recognise intangible asset intangible asset deem provide declare board ofdirector indefinite life long amortise instead test defer taxation annually potential impairment separate intangible asset uk gaap defer taxation account finite life continue amortise useful life extent probable taxation liability benefit group adopt sfas st january payable crystallise foreseeable future extensive effort need adopt sfas practical gaap sfas accounting income taxis requires defer fully estimate impact adopt sfas group taxation provide liability basis valuation financial statement st december group allowance establish respect defer tax asset unamortise goodwill approximately billion total goodwill likelythan portion amortisation amortisation indefinitelive intangible asset realise approximately billion million respectively year end st december incur exceptional item usgaap item classify exceptional uk gaap meet definition extraordinary gaap june fasb approve sfas accounting classify operate expense obligation associate retirement longlived asset require implement group effect consolidated statement cash flow st january standard require fair value usgaap cash flow statement report change cash liability asset retirement obligation recognise cash equivalent include shortterm highly liquid period incur reasonable estimate fair value investment original maturity month associated asset retirement cost capitalise onlythree category cash flow report operate carry asset depreciate activity include tax interest investing activity include useful life october fasb issue sfas accounting capital expenditure acquisition disposal impairment disposal longlive asset cashflow available sale current asset investment require implement group effect st andfinance activity include dividend pay statement january standard develop accounting model ofcash flow present longlived asset include discontinued operation dispose cash cash equivalent sale group currently assess impact uk gaap cash balance include cash bank standard cash balance usgaap cash cash equivalent include cash bank certain liquid investment original maturity month comprehensive income statement requirement sfas report comprehensive income provide comprehensive income statement meet ukgaap statement total recognise gain loss page statement comprehensive income usgaap year period end st december present page usgaap statement include net impact gain loss equity liquid investment translation adjustment recent fasb pronouncement july financial accounting standard board fasb issue statement business combination sfas statement goodwill intangible asset sfas sfas prohibit poolingofinterest method accounting business combination require purchase method accounting business combination initiate th june prescribe initial recognition measurement goodwill intangible asset account negative goodwill require disclosure respect business combination glaxosmithkline note financial statement reconciliation accounting principle continue glaxo glaxo smithkline gaap smithkline uk gaap adjustment gaap reconciliation consolidated income statement revenue cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense amortisation goodwill intangible asset writeoff inprocess rd acquire product divestment merger transaction cost operate profit share profitslosse joint venture associate undertaking lossprofit disposal interest associate profit dissolution joint venture disposal business provision loss disposal loss disposal subsidiary utilisation provision profit interest net interest expense profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholdersnet lossincome basic lossearning share gaap pence p dilute lossearning share gaap pence p basic lossearning ad usgaap diluted lossearning ad gaap consolidate statement comprehensive income change shareholder equity usgaap shareholders equity beginning year net lossincome exchange movement overseas net asset unrealise lossgain equity investment net tax unrealise lossgain liquid investment net tax cumulative effect change accounting principle comprehensive lossincome dividend share purchase cancel share issue employee share ownership plan share issue purchase smithkline beecham shareholders equity end year note financial statementsglaxosmithkline smithkline smithkline glaxo beecham glaxo glaxo beecham glaxo smithkline preacquisition gaap smithkline smithkline preacquisition gaap smithkline uk gaap uk gaap adjustment gaap uk gaap uk gaap adjustment gaap p p p p glaxosmithkline note financial statement reconciliation accounting principle continue consolidated balance sheet underus gaap asset current asset cash cash equivalent marketable security account note receivable inventory prepaid expense defer income taxis total current asset goodwill intangible asset property plant equipment investment affiliate asset defer income taxis total asset liability shareholder equity current liability cash overdraft account payable shortterm borrowing capital lease obligation income taxis dividend payable deferred income taxis accrue liability total current liability longterm borrowing capital lease obligation liability defer income taxis total liability minority interest contingency commitment note shareholder equity common stock share par value share authorise share issue redeemable preference share share par value share authorise nil share outstanding additional paidin capital retain deficit cumulative comprehensive loss treasury stock total shareholder equity total liability shareholder equity certain balance sheet item st december reclassify comparative purposesnote financial statementsglaxosmithkline reconciliation accounting principle continue consolidated statement cash flow usgaap cash flow operating activity net lossincome adjustment reconcile net income net cash provide operating activity depreciation amortisation goodwill intangible writeoff inprocess rd acquire impairment lossgain sale fix asset productive asset defer taxis tax benefit exercise stock option income associate loss sale associate investment change operate asset liability net acquisition decreaseincrease inventory increase trade debtor increase trade creditor increase pension provision derivative net cash provide operating activity cash flow invest activity acquisition fix asset acquisition intangible asset acquisition smithkline beecham cash receive acquisition acquisition new business net cash acquire proceed disposition fix asset business proceed sale intangible fix asset decreaseincrease liquid investment decreaseincrease equity investment net cash inby provide investing activity cash flow financing activity proceed additional borrowing reduction debt purchase treasury stock dividend pay net repayment ofincrease shortterm loan net increase inrepayment cash overdraft redemption preference share issue subsidiary ordinary share purchase cancellation issue share capital net cash financing activity net decreaseincrease cash cash equivalent exchange rate movement cash cash equivalent begin year cash cash equivalent end year supplemental cash flow information cash pay year interest income taxis noncash investing financing activity purchase acquisition date th december group acquire outstanding share smithkline beecham exchange share ofglaxosmithkline conjunction acquisition liability assume follow fair value asset acquire fair value share issue fair value liability assume glaxosmithkline note financial statement reconciliation accounting principle continue cthe market value investment include book value smithkline beecham net asset gaap acquisition smithkline beecham increase investment relate increase fair market gaap financial statement glaxosmithkline prior tothe value nonmarketable security st december merger glaxo wellcome gaap accounting acquirer include inthis increase equity investment acquisition smithkline beecham account equity investment measure fair value purchase method date merger thdecember excess fair value underlie tangible asset liability recognise goodwill investment purchase accounting adjustment goodwill amortise year order determine proper allocation purchase price relate acquire asset smithkline beecham gaap dthe fair value attribute pension obligation reflect purchase accounting cost acquisition calculate recognition previously unrecognised actuarial gainslosse market value share issue fair value vest option prior service cost transition amount amount recognise exchange direct external acquisition cost allocate base actuarial assessment acquisitiondate fair value net asset acquire result fair value ethe fair value attribute intangible asset relate exercise increase value smithkline beecham inventory primarily management estimate value product tangible fix asset investment pension obligation right inclusive respective patent trademark recognise fair market value attribute intangible onexisting product assemble workforce thefair asset mainly product right inclusive patent trademark value product right determine base assemble workforce inprocess research development discount net future cash flow analysis current approve appropriate defer taxation effect difference product portfolio include exist approve product cost acquisition fair value asset pharmaceutical therapeutic area consumer liability smithkline beecham record asgoodwill healthcare product portfolio supplemental product allocate inprocess research development development process build exist chemical entity require gaap expense immediately thefirst exist area andwhich subject separate reporting period business combination food drug administration approval include glaxosmithkline period end stdecember fair management base estimate weight average value adjustment record inventory useful life product right future period expense additional amortisation depreciation substantial majority estimate net future cash flow berecorde respect fair value adjustment tangible value expect realise approximately year intangible asset result goodwill period pharmaceutical year consumer healthcare brand respective economic useful life fair value assemble workforce amortise adjustment asset liabilities smithkline beecham year period base smithkline beecham historical reflect fair value allocation excess purchase turnover rate consider goodwill sfas consideration fair value net asset acquire base f total consideration allocate smithkline onmanagement good estimate fair value summarise beecham inprocess research development project iprd thetable opposite discuss estimate current estimate status athe total assume purchase consideration calculate prospect rd portfolio iprd include bymultiplye number glaxosmithkline share issue identify project advanced stage development tosmithkline beechams shareholders outstanding management believe reasonable estimate project smithkline beecham share average fair value glaxo cash flow prepare include basic discovery wellcome security average fair value glaxo wellcome portfolio gene patent report iprd value security calculate period day prior intend reflect present value development subsequent theannouncement merger activity currentlyunderway value allocate iprd th january total assume purchase consideration determine utilise risk adjusted income approach include fair value smithkline beecham vested include earning discount appropriate cost capital option exchange vested option glaxosmithkline investment estimate future cash flow related total number smithkline beecham vest option individual iprd project base exist estimate multiply bythe respective fair value ordinary revenue contribution margin project share adr plan determine thjanuary gadditional liability relate restructure cost directly link bthe increase fair value inventory fix asset plan place date acquisition determine base difference carry value liability reflect cost close certain smithkline beecham market value asset increase inventory manufacture site redundancy cost liability expense inventory sell increase relate additional defer tax liability previously infix asset allocate respective category recognise depreciate remain useful life asset hdeferre taxis compute excess fair value book value goodwill inprocess research development applicable weighted average statutory tax rate goodwill represent remainder unallocated purchase consideration goodwill amortise expect economic life year note financial statementsglaxosmithkline reconciliation accounting principle continue purchase accounting adjustment total assume purchase consideration outstanding share cost fee transaction book value smithkline beecham net asset gaap goodwill excess fair value inventory b excess fair value tangible fix asset b excess fair value investment c excess fair value pension asset fair value attribute intangible asset e fair value attribute workforce e fair value attribute inprocess rd project f additional liability assume g defer tax liability relate purchase price adjustment h goodwill acquisition smithkline beecham plc block drug company inc pro forma result unaudite follow table reflect result operation gaap pro forma basis january acquisition block drug complete st january december acquisition smithkline beecham complete st january pro forma result operation include amortisation acquire goodwill intangible butdonot include writeoff inprocess rd orinventory adjustment net sale earning interest income taxis minority interest net income pence pence earning share dilute earning share earning ad dilute earning ad pro forma financial information necessarily indicative theoperating result occur acquisition consummate date indicate necessarily indicative future operating result glaxosmithkline note financial statement reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap apply instead uk gaap adjustment reflect balance sheet income statement present accordance usgaap profit profit attributable shareholder uk gaap smithkline beecham preacquisition profit attributable shareholder uk gaap merger alignment adjustment usgaap adjustment writeoff smithkline beecham inprocess rd acquire capitalise interest computer software purchase intangible amortisation goodwill amortisation intangible asset recognition cost sale fair value stepup inventory disposal purchase investment loss disposal subsidiary pension stockbase compensation provision esot share derivative instrument restructure tax benefit exercise stock option merger transaction cost defer taxation impairment equity investment net lossincome gaap equity shareholder fund equity shareholder fund uk gaap usgaapadjustment inventory tangible fix asset investment workforce product right capitalise interest computer software goodwill intangible asset unrealise gain marketable security pension postretirement benefit employee share ownership trust restructuring cost derivative instrument dividend defer taxation shareholder equity gaap certain item year end st december reclassify comparative purposesnote financial statement glaxosmithkline reconciliation accounting principle continue earning share gaap weight average number share issue million million million basic adjustment share option dilute adsshare hold employee share ownership trust exclude share issue taxation total tax expense uk gaap current tax expense defer tax expense total tax expense gaap current tax expense defer tax expense total tax expense defer taxation usgaap classification glaxosmithkline defer taxation liability asset gaap follow liability stock valuation adjustment current defer taxation liability accelerate capital allowance unremitte foreign investment income product right time difference total defer taxation liability asset intragroup profit time difference current defer taxation asset asset disposal pension postretirement benefit manufacturing restructure tax loss time difference total defer taxation asset net defer taxation gaap difference uk effective taxation rate effective taxation rate primarily relate fair value adjustment goodwill intangible relate acquisition wellcome smithkline beecham glaxosmithkline note financial statement reconciliation accounting principle continue segment information usgaap uk gaap segment information present note include result operation information historical combine glaxo wellcome smithkline beecham basis gaap segment information result operation reflect merge operation glaxosmithkline relate glaxo wellcome period practical purpose regard prior acquisition smithkline beecham glaxo wellcome operate segment pharmaceutical segment information respect asset relate glaxo wellcome smithkline beecham consolidated basis st december acquisition smithkline beecham glaxo wellcome occur th december turnover location customer usa europe rest world external turnover turnover business sector pharmaceutical consumer healthcare external turnover operate profitloss business sector pharmaceutical consumer healthcare operate profitloss turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operate profitloss share profit joint venture associate undertaking lossprofit disposal subsidiary associate net interest payable profitloss taxation profitloss taxation taxation minority interest preference share dividend earningsnet incomeloss note financial statementsglaxosmithkline reconciliation accounting principle continue total asset business sector pharmaceutical consumer healthcare total asset total asset location subsidiary undertaking usa europe rest world total operating asset cash cash equivalent marketable security total asset plant land equipment computer asset total total building vehicle software construction tangible fix asset location subsidiary undertaking usa europe rest world total uk segment information give separately respect uk include group europe market region consider group home segment purpose segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset glaxosmithkline note financial statement reconciliation accounting principle continue pension usgaap sfas disclosure year end st december provide relation employee glaxosmithkline income statement disclosure provide relation employee glaxo wellcome balance sheet disclosure provide consolidated basis relation employee glaxo wellcome smithkline beecham disclosure provide relation employee glaxo wellcome average number person employ group include director year number number number manufacturing sell general administration research development pension postretirement cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost disclosure include additional information require sfas pension cost uk major overseas define benefit pension plan restate follow table accordance gaap pension cost million million million respect minor retirement plan recalculate accordance requirement sfas exclude net periodic pension costincome major retirement plan comprise service cost interest cost expect return plan asset amortisation prior service cost amortisation transition obligation recognise net actuarial gain net periodic pension costincome gaap termination benefit curtailment cost major assumption compute pension incomecost pa pa pa rates future pay increase discount rate expect longterm rate return plan asset aggregate average international plan assumption vary significantly assumptionsnotes financial statementsglaxosmithkline reconciliation accounting principle continue change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial loss benefit pay acquisition termination benefit curtailment cost exchange benefit obligation end year benefit obligation end year pension plan accumulate benefit obligation excess plan asset change plan asset fair value plan asset begin year actual return plan asset employer contribution plan participant contribution benefit pay acquisition exchange fair value plan asset end year fair value plan asset end year pension plan accumulate benefit obligation excess plan asset plan asset consist primarily investment uk overseas equity fix interest security security link uk index retail price inflation property st december uk equity include million glaxosmithkline share million glaxowellcome share market value million million fund status fund status unrecognise net actuarial gainloss unrecognise prior service cost unrecognised transition obligation net recognise amount recognise statement financial position consist prepay benefit cost accrue pension liability additional require liability intangible asset accumulate comprehensive income net recognise glaxosmithkline note financial statement reconciliation accounting principle continue postretirement healthcare usgaap disclosure provide relation employee glaxosmithkline income statement disclosure provide relation employee glaxo wellcome balance sheet disclosure provide consolidated basis relation employee glaxo wellcome smithkline beecham disclosure provide relation employee glaxo wellcome net healthcare cost service cost interest cost amortisation prior service cost net healthcare cost major assumption calculate net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation rate reflect fact benefit certain group participant cap change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial loss benefit pay acquisition curtailment exchange benefit obligation end year change plan asset fair value plan asset begin year employer plan participant contribution benefit pay fair value plan asset end year fund status fund status unrecognise net actuarial loss unrecognise prior service cost accrue postretirement healthcare cost decrease increase impact cent variation rate future healthcare inflation effect total service interest cost effect provision postretirement benefit note financial statement glaxosmithkline principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group stdecember detail give country incorporation principal country operation location headquarters business segment business activity share capital undertaking comprise ordinary share wholly own group interest show europe location subsidiary undertaking segment activity england greenford glaxosmithkline services plc glaxo wellcome plc ph h brentford smithkline beecham plc phch h r p e greenford glaxo group ltd ph h brentford smithkline beecham research ltd ph brentford smithkline beecham investments ltd phch f brentford glaxosmithkline research development ltd ph r glaxo wellcome research development ltd brentford glaxosmithkline export ltd glaxo wellcome export ltd ph e greenford wellcome foundation ltd ph h r p greenford wellcome limited phch h brentford smithkline beecham swg ltd ch e stockley park glaxo operation uk ltd ph p stockley park glaxo wellcome uk ltd ph h p brentford staffordmiller ltd ch p austria vienna glaxosmithkline pharma gmbh glaxo wellcome pharma gmbh ph belgium genval glaxosmithkline belgium sa glaxo wellcome belgium sa ph rixensart glaxosmithkline biological sa smithkline beecham biological sa ph p e wavre glaxosmithkline biological manufacture sa ph p e smithkline beecham biological manufacture sa channel st peter port sb insurance ltd phch islands denmark ballerup smithkline beecham ch brndby glaxosmithkline pharma glaxo wellcome ph finland espoo glaxosmithkline oy glaxo wellcome oy ph france paris glaxosmithkline sante grand publique smithkline beecham ch sant et hygiene sas paris groupe glaxo wellcome ph r p germany buehl glaxosmithkline consumer healthcare gmbh co kg smithkline ch beecham gmbh co kg munich smithkline beecham gmbh ph greece athens glaxo wellcome aebe ph h p athens smithkline beecham cisa phch hungary budapest glaxosmithkline kft smithkline beecham kft phch ireland carrigaline smithkline beecham cork ltd note ph p carrigaline smithkline beecham manufacturingltd note ph p dublin glaxo wellcome international note phch h dublin smithkline beecham ireland ltd note phch dublin sterling health ltd note ch dublin smithkline beecham consumer brands ltd note ch dublin beecham products ireland ltd note ch dublin smithkline beecham pharmaceuticals ltd note ph italy verona glaxosmithkline spa glaxo wellcome spa ph milan glaxosmithkline consumer healthcare spa maggioni spa ch h luxembourg glaxosmithkline international luxembourg sa phch h glaxosmithkline luxembourg sa phch h glaxosmithkline note financial statement principal group company continue europe location subsidiary undertaking segment activity netherland rijswijk glaxosmithkline bv smithkline beecham farma bv ph zeist glaxosmithkline consumer brand bv smithkline beecham ch consumer brand bv zeist glaxo wellcome international bv phch h zeist glaxo wellcome investment bv phch h norway oslo glaxosmithkline glaxo wellcome ph poland poznan glaxosmithkline pharmaceuticals sa glaxo wellcome sa ph p warsaw glaxosmithkline consumer healthcare sp zoo smithkline ch beecham polska sp zoo portugal lisbon instituto lusofarmaco lda ph spain madrid glaxo wellcome sa ph r p madrid smithkline beecham sa ph sweden mlndal glaxosmithkline ab smithkline beecham ab ph switzerland thoerihaus glaxosmithkline investments switzerland gmbh phch h thoerihaus glaxosmithkline international switzerland gmbh phch h berne glaxo wellcome ag ph zug adechsa gmbh ph e turkey istanbul glaxo wellcome isas ph p usa usa philadelphia smithkline beecham corporation phch h r p e pittsburgh glaxosmithkline consumer healthcare lp smithkline ch p beecham consumer healthcare lp note ii jersey city block drug company inc ch h p wilmington glaxosmithkline financial inc glaxo wellcome financial inc phch f wilmington smithkline beecham holdings corporation phch h wilmington glaxosmithkline holdings americas inc phch h smithkline beecham holdings americas inc americas bermuda hamilton glaxosmithkline insurance ltd phch glaxo wellcome insurance bermuda ltd canada mississauga glaxosmithkline inc phch r p asia pacific australia boronia glaxo wellcome australia ltd ph p dandenong smithkline beecham australia pty ltd phch china hong kong glaxo wellcome china ltd ph tianjin sinoamerican tianjin smith kline french laboratories ltd ph india mumbai glaxosmithkline pharmaceuticals ltd glaxo india ltd note ii ph p nabha smithkline beecham consumer healthcare ltd note ii ch p malaysia selangor glaxosmithkline pharmaceutical sdn bhd ph darul ehsan glaxo wellcome malaysia sdn bhd new zealand auckland glaxo wellcome new zealand ltd ph p pakistan karachi glaxo wellcome pakistan ltd ph p karachi beecham pakistan private ltd phch philippines manila glaxo wellcome philippines inc ph singapore singapore glaxo wellcome manufacturing pte ltd ph p south korea seoul glaxosmithkline korea glaxo wellcome korea ph p taiwan taipei glaxo wellcome taiwan ltd ph p mnote financial statementsglaxosmithkline principal group company continue japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk glaxo wellcome kk ph r p kobe block drug japan inc ch latin america argentina buenos aires glaxosmithkline argentina sa smithkline beecham argentina sa phch p brazil rio de janeiro glaxo wellcome sa ph p rio de janeiro smithkline beecham brasil ltda phch colombia bogota glaxosmithkline colombia sa smithkline beecham colombia sa phch mexico mexico city glaxo wellcome mexico sa de cv ph p cuernavaca smithkline beecham mexico sa de cv phch p puerto rico san juan glaxo wellcome puerto rico inc ph hato rey sb pharmco puerto rico inc ph p venezuela caracas glaxo wellcome ph p middle east africa egypt cairo glaxo wellcome egypt sae ph p south africa midrand glaxo wellcome south africa pty ltd ph p johannesburg smithkline beecham consumer healthcare pty ltd ch p usa location associated undertaking usa teterboro quest diagnostics inc new jersey notes exempt provision section company amendmentact ireland ii consolidated subsidiary undertaking accordance section company act ground significant influence business segment phpharmaceutical chconsumer healthcare business activity ddevelopment eexporte ffinance hholde company iinsurance mmarketing pproduction rresearch detail group subsidiary associate undertaking attach company annual return file registrar ofcompanie glaxosmithkline principal financial statement follow information provide convenience shareholder accordance requirement new york stockexchange principal financial statement prepare ukgaap sterling translate consolidate profit loss account consolidate statement recognise gain loss consolidate cash flow statement average exchange rate consolidate balance sheet period end exchange rate exchange rate give note tothe financial statement consolidated profit loss account business total business total business total turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate profit disposal interest associate product divestment merger transaction cost disposal business loss disposal utilisation provision profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning ad adjust earning ad columnar presentation profit loss account adopt order illustrate underlie business performance primary measure management forthispurpose certain item exclude business performance business column present column item comprise merger item include product divestment cost relate previously announce manufacturing restructuring effect business disposal prior year consolidated statement total recognise gain loss profit attributable shareholder exchange movement overseas net asset uk tax exchange movement total recognise gain loss principal financial statement usglaxosmithkline consolidated cash flow statement net cash inflow operating activity earning joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash outflowinflow management liquid resource finance management liquid resource finance decreaseincrease cash year consolidated balance sheet goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset call share capital share premium account reserve profit loss account equity shareholder fund nonequity minority interest equity minority interest capital employ glaxosmithkline financial record quarterly trend analysis provide quarter group result sterle financial year analysis business performance result total result pharmaceutical sale therapeutic area profit loss account business performance month q cer cer sales pharmaceutical consumer healthcare total sale cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning share p p profit loss account total sale pharmaceutical consumer healthcare total sale cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate disposal business product divestment merger transaction cost profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder earning share p pfinancial record glaxosmithkline month q month q q cer cer cer cer cer p p p p p p p p p p glaxosmithkline financial record pharmaceutical sale total group q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale usa q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale glaxosmithkline financial record pharmaceutical sale europe q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale rest world q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterial augmentin zinnatceftin fortum amoxil antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale glaxosmithkline financial record year record record financial performance provide analysed accordance current reporting practice sale business segment pharmaceutical consumer healthcare retain business healthcare service pharmaceutical sale therapeutic area central nervous system disorder respiratory antibacterial antiviral metabolic gastrointestinal vaccine oncology emesis cardiovascular arthritis continue business divest product pharmaceutical sale geographic area usa europe rest world asia pacific japan latin america middle east africa canada total rest world consumer healthcare sale otc medicine oral care nutritional healthcare continue business divest product financial recordglaxosmithkline business performance result retain business sale rd expenditure cent sale trading profit cent sale net interest payable profit taxation earning profit attributable shareholder business performance primary performance measure management present exclude merger item integration restructuring cost disposal subsidiary management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement include consolidated statement profit loss page prepare accordance ukgaap total result include nonrecurre item merger restructure disposal subsidiary manufacture restructuring merger cost product divestment item lossprofit taxation lossprofit attributable shareholder total result sale profit taxation earning profit attributable shareholder dividend retain profit return capital employ cent return capital employ calculated total profit taxation percentage average capital employ year share statistic earning share p dividend glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend glaxosmithkline ad glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline sharead merger glaxo wellcome smithkline beecham thdecember shareholders adr holder receive share glaxosmithkline follow ratio glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline share glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss glaxosmithkline ad represent glaxosmithkline share glaxosmithkline financial record net asset fix asset asset liability net operating asset net debt capital employ share capital share premium goodwill reserve reserve equity shareholder fund minority interest capital expenditure tangible fix asset number employees usa europe rest world asia pacific japan latin america middle east africa canada total rest world manufacturing selling administration research development number employee number permanent employ staff end financial period exclude employee employ manage glaxosmithkline contract basis consequence time take complete merger glaxosmithkline replace need leaver contractor year end level contractor disproportionately high movement compare reflect conversion contract employee permanent employee redundancie merger integration additional employee acquisition block drugglaxosmithkline investor information section discuss shareholder return return shareholder form dividend share price movement provide information shareholder shareholder return taxation information shareholder shareholder information share capital glaxosmithkline shareholder return merger glaxo wellcome smithkline beecham dividend glaxosmithkline pay dividend quarterly present expect board glaxo wellcome smithkline beecham level dividend quarter announce th january agree term high dividend fourth quarter quarter dividend propose merger equal company subject announce time quarterly result announcement shareholder approval regulatory clearance base relative stock market valuation glaxo wellcome smithkline glaxosmithkline dividend payout policy set beecham month precede announcement document glaxo wellcomesmithkline beecham merger merger shareholder glaxo wellcome hold issue shareholder assume earning continue approximately cent shareholder smithkline grow glaxosmithkline maintain annual dividend beecham approximately cent combine group pence share line glaxo wellcome dividend penny glaxo wellcome share whilstbuilde high follow shareholder approval clearance regulatory dividend cover ratio distributable profitsand dividend authority merger effective th december board declare dividend follow merger implement way scheme arrangement new hold company glaxosmithkline plc acquire glaxo wellcome smithkline beecham accordance gw sb agree merger term shareholder glaxo wellcome dividend share pence pence pence smithkline beecham receive exchange exist interim share share glaxosmithkline follow second interim interim glaxo wellcome ordinary share glaxosmithkline fourth interim ordinary share total smithkline beecham ordinary share glaxosmithkline ordinary share dividend pay represent dividend pay glaxo case share hold american depositary share adss wellcome smithkline beecham shareholder express evidence american depositary receipt adr glaxo dividend glaxosmithkline share wellcome ad represent glaxo wellcome ordinary share smithkline beecham ad represent smithkline dividend beecham ordinary share glaxosmithkline ad represent respect financial year end st december glaxosmithkline ordinary share accordingly holder glaxo wellcome adrs holders smithkline beecham adr glaxo wellcome pay interim dividend p ordinary share receive second interim dividend p ordinary share total dividend glaxo wellcome share year p total glaxo wellcome ad glaxosmithkline ad equivalent dividend glaxosmithkline ordinary share p smithkline beecham ad glaxosmithkline adss smithkline beecham pay second interim dividend glaxosmithkline share commence trading london stock p ordinary share fourth interim dividend p exchange glaxosmithkline adss commenced trading ordinary share total dividend share year p new york stock exchange th december total equivalent dividend glaxosmithkline ordinary share p taxation general information concern uk tax effect share ownership set taxation information shareholder shareholder doubt taxation position consult professional adviser general guide shareholder glaxosmithkline receive advice merger direct effect tax position uk resident shareholder resident shareholder information contain scheme document issue shareholder th july shareholder return glaxosmithkline dividend adss share price guide holder adr table set dividend pay ad dollar year dividend share price gsk gsk gw sb adjust uk tax credit withholding tax applicable st january translate dollar applicable exchange rate high year th april claim refund tax credit dividend low year uk tax authority negligible benefit th december shareholders st december increasedecrease year year gsk gw sb table set middle market quotation share london stock exchange derive daily official list company share price decline cent price st january st december decline compare decrease ftse index dividend pay glaxo wellcome smithkline beecham adr cent year relative outperformance holder express dividend glaxosmithkline ad glaxosmithkline investor preference defensive growth characteristic pharmaceutical sector dividend calendar uncertain economic period glaxosmithkline quarter strong business performance year result announcement th april market capitalisation exdividend date st market capitalisation glaxosmithkline st december record date rd billion date glaxosmithkline large payable th july company market capitalisation ftse index second quarter smithkline beecham plc float rate unsecured loan stock result announcement th july exdividend date st july record date nd august loan stock list exchange holder payable rd october require smithkline beecham plc redeem loan stock par ie loan stock hold business day quarter march june september december holder wish redeem result announcement rd october loan stock complete notice exdividend date th october loan stock certificate return registrar record date st november arrive day relevant redemption date payable rd january glaxosmithkline taxation information shareholder information shareholder stamp duty uk stamp duty case stamp duty reserve tax summary principal tax consequence holder sdrt subject certain exemption payable share adr citizen resident unite kingdom purchase share rate cent purchase price united states set complete analysis minimum charge stamp duty liability arise possible tax consequence purchase ownership security holder security advise consult shareholder tax adviser respect tax consequence purchase ownership share adrs include taxation dividend specifically consequence state local tax law gross dividend receive include amount united states respect associate tax credit uk withholding tax treat foreign source dividend income tax purpose new ukus income tax convention sign eligible dividend receive deduction allow date set ratification statement corporation dividend adr payable dollar united kingdom united states tax law dividend share payable pound sterling dividend practice set base law pay pound sterling include income practice force date report dollar calculate reference exchange rate holder adr generally treat owner day dividend receive holder uk tax underlie share purpose current united withhold dividend distribution eligible credit statesunite kingdom double taxation convention relate holder federal income tax liability subject generally income gain income tax convention estate gift taxis applicable limitation holder tax position estate gift tax convention purpose determine effective use credit uk internal revenue code amend code withholding tax tax liability th april rate tax credit reduce follow analysis deal dividend pay th april ninth act abolish consequently claim refund advance corporation tax act abolish tax credit dividend pay date dividend pay date negligible benefit shareholders uk shareholders taxation capital gain taxation dividend generally holder subject uk capital gain tax th april rate tax credit reduce subject tax capital gain realise sale ninth result compensating reduction rate tax disposal share adr dividend income increase tax bear uk resident individual shareholder tax credit estate gift taxis long repayable shareholder tax liability estate gift tax convention shareholder associate tax credit generally subject uk inheritance tax taxation capital gain stamp duty uk shareholder liable uk tax gain uk stamp duty case sdrt subject disposal share adrs entitle certain exemption payable issue transfer share indexation relief taper relief sale indexation relief adr custodian depository rate cent calculate market value share st march price issue consideration provide cost subsequent purchase date transfer sale value transfer purchase indexation relief individual shareholder cease consideration th april taper relief available individual shareholder sdrt payable transfer adr uk hold deem hold share year stamp duty payable transfer adr provide sell instrument transfer execute remain time outside uk stamp duty transfer adr inheritance tax payable rate cent consideration individual shareholder liable inheritance tax transfer sale underlie share result transfer share adrs tax charge liability uk stamp duty case sdrt rate value shareholder estate reduce cent result transfer way gift disposal market value exceptionally gift disposal minimum charge stamp duty liability subject uk inheritance tax estate gift tax arise estate gift tax convention generally provide tax pay united states credit tax payable united kingdomglaxosmithkline shareholder information ordinary share investor hold share company nominee service arrange nominee service appoint proxy company share list london stock exchange respect shareholding order attend vote meeting registrar company share register administer lloyds tsb adr holder wish attend meeting obtain proxy registrar provide follow services bank new york enable attend meeting vote business transact adr holder glaxosmithkline investment plan instruct bank new york share plan enable shareholder reinvest quarterly dividend represent adrs vote complete andor monthly investment company ordinary return voting card provide bank new york share special dealing arrangement accordance instruction give glaxosmithkline individual saving account glaxosmithkline individual saving account isa financial reporting taxefficient way invest company ordinary share financial reporting calendar glaxosmithkline corporate sponsor nominee announcement st quarter result th april corporate sponsor nominee provide facility announcement nd quarter result th july shareholder hold share need share publication halfyear reportreview august certificate shareholder detail hold main share register remain confidential announcement rd quarter result rd october preliminary announcement annual result february shareview service publication annual reportreview march shareview portfolio service provide shareholder information investment company shareholder register service wwwshareviewcouk result announcement result announcement issue london stock share deal facility exchange lse available lse news service natw stockbroker limit offer sharedealing service time shortly issue medium behalf company shareholder wish buy sell available company web site file company share usa securities exchange commission sec new york stock exchange share price information share price information available company web site financial report wwwgskcom information available ceefax teletext company publish annual report investor ft cityline call need detail report annual review interim call charge p minute time report review publish halfyear financial report send shareholder date american depositary share publication available date company company share list new york stock exchange web site shareholder provide review elect form american depositary share adss receive report evidence american depositary receipt adr copy previous financial report available company represent ordinary share web site print copy obtain company registrar uk company customer response adr programme administrator center usa adr programme administer bank new york provide follow service publication global buydirect time glaxosmithkline produce social global buydirect direct ad purchasesale dividend environmental review entitle performance integrity reinvestment plan adr holder incorporate information press issue core business generate significant interest annual general meeting external shareholder include medicine develop world community involvement environmental health queen elizabeth ii conference centre th safety performance integrity available broad sanctuary westminster secretariat companys head office company london swp ee web site wwwgskcom annual general meeting company principal forum communication private shareholder addition formal resolution meeting presentation chief executive officer performance business future development opportunity question board chairmen board committee question matter relate committee glaxosmithkline share capital nature trading market glaxo wellcome penny share ordinary share company list london fiscal period th december high low stock exchange th december share quarter end st december list new york stock exchange inthe form american quarter end th september depositary share adss date quarter end th june quarter end st march follow table set period indicate high low middle market quotation pence share london stock exchange derive daily official list high low report sale price dollar adss new york stock exchange derive new dollar ad york stock exchange composite tape fiscal period th december high low information relate share ad price glaxo quarter end st december wellcome smithkline beecham prior date merger quarter end th september give quarter end th june quarter end st march glaxosmithkline pence share fiscal period th december high low quarter end st march february january december smithkline beecham pence share november fiscal period th december high low october quarter end st december september quarter end th september quarter end st december quarter end th june quarter end th september quarter end st march quarter end th june quarter end st march th st december dollar ad dollar ad fiscal period th december high low fiscal period th december high low quarter end st march quarter end st december february quarter end th september january quarter end th june december quarter end st march november october september quarter end st december quarter end th september quarter end th june th december quarter end st march th st december th march share capital glaxosmithkline analysis shareholding number total number analysis shareholding st december account account total share hold share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit total bank new york hold hold bny nominees limited represent company adr programme ad represent ordinary share p nominal value th march number holder record share usa holdings share thenumberof register holder adr holding adr certain share adrs hold broker nominee number holder record register holder usa representative number beneficial holder orofthe residence beneficial holder control company far know company directly indirectly own control corporation government thecompany know arrangement operation result change control company substantial shareholding th march company receive notification follow interest cent share bnynominee limited hold share represent cent share hold behalf holder american depositary receipt far know company person owner cent share company director officer interest director officer company define thecompanie act share option company give remuneration report page exchange control limitation affect securityholder currently uk law decree regulation restrict import export capital affect remittance dividend orother payment holder companys share nonresident uk limitation relate non resident uk english law company memorandum article association right tobe holder vote respect company share glaxosmithkline cross reference form f table provide cross reference information include annual report requirement form f item item identity director senior management adviser na financial information consolidate statement financial information offer statistic expect timetable na financial statement item key information legal proceeding select financial datum b significant change na risk factor offer list information company share price history history development company c markets b business overview product additional information competition b memorandum articles association note regulation c material contract marketing distribution exchange control manufacture supply e taxation research development h document display intellectual property quantitative qualitative disclosure market risk information technology treasury policy environment health safety note financial instrument relate disclosure global community partnership description security equity security na access medicine develop world default dividend arrearage delinquencie na c organisational structure property plant equipment material modification right security holder environmental responsibility use proceed na note segment information reserve note tangible fix asset reserve operate financial review prospect financial statement na operating result financial statement director statement responsibility independent auditor report accounting principle consolidate statement profit loss b liquidity capital resource consolidate statement total recognise gain loss c research development patent license etc consolidated statement cash flow trend information consolidate balance sheet director senior management employee reconciliation movement equity shareholder fund director senior management company balance sheet b compensation note financial statement remuneration report exhibit c board practice corporate governance employee note glaxosmithkline people information responsive item incorporate reference note employee cost memorandum articles association glaxosmithkline financial record page group annual report form f e share ownership year end st december glaxosmithkline people note employee share scheme share option incentive plan director interest major shareholder relate party transaction major shareholder b relate party transaction cross reference form f glaxosmithkline cautionary factor affect future result relate party transaction group report file securities exchange glaxosmithkline cent interest quest diagnostic commission commission include annual report inc activity quest company core form f year end st december business interest hold investment form f contain write information release oral statement public future behalf material contract group contain forwardlooke statement forward board glaxo wellcome plc smithkline beecham plc look statement thegroup current expectation announce th january term agreement forecast future event aninvestor identify forthe propose merger company merger statement fact donot relate strictly historical wasimplemente way scheme arrangement current fact use word anticipate estimate thdecember date glaxosmithkline plc expect intend project plan believe acquire thewhole issue share capital glaxo word term similar meaning connection wellcome plc andsmithkline beecham plc discussion future operate financial performance particular include statement relate future action january glaxosmithkline complete acquisition prospective product product approval future performance block drug company inc manufacturer toothpaste result current anticipate product sale effort oral healthcare consumer product million expense outcome contingency legal million proceeding financial result group undertake obligation update forwardlooke statement document display result new information future event document refer annual report available forwardlooke statement involve inherent risk inspection register office company uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report glaxosmithkline glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation advance corporation tax act advance payment uk tax dividend pay direct equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc creditor account payable currency swap exchange currency couple subsequent reexchange currency agree exchange rate date debtor account receivable define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derive value price rate underlie item dilute earning share diluted income share dividend cover profit attributable shareholdersnet income divide dividend payable shareholder earning share basic income share employee share ownership trust trust establish group satisfy share base employee incentive plan equity shareholder fund aggregation share reserve own shareholder equivalent shareholder equity finance lease capital lease free cash flow cash resource available payment dividend shareholder acquisition freehold ownership absolute right perpetuity gearing ratio net debt percentage shareholder fund net debt minority interest group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement bymake offset commitment intangible fix asset asset physical substance brand licence patent knowhow marketing right purchase outside party interest cover number time profit interest exceed net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit loss account reserve retain earning profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement total recognise gain loss statement comprehensive income stock inventory subsidiary undertaking affiliate glaxosmithkline hold majority shareholding andor exercise control tangible fix asset property plant equipment turnover revenueglaxosmithkline index contact detail inside cover financial statement access medicine contaminate land financial summary accountability audit contingent liability financial trend ratio accounting policy control company fix asset investment accounting standard corporate executive team foreign exchange risk management acquisition disposal corporate governance forwardlooke statement corporate social responsibility committee adr programme administrator critical accounting policy g inside cover cross reference form f gearing ratio american depositary share global community partnership animal research global supply initiative annual general meeting derivative financial instrument glossary term antitrust go concern basis antibacterial dermatological goodwill description business antiviral dialogue shareholder directtoconsumer advertising governmental investigation associate company director senior management group company director h interest healthcare service audit committee interest contract hedge auditor independent remuneration history development company b report hiv aids balance sheet responsibility service contract share option impairment asset block drug share ownership guideline diversity independent auditor board executive divest business information technology board committee divest product inlicense business community dividend intangible asset business performance e intellectual property early drug discovery business segment earningsearning share interest cover c interest rate risk management capital employ internal control capital expenditure employee investment cardiovascular cost diversity cash flow involvement investor information number j cautionary factor affect performance reward joint venture future result share scheme associate centralnervoussystemcnsdisorder train development employee share ownership trust centre excellence drug discovery l chairman chief executive lease officer statement environment health safety legal proceeding charitable donation liquid investment chlorofluorocarbon cfc equity risk management combine code european monetary union loan overdraft commitment exchange control communication exchange rate lymphatic filariasis community investment competition external supplier consumer healthcare malaria f business sectorsegment manufacture supply fair value finance committee competition manufacturing restructure financial asset liability manufacture supply financial highlight marketing distribution market capitalisation financial instrument new product marketing distribution financial period sale maturity counterparty risk financial position research development memorandum article financial record regulation association year record trade mark merger accounting adjustment quarterly trend constant exchange rate cer metabolic gastrointestinal financial reporting calendar glaxosmithkline index n r u net debt reconciliation equity uk segment shareholder fund gaap reconciliation accounting net interest payable principle registrar consolidated balance sheet regulation consolidated income statement new product remuneration nomination comprehensive income nonexecutive director committee change shareholder equity noon buying rate remuneration report consolidate statement cash flow nutritional healthcare report director earning sharead research collaboration material difference research development uk gaap accounting policy postretirement benefit oncology emesis animal research purchase accounting consumer healthcare result usaccounte principle operate financial review disease develop world segment information prospect expenditure select financial datum oral care taxation operating incomeexpense pharmaceutical convenience translation principal pipeline financial statement outlook respiratory overthecounter otc medicine v p return capital employ vaccine patent revenue accounting policy payment policy risk factor w pension postretirement risk oversight compliance council rocc world economy benefit world market sale performace integrity consumer healthcare pharmaceutical approval submission pharmaceutical business sector competition sb clinical laboratory manufacture supply segment information marketing distribution select financial datum product senior management compensation sale interest share buyback research development share capital regulation share premium patent trade mark share price pipeline share purchase presentation financial statement share statistic price control shareholder information principal financial statement shareholder return shareholder fund profit loss account shareholding analysis statement total recognise gain loss property plant equipment strategic master plan provision liability charge taxation taxation information shareholder tax rate trade mark treasury operation treasury policy tuberculosis contact detail internet information investor company available glaxosmithkline corporate web site wwwgskcom head office register office glaxosmithkline plc great west road brentford middlesex tw gs tel united kingdom united states america investor relations europe investor relation great west road franklin plaza brentford po box middlesex tw gs philadelphia tel tel fax fax registrar adr programme administrator lloyds tsb registrar bank new york causeway shareholder relation worthe po box west sussex bn da church street station new york ny general enquiry annual report orderline tel toll free corporate nominee service tel outside usa tel inside uk tel outside uk customer response center tel toll free shareholder investment plan dividend reinvestment query tel inside uk tel outside uk monthly saving plan query tel inside uk tel outside uk isa enquiry tel inside uk tel outside uk glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck hp sz tel corporate share deal facility natw stockbroker corporate employee service mansell street london e tel inside uk tel outside uk paper production document pulp harvest sustainable forest sawmill residue forest thinning elemental chlorinefree print hyway uk waterless print process solvent free inkswwwgskcom